



DEPARTMENT OF HEALTH & HUMAN SERVICES

Office of the Secretary

Assistant Secretary for Public Affairs
Washington, D.C. 20201

Case No. 2020-00719-FOIA-OS

American Oversight v. HHS, Civil No. 20-cv-00947

November 25, 2020

Austin Evers

Executive Director

American Oversight

Sent via email: foia@americanoversight.org

Dear Mr. Evers:

This letter is the third interim response to your March 18, 2020, Freedom of Information Act (FOIA) request.

American Oversight requests all email communications (including email messages, complete email chains, email attachments, calendar invitations) sent by the government officials specified below containing any of the following key terms:

- | | |
|--------------------------------|--------------------------------|
| 1. EUA | 17. "Thermo Fisher" |
| 2. "Emergency Use" | 18. Thermofisher |
| 3. Test | 19. Hologic |
| 4. Testing | 20. "Panther Fusion" |
| 5. "the WHO" | 21. Wadsworth |
| 6. W.H.O. | 22. RT-PCR |
| 7. "World Health Organization" | 23. Oscar |
| 8. Kit | 24. CureVac |
| 9. LDT | 25. "University of Washington" |
| 10. CLIA | 26. "Seattle Flu study" |
| 11. RNA | 27. Greiner |
| 12. Extraction | 28. POTUS |
| 13. Quest | 29. Reagent 30. 564 |
| 14. LabCorp | 30. 564(b) |
| 15. Roche | 31. "mainland China" |
| 16. Qiogen | 32. "close contact" |
| | 33. "issue guidance" |

HHS Officials:

1. Assistant Secretary for Health Brett Giroir
2. Anyone serving as Chief of Staff to Assistant Secretary for Health Giroir, including, but not limited to, Carla Haddad
3. Principal Deputy Assistant Secretary for Health Sylvia Trent-Adams
4. Deputy Assistant Secretary for Health Paul Reed
5. Assistant Secretary for Preparedness & Response Robert Kaldec
6. Principal Deputy Assistant Secretary for Preparedness & Response Kevin Yeskey
7. Deputy Assistant Secretary for Preparedness & Response & BARDA Director Rick Bright

FDA Officials:

1. Jeffrey Shuren, Director of the Center for Devices and Radiological Health
2. William Maisel, Director of the Office of Product Evaluation and Quality
3. Timothy Stenzel, Office of Health Technology 7 (In Vitro Diagnostics and Radiological Health)
4. Denise Hinton, Chief Scientist
5. Uwe Scherf, Director, Division of Microbiology Devices, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health

Case No. 2020-00719-FOIA-OS
American Oversight v. HHS, Civil No. 20-cv-00947

CDC Officials:

1. Robert Redfield, Director
2. Anne Schuchat, Principal Deputy Director
3. Stephen Lindstrom, Team Lead, Respiratory Virus Diagnostics Team, Centers for Disease Control and Prevention
4. Daniel Jernigan, Influenza Division at Centers for Disease Control and Prevention
5. Toby Merlin, Director, Division of Preparedness and Emerging Infections (DPEI)
6. Mark Frank, Deputy Director, Division of Emergency Operations at Centers for Disease Control and Prevention

During the course of litigation, American Oversight modified the scope of its request.

The Department processed **641 pages** of potentially responsive records captured in the agency's search for FOIA request 2020-00719-FOIA-OS. After a careful review of these pages, I have determined to release **99 pages** to you in their entirety, I am further releasing **208 pages** in part, with portions redacted, pursuant to Exemptions (b)(4), (b)(5), and (b)(6) of the FOIA (5 U.S.C. §552 (b)(5) and (b)(6)). Furthermore, I have determined that **334 pages** should be sent for consultation to others and returned to this Department for final disposition.


FOIA exemption (b)(4) permits agencies, as a matter of discretion, to withhold trade secrets and commercial or financial information obtained from a person which is privileged or confidential.

FOIA exemption (b)(5) protects inter-agency or intra-agency memoranda or letters which would not be available by law to a party other than an agency in litigation with the agency. This exemption protects documents that would be covered by any privilege an agency could assert in a civil proceeding. These privileges include, among others, the deliberative process privilege, the attorney-client privilege, the attorney work-product privilege and the presidential communications privilege.

FOIA exemption (b)(6) permits a Federal agency to withhold information and records about individuals in "personnel and medical files and similar files, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy." The definition of "similar files" has historically been broadly interpreted to include a wide variety of files, and the United States Supreme Court has held that Congress intended the term "similar files" to be interpreted broadly, rather than narrowly. I have analyzed these records and find they meet the threshold requirement of this exemption. Additionally, I have reviewed and weighed the public interest in disclosure of this information against the privacy interest in nondisclosure, and found that the privacy interest outweighs the public's interest in disclosure.

We will continue to review the remaining records as efficiently and expeditiously as possible, consistent with our available resources. Should you have questions or concerns regarding the Department's response and/or the processing of your request, any such issues should be communicated to your legal counsel and Department of Justice Attorney representing the Department in this matter.

Sincerely yours,



for
Brandon J. Gaylord
Director
FOI/Privacy Division

Enclosure(s)

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Pratt, Michael (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c8eed0423de458d801882c30fd16c99-Pratt, Mich>
CC:	Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; ASPA-Deputies </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=884d75c735db47cca76a4c0fc74a06b8-ASPA-Deputi>; Bonds, Michelle E. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=458a7c66b66a4e9ca7bc1963da0bcb81-michelle.bo>
Subject:	RE: Social monitoring - testing
Date:	2020/03/10 22:40:00
Priority:	Normal
Type:	Note

Ok

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Pratt, Michael (OS/ASPA) <Michael.Pratt@hhs.gov>

Sent: Tuesday, March 10, 2020 10:36 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Cc: Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; ASPA-Deputies <ASPA-Deputies@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>

Subject: Re: Social monitoring - testing

More:

<https://twitter.com/ncdhhs/status/1237408712559669250?s=21>

<https://twitter.com/billkristol/status/1237566901603065858?s=21>

<https://twitter.com/jsodonoghue/status/1237562508258340869?s=21>

Sent from my iPhone

On Mar 10, 2020, at 8:28 PM, Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>wrote:

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Sent: Tuesday, March 10, 2020 8:24 PM

To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>

Cc: Pratt, Michael (OS/ASPA) <Michael.Pratt@hhs.gov>; ASPA-Deputies <ASPA-Deputies@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>

Subject: Re: Social monitoring - testing

(b)(5)

Sent from my iPhone

On Mar 10, 2020, at 7:37 PM, Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>wrote:

☐

(b)(5)

On Mar 10, 2020, at 6:34 PM, Pratt, Michael (OS/ASPA)
<Michael.Pratt@hhs.gov>wrote:

□

<https://twitter.com/jaketapper/status/123750045222222336>

Jake Tapper

@jaketapper Washington firefighters who responded to nursing home face longer quarantine as bottlenecks delay testing:

<https://t.co/tmgYJ3ijbv?amp=1>

<https://twitter.com/jaketapper/status/1237489777118674944>

Jake Tapper

@jaketapper

CNN's @OmarJimenez reports that a spokesman for Life Care Center in Kirkland WA says the nursing facility has finally begun testing employees after what many considered a long delay. Test results are not yet available for 30 employees who were tested off site.

1/

<https://twitter.com/NitzaSoledad/status/123750274196819149>

0

Nitza Soledad Perez

@NitzaSoledad

While Germany has drive-in testing facilities, ppl in the US struggle to get screened for coronavirus. Health and Human Services □

@SecAzar

□ just said to the public that there is a surplus of tests. The misinformation from the White House continues. #COVID19 #coronavirus

<https://twitter.com/markknoller/status/1237502685839945728>

Mark Knoller

@markknoller

Though millions of Coronavirus tests are being produced, @SecAzar says persons who want to be tested need to go through their doctor or hospital and cannot just demand a test. Stresses persons should call their doctor and ask to be considered for a Coronavirus test.

<https://twitter.com/chrislhayes/status/1237502187762257931>

Chris Hayes

@chrislhayes

Hey doctors: as @SecAzar says there's actually a "surplus" of tests available, I'm curious if this your experience at point of care as of today, March 10th.

<https://twitter.com/laallergydoc/status/1237503671534927872>

Marc Meth, MD

@chrislhayes The answer is no. I've tried to get swabs to actually perform the testing if needed to give to Quest or Labcorp and there are NONE available.

<https://twitter.com/rcbutter1/status/1237502598791512065>

RB

@rcbutter1

No! I cant keep hearing these answers. I'm a primary care doctor in Albany, NY. There are no tests unless a patient meets strict criteria which DO NOT include travel to Seattle, Westchester or California!

<https://twitter.com/MORDE110/status/1237503914703904768>

MORDE1

@MORDE110

Untrue.

Sick patients must meet a critical 3+ level to be tested in California.

[https://twitter.com/MollyJongFast/status/12375027694955069](https://twitter.com/MollyJongFast/status/1237502769495506946)

46

Molly Jong-Fast

@MollyJongFast

"there are millions of tests out there now," say @SecAzar but this doesn't sound right

Michael J. Pratt

Director, Strategic Communications & Campaigns
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health and Human Services

michael.pratt@hhs.gov

202.690.7471 | 202.875.0956 (m)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Pratt, Michael (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c8eed0423de458d801882c30fd16c99-Pratt, Mich>;

	Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; ASPA-Deputies </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=884d75c735db47cca76a4c0fc74a06b8-ASPA-Deputi>; Bonds, Michelle E. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=458a7c66b66a4e9ca7bc1963da0bcb81-michelle.bo>
Sent Date:	2020/03/10 22:40:39
Delivered Date:	2020/03/10 22:40:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1e50fbf05c64442fb27c1dd6897ea0a6-Brooks, Joh>
CC:	Meaney Delman, Dana M. (CDC/DDID/NCBDDD/DBDID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=07bb5761d38348fcaa1881a0255ba2c9-dana.meaney>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e5650d24c4b64bf5aaee4e3fe0799026-Armstrong,>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>
Subject:	RE: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo CONTAINMENT_3_8_2020_JB_DMD
Date:	2020/03/09 18:15:00
Priority:	Normal
Type:	Note

OK I am on it

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Sent: Monday, March 9, 2020 5:03 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>
Cc: Meaney Delman, Dana M. (CDC/DDID/NCBDDD/DBDID) <vmo0@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Subject: RE: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo CONTAINMENT_3_8_2020_JB_DMD

(b)(5)

Dan.

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Monday, March 9, 2020 5:01 PM

To: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Cc: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>

Subject: RE: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo
CONTAINMENT_3_8_2020_JB_DMD

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Sent: Monday, March 9, 2020 3:41 PM


To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Cc: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>


Subject: RE: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo
CONTAINMENT_3_8_2020_JB_DMD

(b)(5)

(b)(5)



John T. Brooks, MD – Chief Medical Officer
CDC Division of HIV/AIDS Prevention
1600 Clifton Road NE, Mailstop D-21
Atlanta, GA 30333
Desk: 404-639-3894
Cell: (b)(6)
Email: zud4@cdc.gov



From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Monday, March 9, 2020 2:07 PM

To: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>

Subject: RE: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo
CONTAINMENT_3_8_2020_JB_DMD

Sure

I am on 12 in Mitch Wolff office

My mobile is (b)(6)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>
Sent: Monday, March 9, 2020 2:05 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Re: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo
CONTAINMENT_3_8_2020_JB_DMD

(b)(5)

John T. Brooks, MD - Chief Medical Officer
CDC, Division of HIV/AIDS Prevention
1600 Clifton Road NE, Mailstop D-21
Atlanta, GA. 30319
404-639-3894

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Monday, March 9, 2020 1:56:47 PM
To: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: RE: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo
CONTAINMENT_3_8_2020_JB_DMD

THANK YOU.

(b)(5)

I am here on 12 and able to chat in person or by phone

BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Sent: Monday, March 9, 2020 1:38 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>

Subject: RE: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo
CONTAINMENT_3_8_2020_JB_DMD

(b)(5)



(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Monday, March 9, 2020 9:29 AM

To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Subject: RE: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo
CONTAINMENT_3_8_2020_JB_DMD

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

From: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Sent: Monday, March 9, 2020 8:48 AM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Subject: Guidance for Termination of Isolation Precautions COVID-19 - Decision Memo
CONTAINMENT_3_8_2020_JB_DMD

ADM Giroir:

(b)(5)

(b)(5)

Dan.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1e50fbf05c64442fb27c1dd6897ea0a6-Brooks, Joh>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=07bb5761d38348fcaa1881a0255ba2c9-dana.meaney>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e5650d24c4b64bf5aaee4e3fe0799026-Armstrong,>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>
Sent Date:	2020/03/09 18:15:29
Delivered Date:	2020/03/09 18:15:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>
Subject:	RE: important for tonight
Date:	2020/03/12 19:45:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>
Sent: Thursday, March 12, 2020 7:44 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: important for tonight

Sir

(b)(5)

Laura

Laura Caliguiri

Associate Commissioner for External Affairs

Office of External Affairs
U.S. Food and Drug Administration
Tel: 301 796-8546
Laura.Caliguiri@fda.hhs.gov



[cid:image001.png@01D1C57E.DFA022A0](#)

[cid:image002.jpg@01D1C57E.DFA022A0](#)
[cid:image003.jpg@01D1C57E.DFA022A0](#)
[cid:image004.jpg@01D1C57E.DFA022A0](#)
[cid:image005.jpg@01D1C57E.DFA022A0](#)
[cid:image006.jpg@01D1C57E.DFA022A0](#)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Caliguir, Laura <Laura.Caliguir@fda.hhs.gov>
Sent Date:	2020/03/12 19:45:23
Delivered Date:	2020/03/12 19:45:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject:	RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!
Date:	2020/03/05 16:06:00
Priority:	Normal
Type:	Note

On it

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Thursday, March 5, 2020 4:04 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: FW: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

FYI

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Thursday, March 5, 2020 4:02 PM
To: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Cc: Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>
Subject: Fwd: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

Keagan. See urgent email from IDT

From: Terrill, Roman <rterill@idtdna.com>
Date: March 5, 2020 at 3:58:22 PM EST
To: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>, Kuhnert-Tallman, Wendi L (CDC) <wdk1@cdc.gov>, Lindstrom, Stephen (CDC) <sql5@cdc.gov>, Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Cc: Villanueva, Julie M (CDC) <jfv3@cdc.gov>, Flannery, Ellen <Ellen.Flannery@fda.hhs.gov>, Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>, Jernigan, Daniel B (CDC) <dbj0@cdc.gov>
Subject: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

To my friends at FDA and CDC, and elsewhere within HHS:

Just to raise to your attention of the urgency of the time and the matter.

If IDT receives confirmation of IDT's permission to ship kits from (b)(4)

(b)(4)

If does not receive said confirmation of its permission to ship kits from (b)(4)

(b)(4)

I'm not prone to the dramatic, but the circumstances warrant it.

Please advise ASAP.

Thanks,

Roman

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent Date:	2020/03/05 16:06:11
Delivered Date:	2020/03/05 16:06:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Pratt, Michael (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c8eed0423de458d801882c30fd16c99-Pratt, Mich>; Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>
CC:	Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>
Subject:	RE: CLEARANCE_0248: CDC "Coronavirus Disease 2019 (COVID-19) Update: Diagnostic test supplies"
Date:	2020/03/12 10:17:00
Priority:	Normal
Type:	Note

concur

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Pratt, Michael (OS/ASPA) <Michael.Pratt@hhs.gov>
Sent: Thursday, March 12, 2020 10:14 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>
Cc: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Subject: FW: CLEARANCE_0248: CDC "Coronavirus Disease 2019 (COVID-19) Update: Diagnostic test supplies"

(b)(5)

From: OS HHSPress (HHS/ASPA) <HHSPress@hhs.gov>
Sent: Thursday, March 12, 2020 10:07 AM
To: Campbell, Taylor (OS/OASH) <Taylor.Campbell@hhs.gov>; OS - ASPA - Clearance <OS.ASPA-Clearance@hhs.gov>; OS OGC-IO ControlDesk (HHS/OS/OGC) <ControlDesk.OGCIO@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Steele, Danielle (HHS/IOS) <Danielle.Steele@hhs.gov>; White, Caroline (HHS/OGC) <Caroline.White@hhs.gov>; Stimson, Brian (HHS/OGC) <Brian.Stimson@hhs.gov>; Charrow, Robert

(HHS/OGC) <Robert.Charrow@hhs.gov>; Keveney, Sean (HHS/OGC) <Sean.Keveney@hhs.gov>; Chang, William (HHS/OGC) <William.Chang@hhs.gov>; Barry, Daniel J (HHS/OGC) <daniel.barry@hhs.gov>; Amin, Stacy (FDA/OC) <Stacy.Amin@fda.hhs.gov>; ASPRCOMMS <ASPRCOMMS@hhs.gov>; ASPRMEDIA (OS/ASPR/COO) <ASPRMEDIA@hhs.gov>; Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>; Wojtowicz, Emma (NIH/OD) [E] <emma.wojtowicz@nih.gov>; Akinso, Woleola (NIH/OD) [E] <akinsow@od.nih.gov>; Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>; Fritz, Craig (NIH/OD) [E] <craig.fritz@nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Channer, Amber (OS/OASH) <Amber.Channer@hhs.gov>; Heck, Mia (HHS/OASH) <Mia.Heck@hhs.gov>; Kotwicki, Lauren (HHS/OASH) <Lauren.Kotwicki@hhs.gov>; Migliaccio-Grabill, Kate (HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>; Sherman, Jennifer (HHS/OASH) <Jennifer.Sherman@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meh0@cdc.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Heldman, Amy B. (CDC/OD/OADC) <evd4@cdc.gov>; Patrick, Kera (CDC/OD/OADC) <ihn7@cdc.gov>; CDC OADC ASPA Clearance <OADCASPAClearance@cdc.gov>
Cc: Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; 2019-nCoV FDA IMG JIC <2019-nCoVFDAMGJIC@fda.hhs.gov>; OCOEAOMA-Press (FDA) <OCOEAOMA-Press@fda.hhs.gov>; OS HHSPress (HHS/ASPA) <HHSPress@hhs.gov>
Subject: RE: CLEARANCE_0248: CDC "Coronavirus Disease 2019 (COVID-19) Update: Diagnostic test supplies"

Hi

(b)(5)

V/r,

From: OS HHSPress (HHS/ASPA)

Sent: Wednesday, March 11, 2020 3:13 PM

To: OS - ASPA - Clearance <OS.ASPA-Clearance@hhs.gov>; OS OGC-IO ControlDesk (HHS/OS/OGC) <ControlDesk.OGCIO@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Steele, Danielle (HHS/IOS) <Danielle.Steele@hhs.gov>; White, Caroline (HHS/OGC) <Caroline.White@hhs.gov>; Stimson, Brian (HHS/OGC) <Brian.Stimson@hhs.gov>; Charrow, Robert (HHS/OGC) <Robert.Charrow@hhs.gov>; Keveney, Sean (HHS/OGC) <Sean.Keveney@hhs.gov>; Chang, William (HHS/OGC) <William.Chang@hhs.gov>; Barry, Daniel J (HHS/OGC) <daniel.barry@hhs.gov>; Amin, Stacy (FDA/OC) <Stacy.Amin@fda.hhs.gov>; ASPRCOMMS <ASPRCOMMS@hhs.gov>; ASPRMEDIA (OS/ASPR/COO) <ASPRMEDIA@hhs.gov>; Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>; Wojtowicz, Emma

(NIH/OD) [E] <emma.wojtowicz@nih.gov>; Akinso, Woleola (NIH/OD) [E] <akinsow@od.nih.gov>; Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>; Fritz, Craig (NIH/OD) [E] <craig.fritz@nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Channer, Amber (OS/OASH) <Amber.Channer@hhs.gov>; Heck, Mia (HHS/OASH) <Mia.Heck@hhs.gov>; Kotwicki, Lauren (HHS/OASH) <Lauren.Kotwicki@hhs.gov>; Migliaccio-Grabill, Kate (HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>; Sherman, Jennifer (HHS/OASH) <Jennifer.Sherman@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Heldman, Amy B. (CDC/OD/OADC) <evd4@cdc.gov>; Patrick, Kera (CDC/OD/OADC) <ihn7@cdc.gov>; CDC OADC ASPA Clearance <OADCASPAclearance@cdc.gov>
Cc: OS HHSPress (HHS/ASPA) <HHSPress@hhs.gov>; Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>; 2019-nCoV FDA IMG JIC <2019-nCoVFDAIMGJIC@fda.hhs.gov>; OCOEAOMA-Press (FDA) <OCOEAOMA-Press@fda.hhs.gov>

Subject: CLEARANCE_0248: CDC "Coronavirus Disease 2019 (COVID-19) Update: Diagnostic test supplies"

Importance: High

(b)(5)

V/r,

Mike Robinson
Strategic Planning, ASPA

202-690-6885 –desk
(b)(6) –mobile

**INTERNAL HHS USE ONLY! INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS
AUTHORIZED BY LAW:**

This information has not been publically disclosed and may be privileged and confidential. This document must not be disseminated, distributed, or copied to persons not authorized to receive the information. Unauthorized disclosure may result in prosecution to the full extent of the law.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Pratt, Michael (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c8eed0423de458d801882c30fd16c99-Pratt, Mich>; Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>
Sent Date:	2020/03/12 10:17:05
Delivered Date:	2020/03/12 10:17:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	OS Secretarys Operations Center </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=32b1f28d808b43b6903c00083291303e-Secretarys>
Subject:	RE: Summary: Presumptive positive case of COVID-19 in Massachusetts
Date:	2020/03/02 23:15:00
Priority:	Normal
Type:	Note

Copy

Thank you

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: OS Secretarys Operations Center <hhs.soc@hhs.gov>
Sent: Monday, March 2, 2020 11:08 PM
To: OS Secretarys Operations Center <hhs.soc@hhs.gov>
Subject: Summary: Presumptive positive case of COVID-19 in Massachusetts

Good evening Dr. Kadlec,

BLUF: - The Massachusetts Department of Public Health today announced its first presumptive positive case of COVID-19 since testing started Friday, 28Feb20, at the State Public Health Laboratory.

- The presumptive positive case is a woman is in her 20s and lives in Norfolk County.
- She recently traveled to Italy with a school group and was symptomatic. She is recovering at home.
- The individual's test results came back positive just this evening. Specimens will be sent to the US Centers for Disease Control and Prevention (CDC) and, if confirmed, this would be the second confirmed positive COVID-19 case in Massachusetts since the outbreak started in the US in January.
- The risk to the public from COVID-19 remains low in Massachusetts.

- Since January, Massachusetts public health officials have tested 12 residents, including the first confirmed case and now the first presumptive positive case. Of those 12, three people have been tested since Friday when the State Public Health Laboratory began testing patients for COVID-19, in accordance with CDC guidelines, after the US Food and Drug Administration gave its approval to use the test kits.
- As of last week, 608 people have been subject to self-quarantine in Massachusetts because of COVID-19. Of those, 377 people have completed monitoring and are no longer quarantined, while 231 are currently quarantined.
- SOC has notified CDC EOC, and is awaiting confirmation/awareness of the situation from the PUI team.

*This notification is limited distribution and is intended for HHS Senior Leadership only. **Do not forward.** This notification was sent to the COVID-19 Senior Leadership distribution list.*

Very Respectfully,

Secretary's Operations Center

U.S. Department of Health and Human Services (HHS)
 Assistant Secretary for Preparedness and Response (ASPR)
 200 Independence Ave. S.W.
 Washington D.C. 20201
 Office (202) 619-7800
 Fax: 800-514-4256
 Email: hhs.soc@hhs.gov

<< OLE Object: Picture (Device Independent Bitmap) >>

Data enclosed in this email are subject to the Privacy Act of 1974, as amended. Contents shall not be disclosed, discussed, or shared with individuals unless they have a direct need-to-know in the performance of their official duties. Unauthorized disclosure of this information may result in civil or criminal penalties.

CONFIDENTIALITY NOTICE: This e-mail communication and any attachments may contain confidential and privileged information for the use of the designated recipients. If you are not the intended recipient, (or authorized to receive for the recipient) you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please destroy all copies of this communication and any attachments and contact the sender by reply e-mail or telephone (202-619-7800).

UNCLASSIFIED // FOR OFFICIAL USE ONLY

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	OS Secretarys Operations Center </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=32b1f28d808b43b6903c00083291303e-Secretarys>
Sent Date:	2020/03/02 23:15:26
Delivered Date:	2020/03/02 23:15:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
CC:	Steele, Danielle (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=38849c1f1ea74f2eb9eff75b531a9544-Steele, Dan>
Subject:	RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!
Date:	2020/03/05 16:12:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Thursday, March 5, 2020 4:04 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: FW: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

FYI

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Thursday, March 5, 2020 4:02 PM
To: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Cc: Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>
Subject: Fwd: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

(b)(5)

From: Terrill, Roman <rterrill@idtdna.com>
Date: March 5, 2020 at 3:58:22 PM EST
To: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>, Kuhnert-Tallman, Wendi L (CDC) <wdk1@cdc.gov>, Lindstrom, Stephen (CDC) <sql5@cdc.gov>, Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Cc: Villanueva, Julie M (CDC) <jfv3@cdc.gov>, Flannery, Ellen <Ellen.Flannery@fda.hhs.gov>, Schwartz,

Suzanne <Suzanne.Schwartz@fda.hhs.gov>, Jernigan, Daniel B (CDC) <dbj0@cdc.gov>

Subject: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

To my friends at FDA and CDC, and elsewhere within HHS:

Just to raise to your attention of the urgency of the time and the matter.

If IDT receives confirmation of IDT's permission to ship kits from (b)(4)

(b)(4)

If does not receive said confirmation of its permission to ship kits from (b)(4)

(b)(4)

I'm not prone to the dramatic, but the circumstances warrant it.

Please advise ASAP.

Thanks,

Roman

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Steele, Danielle (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=38849c1f1ea74f2eb9eff75b531a9544-Steele, Dan>
Sent Date:	2020/03/05 16:12:24
Delivered Date:	2020/03/05 16:12:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Schwartz, Suzanne (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bce62c458594ca8b15ecc04fe792094-suzanne.sch>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bced884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>
Subject:	RE: IDT Call
Date:	2020/03/06 12:58:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Sent: Friday, March 6, 2020 12:54 PM

To: Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>; Haddad, Carla (HHS/OASH) <Carla.Haddad@hhs.gov>

Subject: RE: IDT Call

(b)(5)

Best,

Tim

Timothy T. Stenzel, MD, PhD

Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

Center for Devices and Radiological Health

U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration

White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993

Ph: 301-796-7692

Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>

Sent: Friday, March 6, 2020 12:52 PM

To: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Giroir, Brett (OS) <Brett.Giroir@hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>; Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>; Haddad, Carla (OS) <Carla.Haddad@hhs.gov>

Subject: RE: IDT Call

Thank you, Tim.

(b)(5)

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Sent: Friday, March 6, 2020 11:27 AM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>; Haddad, Carla (HHS/OASH) <Carla.Haddad@hhs.gov>

Cc: Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>

Subject: RE: IDT Call

(b)(5)

Best,
Tim

Timothy T. Stenzel, MD, PhD

Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

Center for Devices and Radiological Health
U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration

White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993

Ph: 301-796-7692

Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

-----Original Appointment-----

From: Gray, Oneika (HHS/OASH) <Oneika.Gray@hhs.gov> **On Behalf Of** Giroir, Brett (HHS/OASH)

Sent: Friday, March 6, 2020 10:57 AM

To: Stenzel, Timothy; Lenihan, Keagan; Berger, Sherri (CDC); Monroe, Stephan S (CDC); Schuchat, Anne (CDC); Schwartz, Suzanne; Shuren, Jeff; Haddad, Carla (OS)

Cc: Kellogg, Rachel (OS)

Subject: IDT Call

When: Friday, March 6, 2020 11:00 AM-11:15 AM (UTC-05:00) Eastern Time (US & Canada).

Where: ASH Conference Room; 716G ; (b)(6) Participants (b)(6)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Stenzel, Timothy < Timothy.Stenzel@fda.hhs.gov >; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Schwartz, Suzanne (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bce62c458594ca8b15ecc04fe792094-suzanne.sch>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bced884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>
Sent Date:	2020/03/06 12:58:17
Delivered Date:	2020/03/06 12:58:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	McKeogh, Katherine (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c652f2c415b44dff8369dd7f4596f030-McKeogh, Ka>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Caccamo, Stephanie (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3b415b3f6cff4b18980c5f723fad2ce0-stephanie.c>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>
Subject:	RE: WSJ questions on COVID-19 test capacity
Date:	2020/03/07 07:14:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>
Sent: Saturday, March 7, 2020 12:44 AM
To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: RE: WSJ questions on COVID-19 test capacity

(b)(5)

From: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Sent: Friday, March 6, 2020 10:05 AM
To: OS Media (HHS/ASPA) <media@hhs.gov>; CDC OADC Media Review <OADCMediaReview@cdc.gov>; ASPRCOMMS <ASPRCOMMS@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>
Subject: RE: WSJ questions on COVID-19 test capacity

(b)(5)

From: OS Media (HHS/ASPA) <media@hhs.gov>
Sent: Friday, March 6, 2020 9:24 AM
To: CDC OADC Media Review <OADCMediaReview@cdc.gov>; ASPRCOMMS <ASPRCOMMS@hhs.gov>
Cc: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; OS Media (HHS/ASPA) <media@hhs.gov>
Subject: FW: WSJ questions on COVID-19 test capacity

From: Loftus, Peter <peter.loftus@wsj.com>
Sent: Friday, March 6, 2020 8:38 AM
To: OS Media (HHS/ASPA) <media@hhs.gov>
Subject: WSJ questions on COVID-19 test capacity

Hello, can HHS provide an update for Friday, 3/6, on the current U.S. testing capacity for the new coronavirus? Will the U.S. meet the goal of one million tests by the end of this week, as laid out this week by FDA Commissioner Hahn and Secretary Azar (who also said that would be enough for about 400,000 people)?


Can you say how many CDC test kits have been shipped to public health labs so far?

Also, VP Pence said yesterday there are not enough tests to meet anticipated demand - can you comment on that?


This is for a story likely to run later today.

--

Peter Loftus
REPORTER

 Image removed by sender. The Wall Street Journal

M: (b)(6) O: +1 215 881 7127
E: peter.loftus@wsj.com
Twitter: @Loftus

 Image removed by sender. Dow Jones

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	McKeogh, Katherine (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c652f2c415b44dff8369dd7f4596f030-McKeogh, Ka>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Caccommo, Stephanie (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3b415b3f6cff4b18980c5f723fad2ce0-stephanie.c>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>
Sent Date:	2020/03/07 07:14:47
Delivered Date:	2020/03/07 07:14:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Pollard, Ashton (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9d4c26448ed441b0aa555971f3c73d6d-Pollard, As>
CC:	Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>; Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Valentine, Steven (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd508090f8984b1caf04069bc6000dc2-Valentine,>
Subject:	RE: Outtakes from Call with Kaiser Permanente and HCA
Date:	2020/03/08 16:31:00
Priority:	Normal
Type:	Note

Thank you

I will be at CDC but will prioritize this to attend virtually (you may have CDC people doing the same and I can join them).

Ashton – if you have materials, please send today if possible

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>
Sent: Sunday, March 8, 2020 4:30 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Pollard, Ashton (OS/IOS) <Ashton.Pollard@hhs.gov>
Cc: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Brookes, Brady (CMS/OA) <Brady.Brookes@cms.hhs.gov>; Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; CMS SV1 <SV1@cms.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Harrison, Brian (HHS/IOS) <Brian.Harrison@hhs.gov>; Herrmann, Jack (OS/ASPR/OEA) <John.Herrmann@hhs.gov>
Subject: Re: Outtakes from Call with Kaiser Permanente and HCA

ADM- we'll get you an invite to the PMO meeting at 1100am and will welcome your participation on these issues if you are available. Ashton please note

Sent from my iPhone

On Mar 8, 2020, at 3:59 PM, Giroir, Brett (HHS/OASH)
<Brett.Giroir@hhs.gov>wrote:

☐
(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>
Sent: Sunday, March 8, 2020 2:45 PM
To: Brookes, Brady (CMS/OA) <Brady.Brookes@cms.hhs.gov>
Cc: Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; CMS SV1 <SV1@cms.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Harrison, Brian (HHS/IOS) <Brian.Harrison@hhs.gov>; Herrmann, Jack (OS/ASPR/OEA) <John.Herrmann@hhs.gov>; Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>
Subject: Re: Outtakes from Call with Kaiser Permanente and HCA

(b)(5)

Sent from my iPhone

On Mar 8, 2020, at 2:04 PM, Brookes, Brady (CMS/OA)
<Brady.Brookes@cms.hhs.gov>wrote:

☐

+ The Administrator

Confidential and deliberative, pre-decisional communication

From: Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
Sent: Sunday, March 8, 2020 1:59 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Harrison, Brian (HHS/IOS) <Brian.Harrison@hhs.gov>; Brookes, Brady (CMS/OA) <Brady.Brookes@cms.hhs.gov>; Herrmann, Jack (OS/ASPR/OEA) <John.Herrmann@hhs.gov>; Harrison, Brian (HHS/IOS) <Brian.Harrison@hhs.gov>; Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>
Subject: Outtakes from Call with Kaiser Permanente and HCA
Importance: High

(b)(5)



(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Pollard, Ashton (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9d4c26448ed441b0aa555971f3c73d6d-Pollard, As>; Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>; Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Valentine, Steven (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd508090f8984b1caf04069bc6000dc2-Valentine,>
Sent Date:	2020/03/08 16:31:42
Delivered Date:	2020/03/08 16:31:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
CC:	Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Schwartz, Suzanne (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bce62c458594ca8b15ecc04fe792094-suzanne.sch>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	RE: IDT Call
Date:	2020/03/06 12:58:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Friday, March 6, 2020 11:52 AM
To: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>; Haddad, Carla (HHS/OASH) <Carla.Haddad@hhs.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>
Subject: Re: IDT Call

(b)(5)

Sent from my iPhone

On Mar 6, 2020, at 11:26 AM, Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov> wrote:

(b)(5)

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

**Center for Devices and Radiological Health
U.S. Food and Drug Administration**

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

-----Original Appointment-----

From: Gray, Oneika (HHS/OASH) <Oneika.Gray@hhs.gov> **On Behalf Of** Giroir, Brett (HHS/OASH)

Sent: Friday, March 6, 2020 10:57 AM

To: Stenzel, Timothy; Lenihan, Keagan; Berger, Sherri (CDC); Monroe, Stephan S (CDC); Schuchat, Anne (CDC); Schwartz, Suzanne; Shuren, Jeff; Haddad, Carla (OS)

Cc: Kellogg, Rachel (OS)

Subject: IDT Call

When: Friday, March 6, 2020 11:00 AM-11:15 AM (UTC-05:00) Eastern Time (US & Canada).

Where: ASH Conference Room; 716G ; (b)(6) Participants (b)(6)

<LAB TESTING UPDATE 3.6.20 V2 UPDATED Tim.docx>

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Lenihan, Keagan < Keagan.Lenihan@fda.hhs.gov >;

	<p>Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Schwartz, Suzanne (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bce62c458594ca8b15ecc04fe792094-suzanne.sch>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bced884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra></p>
Sent Date:	2020/03/06 12:58:46
Delivered Date:	2020/03/06 12:58:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Boehler, Adam <Adam.Boehler@dfc.gov>
Subject:	FW: Urgent -- Coronavirus Test Kits
Date:	2020/03/14 09:50:00
Importance:	High
Priority:	Urgent
Type:	Note

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Giroir, Brett (HHS/OASH)
Sent: Friday, March 13, 2020 4:56 PM
To: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Brett Giroir (HHS/OASH) (Brett.Giroir@hhs.gov) <Brett.Giroir@hhs.gov>
Subject: FW: Urgent -- Coronavirus Test Kits
Importance: High

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Bradshaw, Sheldon <SBradshaw@KSLAW.com>
Sent: Friday, March 13, 2020 3:53 PM
To: HHS ASH (HHS/OASH) <ASH@hhs.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>

Subject: Urgent -- Coronavirus Test Kits
Importance: High

Dr. Giroir and Rachel,

Based on my prior experience as Chief Counsel of the FDA, I know how busy you are right now and would not be writing unless it was urgent. (b)(4)

(b)(4)

Sheldon

(b)(4)

Sheldon Bradshaw

Partner

King & Spalding LLP

1700 Pennsylvania Ave., NW | Washington, DC 20006

📞 +1 202.626.9225 | 📠 +1 202.626.3737 | ✉️ sbradshaw@kslaw.com

King & Spalding Confidentiality Notice:

This message is being sent by or on behalf of a lawyer. It is intended exclusively for the individual or entity to which it is addressed. This communication may contain information that is proprietary, privileged or confidential or otherwise legally exempt from disclosure. If you are not the named addressee, you are not authorized to read, print, retain, copy or disseminate this message or any part of it. If you have received this message in error, please notify the sender immediately by e-mail and delete all copies of the message. [Click here to view our Privacy Notice.](#)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
----------------	---

Recipient:	Boehler, Adam <Adam.Boehler@dfc.gov>
Sent Date:	2020/03/14 09:51:26
Delivered Date:	2020/03/14 09:50:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Dreyzehner, John (CDC/DDPHSIS/CPR/OD) <PWN3@cdc.gov>
Subject:	RE: Your Question RE:IEA/CDC call
Date:	2020/03/11 06:34:00
Priority:	Normal
Type:	Note

John

(b)(5)

Thank you

BG

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

From: Dreyzehner, John (CDC/DDPHSIS/CPR/OD) <PWN3@cdc.gov>

Sent: Tuesday, March 10, 2020 11:33 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Subject: Your Question RE:IEA/CDC call

Good evening Adm Giroir,

(b)(5)

(b)(5)

Hope that helps, more to come.

Best regards,
John

John J. Dreyzehner, MD, MPH, FACOEM
Director
Center for Preparedness and Response
Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE MS H21-6, Atlanta, GA 30329
404-718-3793
E-mail: jdreyzehner@cdc.gov



Image

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Tuesday, March 10, 2020 8:29 PM
To: Trueman, Laura (HHS/IEA); White, Susan (CDC/ONDIEH/NCCDPHP); Beck, Gary

(OS/IEA)

Cc: Anderson, Jade (CDC/DDPHSIS/CPR/DSLR); Murphy, Ryan (OS/ASPA)

Subject: RE: IEA/CDC call

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: [202-690-7694](tel:202-690-7694)

From: Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>

Sent: Tuesday, March 10, 2020 8:25 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; White, Susan (CDC/ONDIEH/NCCDPHP) <sfw5@cdc.gov>; Beck, Gary (OS/IEA) <Gary.Beck@hhs.gov>

Cc: Anderson, Jade (CDC/DDPHSIS/CPR/DSLR) <ypm6@cdc.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>

Subject: Re: IEA/CDC call

(b)(5)

On: 10 March 2020 18:49,

"Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>wrote:

Good evening,

(b)(5)

Many thanks

BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Sent: Tuesday, March 10, 2020 6:03 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: IEA/CDC call

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Dreyzehner, John (CDC/DDPHSIS/CPR/OD) <PWN3@cdc.gov>
Sent Date:	2020/03/11 06:34:15
Delivered Date:	2020/03/11 06:34:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Steve Hahn <SH1@fda.hhs.gov>; Johnston, Darcie (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6a8047840ca4406b5ac6bc5cf259937-Johnston, D>
CC:	Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Lenihan, Keagan (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7aa9d3462c324d65a1da026ba1e76aa5-Lenihan, Ke>
Subject:	RE: FYSA
Date:	2020/03/12 20:22:00
Priority:	Normal
Type:	Note

copy

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

-----Original Message-----

From: Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
 Sent: Thursday, March 12, 2020 8:01 PM
 To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Steve Hahn <SH1@fda.hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>
 Cc: Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Lenihan, Keagan (HHS/IOS) <Keagan.Lenihan@hhs.gov>
 Subject: FYSA

S1 called Mayor DeBlasio called ref testing COVID-19 shortage of test kits and reagent. S1 asked Darcie to connect Tim atFDA to provide TA.

Sent from my iPhone

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Steve Hahn <SH1@fda.hhs.gov>; Johnston, Darcie (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6a8047840ca4406b5ac6bc5cf259937-Johnston, D>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Lenihan, Keagan (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7aa9d3462c324d65a1da026ba1e76aa5-Lenihan, Ke>
Sent Date:	2020/03/12 20:22:45
Delivered Date:	2020/03/12 20:22:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>
CC:	McKeogh, Katherine (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c652f2c415b44dff8369dd7f4596f030-McKeogh, Ka>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Caccamo, Stephanie (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3b415b3f6cff4b18980c5f723fad2ce0-stephanie.c>
Subject:	RE: WSJ questions on COVID-19 test capacity
Date:	2020/03/07 07:19:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>
Sent: Saturday, March 7, 2020 7:18 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>
Subject: Re: WSJ questions on COVID-19 test capacity

(b)(5)

Sent from my iPhone

On Mar 7, 2020, at 7:14 AM, Giroir, Brett (HHS/OASH)
<Brett.Giroir@hhs.gov> wrote:

☐

(b)(5)

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>
Sent: Saturday, March 7, 2020 12:44 AM
To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: RE: WSJ questions on COVID-19 test capacity

(b)(5)

From: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Sent: Friday, March 6, 2020 10:05 AM
To: OS Media (HHS/ASPA) <media@hhs.gov>; CDC OADC Media Review <OADCMediaReview@cdc.gov>; ASPRCOMMS <ASPRCOMMS@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>
Subject: RE: WSJ questions on COVID-19 test capacity

(b)(5)

From: OS Media (HHS/ASPA) <media@hhs.gov>
Sent: Friday, March 6, 2020 9:24 AM
To: CDC OADC Media Review <OADCMediaReview@cdc.gov>; ASPRCOMMS <ASPRCOMMS@hhs.gov>
Cc: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; OS Media (HHS/ASPA) <media@hhs.gov>
Subject: FW: WSJ questions on COVID-19 test capacity

From: Loftus, Peter <peter.loftus@wsj.com>
Sent: Friday, March 6, 2020 8:38 AM
To: OS Media (HHS/ASPA) <media@hhs.gov>
Subject: WSJ questions on COVID-19 test capacity

Hello, can HHS provide an update for Friday, 3/6, on the current U.S. testing capacity for the new coronavirus? Will the U.S. meet the goal of one million tests by the end of this week, as laid out this week by FDA Commissioner Hahn and Secretary Azar (who also said that would be enough for about 400,000 people)?

Can you say how many CDC test kits have been shipped to public health labs so far?

Also, VP Pence said yesterday there are not enough tests to meet anticipated demand - can you comment on that?

This is for a story likely to run later today.

--

Peter Loftus
REPORTER

<image002.jpg>

M: (b)(6) O: +1 215 881 7127
E: peter.loftus@wsj.com
Twitter: @Loftus

<image002.jpg>

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; McKeogh, Katherine (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c652f2c415b44dff8369dd7f4596f030-McKeogh, Ka>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Caccamo, Stephanie (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3b415b3f6cff4b18980c5f723fad2ce0-stephanie.c>
Sent Date:	2020/03/07 07:19:40
Delivered Date:	2020/03/07 07:19:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	Colleen Silcox <Colleen.Silcox@gatesfoundation.org>
CC:	Trevor Mundel <Trevor.Mundel@gatesfoundation.org>; Andrew Trister <Andrew.Trister@gatesfoundation.org>; Arunan Skandarajah <Arunan.Skandarajah@gatesfoundation.org>; Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Subject:	RE: Technical approach to
Date:	2020/03/12 20:33:00
Priority:	Normal
Type:	Note

I got it!!!!

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Colleen Silcox <Colleen.Silcox@gatesfoundation.org>
Sent: Thursday, March 12, 2020 7:15 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Trevor Mundel <Trevor.Mundel@gatesfoundation.org>; Andrew Trister <Andrew.Trister@gatesfoundation.org>; Arunan Skandarajah <Arunan.Skandarajah@gatesfoundation.org>; Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Subject: RE: Technical approach to

Dear Adm Giroir,

It appears that one of our attachments did not load on the previous email. Adding the additional file here.

Regards,
Colleen

From: Dan Wattendorf
Sent: Thursday, March 12, 2020 4:04 PM
To: Brett Giroir (brett.giroir@hhs.gov) <brett.giroir@hhs.gov>
Cc: Trevor Mundel (Trevor.Mundel@gatesfoundation.org) <Trevor.Mundel@gatesfoundation.org>; Andrew Trister (Andrew.Trister@gatesfoundation.org) <Andrew.Trister@gatesfoundation.org>; Arunan Skandarajah <Arunan.Skandarajah@gatesfoundation.org>
Subject: Technical approach to

ADM Giroir (Brett),

Attached are documents describing technical information we have detailing testing via drive through kiosk at retail pharmacies, as well as an approach to stage an immediate transition from health care professional collection to consumer collection in the car at the drive through site (allowing clerk versus health professional), then transitioning to performing this procedure in the home.

(b)(4)

Regards,
Dan

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Colleen Silcox <Colleen.Silcox@gatesfoundation.org>; Trevor Mundel <Trevor.Mundel@gatesfoundation.org>; Andrew Trister <Andrew.Trister@gatesfoundation.org>; Arunan Skandarajah <Arunan.Skandarajah@gatesfoundation.org>; Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Sent Date:	2020/03/12 20:33:06
Delivered Date:	2020/03/12 20:33:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	Moreno, Rafael (OS/ASPR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1dcc2da7031645b39c430a140fd4c446-Moreno, Raf>
CC:	Phillips, Sally (OS/ASPR/SPPR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5d6ce8134846423cb83b5b28464edb60-Phillips, S>; Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbec2d9b4db2a0f-Jernigan, D>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Strategic COVID-19 Tracker Team </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5fba919a76f24cbe8da03fd493758848-COVID19STT>; Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Waters, Cicely (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00e638c4ddf64006bcc009e8032dd700-Waters, Cic>
Subject:	RE: Guidance for Termination of Isolation
Date:	2020/03/10 11:27:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Moreno, Rafael (OS/ASPR) <Rafael.Moreno@hhs.gov>
Sent: Tuesday, March 10, 2020 11:24 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Phillips, Sally (OS/ASPR/SPPR) <Sally.Phillips@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Strategic COVID-19 Tracker Team <covid19stt@hhs.gov>; Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>; Moreno, Rafael (OS/ASPR) <Rafael.Moreno@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>
Subject: RE: Guidance for Termination of Isolation

Good morning sir,

(b)(5)

V/r

Rafael Moreno III

Special Assistant to the ASPR

Immediate Office, Assistant Secretary for Preparedness and Response (ASPR)

US Dept. Health and Human Services (HHS)

Desk: (202) 260-1042

Cell: (b)(6)

rafael.moreno@hhs.gov

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Monday, March 9, 2020 6:25 PM

To: Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>

Cc: Phillips, Sally (OS/ASPR/SPPR) <Sally.Phillips@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Moreno, Rafael (OS/ASPR) <Rafael.Moreno@hhs.gov>

Subject: Guidance for Termination of Isolation

Importance: High

RK -

(b)(5)

V/r

BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Moreno, Rafael (OS/ASPR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1dcc2da7031645b39c430a140fd4c446-Moreno, Raf>; Phillips, Sally (OS/ASPR/SPPR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5d6ce8134846423cb83b5b28464edb60-Phillips, S>; Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbee2d9b4db2a0f-Jernigan, D>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Strategic COVID-19 Tracker Team </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5fba919a76f24cbe8da03fd493758848-COVID19STT>; Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Waters, Cicely (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00e638c4ddf64006bcc009e8032dd700-Waters, Cic>
Sent Date:	2020/03/10 11:27:58
Delivered Date:	2020/03/10 11:27:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Kane, Elleen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user25dbd6c7>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Broido, Tara (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c3cd5c5afe049b6a8b48c25324c7465-Broido, Tar>; Migliaccio-Grabill, Kate (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f902e34652a84a61ac85adaa853d80f6-Migliaccio,>
CC:	Galatas, Kate (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9e6fa4be928e48408ba114add868123e-Galatas, Ka>; Bonds, Michelle E. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=458a7c66b66a4e9ca7bc1963da0bcb81-michelle.bo>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0632b4526d6447b5af26552afde05c33-Michael, Gr>; Waters, Cicely (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00e638c4ddf64006bcc009e8032dd700-Waters, Cic>; Hall, Bill (HHS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=02b39f27f3b4469a960054b23545cc24-Hall, Bill>
Subject:	RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees
Date:	2020/03/09 18:33:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Giroir, Brett (HHS/OASH)
Sent: Monday, March 9, 2020 6:31 PM
To: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Migliaccio-Grabill, Kate (HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>
Cc: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill

(HHS/ASPA) <bill.hall@hhs.gov>

Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

Importance: High

Sorry.

(b)(5)

(b)(6)

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

From: Giroir, Brett (HHS/OASH)

Sent: Monday, March 9, 2020 6:10 PM

To: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Migliaccio-Grabill, Kate (HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>

Cc: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>

Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>
Sent: Monday, March 9, 2020 6:06 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Migliaccio-Grabill, Kate (HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>
Cc: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Monday, March 9, 2020 6:04 PM
To: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Migliaccio-Grabill, Kate (HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>
Cc: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>

Sent: Monday, March 9, 2020 5:37 PM

To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS/IOS)

<Judy.Stecker@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Migliaccio-Grabill, Kate

(HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Cc: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC)

<meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA)

<Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill

(HHS/ASPA) <bill.hall@hhs.gov>

Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)

From: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>

Sent: Monday, March 9, 2020 5:14 PM

To: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Stecker, Judy (OS/IOS)

<Judy.Stecker@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Migliaccio-Grabill, Kate

(HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>

Cc: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC)

<meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA)

<Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>

Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

Added you to the chain

From: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>

Sent: Monday, March 9, 2020 4:57 PM

To: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Migliaccio-Grabill, Kate (HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>

Cc: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>

Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)

From: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>

Sent: Monday, March 9, 2020 4:44 PM

To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>

Cc: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>

Subject: Re: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)

Sent from my iPhone

On Mar 9, 2020, at 4:34 PM, Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov> wrote:

☐

(b)(5)

From: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>

Sent: Monday, March 9, 2020 4:17 PM

To: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>

Cc: Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely

(OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)

Vr, Elleen

From: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>

Sent: Monday, March 9, 2020 3:53 PM

To: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>

Cc: Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>

Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)

Kate Galatas, MPH
Deputy Associate Director for Communication
Centers for Disease Control and Prevention
Office: 404-639-2064
Cell: (b)(6)
Email: kkg2@cdc.gov
<image001.jpg>

From: Galatas, Kate (CDC/OD/OADC)
Sent: Monday, March 9, 2020 3:16 PM
To: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>
Cc: Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

Rest is fine.

Kate Galatas, MPH
Deputy Associate Director for Communication
Centers for Disease Control and Prevention
Office: 404-639-2064
Cell: (b)(6)
Email: kkg2@cdc.gov
<image002.jpg>

From: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>
Sent: Monday, March 9, 2020 3:10 PM
To: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>
Cc: Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

Thanks. Anything else?

From: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>
Sent: Monday, March 9, 2020 3:08 PM
To: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>
Cc: Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)

Kate Galatas, MPH

Deputy Associate Director for Communication
Centers for Disease Control and Prevention
Office: 404-639-2064

Cell: (b)(6)

Email: kkg2@cdc.gov

<image003.jpg>

From: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>

Sent: Monday, March 9, 2020 2:48 PM

To: Bonds, Michelle E. (CDC/OD/OADC) <meh0@cdc.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>


Cc: Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>

Subject: nCoV - ASPR - Washington Post on quarantining Lackland evacuees

(b)(5)



(b)(5)



From: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>
Sent: Monday, March 9, 2020 1:21 PM
To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Cc: Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Rigas, Laura (HHS/IEA) <Laura.Rigas@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>
Subject: Re: PLEASE READ FW: Washington Post reporter -- story on COVID-19 response on quarantining Lackland patients that ASPR has now taken over. deadline urgent

(b)(5)

Sent from my iPhone

On Mar 9, 2020, at 12:54 PM, Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov> wrote:

☐

(b)(5)

(b)(5)

- Ryan

From: Thorman, Caroline (ACF) <Caroline.Thorman@acf.hhs.gov>
Sent: Monday, March 9, 2020 12:40 PM
To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Subject: FW: Washington Post reporter -- story on COVID-19 response on quarantining Lackland patients that ASPR has now taken over. deadline urgent

Can you confirm ASPR is now in charge? Will ASPR continue to allow releasing quarantined people from Lackland to leave after 14 days and two sequential negative tests, for those that agree to be tested, even though San Antonio filed an unsuccessful emergency lawsuit asking that the number of tests be three and the quarantine period be extended to 28 days? And what will the protocol be for those who test positive at the base and must be treated at a hospital or go to a negative pressure room for 14 days if they're asymptomatic? Will they also be allowed to go after two sequential negative tests? Importantly, our story will also note that the UNMC protocol for positive COVID-19 patients is different; it's THREE sequential tests, not two.

Many thanks,

Caroline Thorman
Director of Communications
Administration for Children & Families (ACF)
Health and Human Services (HHS)
Desk: (202) 401-4777
Cell: (b)(6)

From: Satija, Neena <Neena.Satija@washpost.com>
Sent: Sunday, March 8, 2020 6:03 PM
To: Thorman, Caroline (ACF) <Caroline.Thorman@acf.hhs.gov>
Subject: Fw: Washington Post reporter -- story on COVID-19 response on quarantining Lackland patients that ASPR has now taken over. deadline urgent

Neena Satija

Investigative Reporter

Washington Post

202-334-7054

@neenareports

From: Satija, Neena <Neena.Satija@washpost.com>

Sent: Sunday, March 8, 2020 3:51 PM

To: gretchen.michael@hhs.gov <gretchen.michael@hhs.gov>;
elaine.kane@hhs.gov <elaine.kane@hhs.gov>

Subject: Washington Post reporter -- story on COVID-19 response on
quarantining Lackland patients that ASPR has now taken over. deadline
urgent

Dear Gretchen and Elaine,

My name is Neena Satija and I'm a reporter for the Washington Post. I have been trying to get in touch with HHS on a story about coronavirus response when it comes to the Wuhan and Diamond Princess (and soon, Grand Princess) cohorts sent to Lackland Air Force Base, and I have had no luck with the CDC. So I'm going to you -- also because we have been told today that ASPR is now in charge of those quarantine ops instead of the CDC. Getting in touch with HHS in general for the past few weeks has been tough; in fact it took me several days simply to confirm, for instance, that OCEPHR was involved in the repatriation effort ... and we really do want to be fair and accurate, so I'm really hoping you can help!!

My colleague Arelis Hernandez and I have a story that may run tomorrow or the following day about the frustration among state and local officials in Texas, especially officials in San Antonio, regarding lack of communication from the administration on COVID-19 response, in particular, what to do with cohorts from Wuhan and the Diamond Princess (and, soon, the Grand Princess) cruise ship. We will report that state and local officials were assured that anyone sent to Lackland from Wuhan back on Feb. 1 would remain quarantined on base -- but instead, after the plane landed, San Antonio officials were immediately called upon not only to take the one woman who tested positive and had symptoms to a community hospital to be treated, but even to secure an ambulance to take her off Lackland.

Essentially state and local officials were given no advanced warning that the DOD would now allow anyone who tested positive for COVID-19 to stay on base, whether asymptomatic or not. It appears as though state and local authorities had the tools in place to plan for these issues quickly. But what happened raises serious questions about the administration's handling of this public health emergency, especially after the release of that patient from Wuhan before a positive test result came back.

I have contacted CDC multiple times for comment on our story with no answer. Then I found out today that ASPR is now in charge of quarantining protocols going forward as opposed to CDC. It's all the more important we hear from you now that dozens more cruise ship passengers, this time from the Grand Princess cruise ship, are now headed to Lackland. The administration has assured folks that it will quarantine them at the base. But what about those who test positive?

Can you confirm ASPR is now in charge? Will ASPR continue to allow releasing quarantined people from Lackland to leave after 14 days and two sequential negative tests, for those that agree to be tested, even though San Antonio filed an unsuccessful emergency lawsuit asking that the number of tests be three and the quarantine period be extended to 28 days? And what will the protocol be for those who test positive at the base and must be treated at a hospital or go to a negative pressure room for 14 days if they're asymptomatic? Will they also be allowed to go after two sequential negative tests? Importantly, our story will also note that the UNMC protocol for positive COVID-19 patients is different; it's THREE sequential tests, not two.

I'm hoping you can help me confirm some of the basic details and perhaps provide any other comment. You can also reach me on my cell at (b)(6)

Thanks!

Neena Satija

Investigative Reporter

Washington Post

202-334-7054

@neenareports

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Kane, Elleen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user25dbd6c7>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Broido, Tara (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c3cd5c5afe049b6a8b48c25324c7465-Broido, Tar>; Migliaccio-Grabill, Kate (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f902e34652a84a61ac85adaa853d80f6-Migliaccio,>; Galatas, Kate (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9e6fa4be928e48408ba114add868123e-Galatas, Ka>; Bonds, Michelle E. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=458a7c66b66a4e9ca7bc1963da0bcb81-michelle.bo>; CDC IMS JIC Media -2 <eocjicmedia2@cdc.gov>; Michael, Gretchen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0632b4526d6447b5af26552afde05c33-Michael, Gr>; Waters, Cicely (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00e638c4ddf64006bcc009e8032dd700-Waters, Cic>; Hall, Bill (HHS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=02b39f27f3b4469a960054b23545cc24-Hall, Bill>
Sent Date:	2020/03/09 18:33:51
Delivered Date:	2020/03/09 18:33:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Schwartz, Suzanne (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bce62c458594ca8b15ecc04fe792094-suzanne.sch>
CC:	Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>; McGowan, Robert (Kyle) (CDC/OD/OCS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a2046e75239f48a28d2854bedbe5f899-robert.mcgo>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>
Subject:	RE: Testing Huddle
Date:	2020/03/11 06:51:00
Priority:	Normal
Type:	Note

We will send a call in

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Wednesday, March 11, 2020 6:45 AM
To: Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>
Cc: Haddad, Carla (HHS/OASH) <Carla.Haddad@hhs.gov>; Bante, Katie (OS/OASH) <Katie.Bante@hhs.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: Re: Testing Huddle

08:30 works for me

Steve Monroe, PhD
Assoc Dir Lab Sci & Safety
CDC
Sent using [Outlook for Android](#)

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Sent: Wednesday, March 11, 2020 6:33:33 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>
Cc: Haddad, Carla (HHS/OASH) <Carla.Haddad@hhs.gov>; Bante, Katie (OS/OASH) <Katie.Bante@hhs.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>
Subject: Re: Testing Huddle

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Date: March 11, 2020 at 6:28:28 AM EDT
To: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>, Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>, Monroe, Stephan S (CDC) <stm2@cdc.gov>
Cc: Haddad, Carla (OS) <Carla.Haddad@hhs.gov>, Bante, Katie (OS) <Katie.Bante@hhs.gov>, McGowan, Robert K (CDC) <omc2@cdc.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: Testing Huddle
Importance: High

(b)(5)

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Schwartz, Suzanne (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bce62c458594ca8b15ecc04fe792094-suzanne.sch>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>; McGowan, Robert (Kyle) (CDC/OD/OCS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a2046e75239f48a28d2854bedbe5f899-robert.mcgo>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>
Sent Date:	2020/03/11 06:51:56
Delivered Date:	2020/03/11 06:51:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Jill Giroir <(b)(6)@gmail.com>
Subject:	FW: White House deploys SWAT teams of technocrats in attempt to fix testing
Date:	2020/03/16 21:37:00
Priority:	Normal
Type:	Note

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

From: Heck, Mia (HHS/OASH) <Mia.Heck@hhs.gov>
Sent: Monday, March 16, 2020 9:33 PM
To: Valentine, Steven (HHS/OASH) <Steven.Valentine@hhs.gov>; Haddad, Carla (HHS/OASH) <Carla.Haddad@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Fwd: White House deploys SWAT teams of technocrats in attempt to fix testing

Fysa

Sent from my iPhone

Begin forwarded message:

From: "Broido, Tara (HHS/OASH)" <Tara.Broido@hhs.gov>
Date: March 16, 2020 at 8:53:04 PM EDT
To: "Heck, Mia (HHS/OASH)" <Mia.Heck@hhs.gov>
Subject: FW: White House deploys SWAT teams of technocrats in attempt to fix testing

□

From: POLITICO Pro Health Care
Sent: Monday, March 16, 2020 8:52:54 PM (UTC-05:00) Eastern Time (US & Canada)
To: Broido, Tara (HHS/OASH)
Subject: White House deploys SWAT teams of technocrats in attempt to fix testing

White House deploys SWAT teams of technocrats in attempt to fix testing

By Dan Diamond

03/16/2020 08:51 PM EDT

As hospitals grapple with more coughing and feverish emergency-room visitors than they can test, the White House has deployed a SWAT team of fixers and technocrats to ramp up coronavirus testing, in an implicit acknowledgment that the Trump administration's response has continued to fall short of what is needed.

About 100 staffers and outside advisers, split between the health department and the White House, are currently working on teams to rapidly increase supplies of test kits and cope with shortages across the country, said four people with knowledge of the strategy.

"This is the A-team of people who get shit done," said one official, who's worked with some of the staffers leading the effort. "We've got to show the American people that we can deliver on the testing promises" after weeks of President Donald Trump vowing that "anybody who needs a test can get a test" — a claim that doesn't match the growing number of doctors, hospitals and patients who have said they're still waiting for access and results.

The lack of testing remains — despite Vice President Mike Pence's assurance that drive-thru testing centers should be operative later this week — the greatest immediate danger to the U.S. response to the crisis, public health experts have warned.

While Johns Hopkins University on Monday reported more than 4,287 confirmed cases of coronavirus across the United States, the true number could easily be more than 10 times higher at this point. That's complicated medical professionals' efforts to focus their resources and hurt public health officials' effort to marshal a response.

"We are far behind where we need to be," tweeted Ashish Jha, director of Harvard's Global Health Institute, who changed his Twitter name to read "Ashish 'We super duper need testing for COVID' Jha." While the Harvard expert this weekend guessed that at least 40,000 people may be infected, "we can't know without testing" how big the problem is, he added.

The SWAT-team effort is being overseen by Brett Giroir, the HHS official who was tapped as the nation's testing coordinator on Friday, and Adam Boehler, a former HHS official who was drawn in to the coronavirus response last week. Brad Smith, a health-industry entrepreneur who only joined the administration in January, is serving as the operational leader.

Outside experts in health care delivery and technology, like Flatiron Health CEO Nat Turner, also have been brought in as advisers.

The officials have spent the past five days in round-the-clock war rooms and strategy sessions, gaming out ways to deploy drive-thru testing as Pence and Trump have promised this week. The initial testing centers will prioritize health workers and vulnerable populations, like people over 65, with a focus on the states that are hardest hit by the coronavirus.

The new SWAT-team approach is similar to the emergency effort to repair HealthCare.gov in 2013, three officials said, although drew distinctions between the Obama-era recovery strategy — to fix the rollout of a long-scheduled website — and the frantic response to a once-in-a-lifetime pandemic.

“This shit hasn’t happened before,” said one senior administration official. “It’s not like we planned for coronavirus, and six months later we had a coronavirus.”

Tapping officials like Giroir and Boehler, who have steered multiple administration priorities like President Donald Trump’s HIV/AIDS strategy and kidney-care overhaul, and a technocrat like Smith, is a tacit acknowledgment of management failures with the existing strategy, said two individuals, with the Trump administration cycling through multiple leaders and tactics — and officials trading blame for why testing has run so far behind.

Much of the Trump administration’s initial strategy rested on coronavirus tests distributed by the Centers for Disease Control, which turned out to have manufacturing problems. CDC Director Robert Redfield has been widely faulted inside the administration for problems with his agency’s tests and miscommunicating to senior officials when replacement tests would be ready.

HHS Secretary Alex Azar, who led the initial response, is frustrated with Redfield, said two people familiar with the situation, and dispatched Giroir earlier this month to the CDC to quietly investigate the problems within the agency, said three individuals briefed on the effort. The health secretary also elevated Giroir and another official, emergency-preparedness chief Robert Kadlec, to take over the department’s coronavirus response.

Meanwhile, two officials blamed Azar himself for not doing more to coordinate the overall response across January and February, leaving the administration well short on the number of necessary tests. Some of the strategies taken in recent days, like working with private labs to ramp up tests, could have been pursued nearly two months ago under Azar’s leadership, the officials said.

Vice President Mike Pence took over the response from Azar about three weeks ago, amid frustrations about the state of the effort and whether Azar’s public health deputies had been too alarmist in their messages. But Pence has focused on coordinating the larger message and his office has lacked operational support to execute on specific initiatives, said two individuals.

The new SWAT team is also a reflection of the growing involvement of White House senior adviser Jared Kushner, Trump’s son-in-law, in the administration’s coronavirus response. Kushner is a longtime friend of Boehler, who led the Medicare innovation center until taking a new role as chief of U.S. international development finance chief last fall, and is viewed as an apolitical Silicon Valley veteran. Meanwhile, Smith is a Boehler ally who inherited his job at the Medicare innovation center before being pulled in to coordinate the SWAT team response.

Asked about the shifting roles and responsibilities, an HHS spokesperson touted the decision to bring on more operational experts like Giroir.

“The Trump Administration has activated a whole of government response to COVID-19 and all of our leaders bring highly valuable experience and expertise to this effort,” the spokesperson

said. “The American people should know that the entire government is working around the clock to prepare for and protect against COVID-19.”

The White House also defended the CDC’s role and response, despite problems with the agency’s tests that led to weeks of limited information about the spread of coronavirus.

“CDC is doing what they could, given their tools and resources,” said Katie Miller, a spokesperson for Pence. “Given the increased demand, the administration is doing as much as to add additional capacity in an expedited manner.”

The nation’s inadequate coronavirus testing has meant that the true scope of the problem is unknown.

One doctor involved in the coronavirus response at a New York City-area hospital, who asked for confidentiality because the doctor did not have permission to speak to the media, said the facility has seen its coronavirus cases jump from just a handful of confirmed patients a week ago to more than a dozen as of Sunday, as more testing has come online. But the true scope of the outbreak still can’t be measured, the doctor added, because patients who aren’t sick enough to be hospitalized aren’t getting tested, and the facility has been turning away dozens of less critically ill people who present with coronavirus symptoms, creating a “big gap” between official numbers and the disease’s likely spread.

Crystal Lucas, a former state legislature candidate in Florida, told POLITICO that her 61-year-old mother-in-law went to the emergency room of Palms West Hospital in Palm Beach, Fla., on Friday with a 102-degree fever and respiratory problems. Four hours later, she was admitted.

“The nurse told us she hadn’t been tested because they didn’t have any test kits,” Lucas said. “She had an infectious disease doctor on her team when she was still in a regular hospital room. She was obviously suspected to have an infectious disease.”

Palms West’s communications office did not respond to requests for comment.

The patient, Vickie Schafer, is now in critical condition, Lucas said. She finally got a coronavirus test on Sunday evening and is awaiting the results.

“Everything points to COVID and they treated it as if it wasn’t even on their radar,” said Lucas. “If we have this going on and this woman presents all the symptoms, why would we not act as if she is already positive?”

If Schafer tests positive, it could indicate the virus has spread in Loxahatchee, the area of Palm Beach County where she lives. As of Monday evening, there were eight cases in the county, according to [the state Department of Health’s website](#).

In addition to worrying about her mother-in-law, Lucas said she worries about the doctors and nurses Schafer might have been exposed to the coronavirus between Friday and Sunday. And she worries about the patients those people might have come into contact with.

Some hospital officials have said they would have developed their own coronavirus tests weeks

ago but were told to stand down by officials at CDC and the Food and Drug Administration.

“We were told two things,” said Alan Wells, medical director of the University of Pittsburgh Medical Center’s clinical laboratories. “One, that they were developing the testing and that CDC and states would be able to handle this. Two, that they were exercising authority to regulate which testing was approved.” Combined with other factors, including limited supplies, Wells’ team decided to shelve their potential coronavirus testing plan six weeks ago, but resumed work as the situation worsened and finally unveiled the tests on Saturday.

Public health leaders, doctors and even Wall Street investors, are growing worried about the lack of transparency around the inadequate response.

“Testing is getting there but with the virus doubling right now at minimum every seven days, each day of testing lost is a day that more people get sick,” Financial services firm Raymond James warned investors on Sunday night.

Alexandra Glorioso contributed to this report.

To view online:

<https://protect2.fireeye.com/url?k=329ce0cd-6ec8f9b1-329cd1f2-0cc47adc5fa2-cb79673063eba8ca&u=https://subscriber.politicopro.com/health-care/article/2020/03/white-house-deploys-swat-teams-of-technocrats-in-attempt-to-fix-testing-1895760>

You received this POLITICO Pro content because your customized settings include: Public Health, Health. To change your alert settings, please go to <https://protect2.fireeye.com/url?k=d3a85f8d-8ffc46f1-d3a86eb2-0cc47adc5fa2-d9d688a9191ae1d0&u=https://subscriber.politicopro.com/settings>.

POLITICOPRO

This email alert has been sent for the exclusive use of POLITICO Pro subscriber, tara.broido@hhs.gov. Forwarding or reproducing the alert without the express, written permission of POLITICO Pro is a violation of copyright law and the POLITICO Pro subscription agreement.

Copyright © 2020 by POLITICO LLC. To subscribe to Pro, please go to politicopro.com.

This email was sent to tara.broido@hhs.gov by:
POLITICO, LLC
1000 Wilson Blvd.
Arlington, VA 22209
USA

Sender: Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

	(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Jill Giroir (b)(6)@gmail.com>
Sent Date:	2020/03/16 21:37:12
Delivered Date:	2020/03/16 21:37:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Colleen Silcox <Colleen.Silcox@gatesfoundation.org>
Subject:	FW: Technical approach to
Date:	2020/03/12 20:33:00
Priority:	Normal
Type:	Note

This is the only one I have

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Colleen Silcox <Colleen.Silcox@gatesfoundation.org>
Sent: Thursday, March 12, 2020 7:15 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Trevor Mundel <Trevor.Mundel@gatesfoundation.org>; Andrew Trister <Andrew.Trister@gatesfoundation.org>; Arunan Skandarajah <Arunan.Skandarajah@gatesfoundation.org>; Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Subject: RE: Technical approach to

Dear Adm Giroir,

It appears that one of our attachments did not load on the previous email. Adding the additional file here.

Regards,
Colleen

From: Dan Wattendorf
Sent: Thursday, March 12, 2020 4:04 PM
To: Brett Giroir (brett.giroir@hhs.gov) <brett.giroir@hhs.gov>
Cc: Trevor Mundel (Trevor.Mundel@gatesfoundation.org) <Trevor.Mundel@gatesfoundation.org>; Andrew Trister (Andrew.Trister@gatesfoundation.org) <Andrew.Trister@gatesfoundation.org>; Arunan Skandarajah <Arunan.Skandarajah@gatesfoundation.org>
Subject: Technical approach to

ADM Giroir (Brett),

Attached are documents describing technical information we have detailing testing via drive through kiosk at retail pharmacies, as well as an approach to stage an immediate transition from health care professional collection to consumer collection in the car at the drive through site (allowing clerk versus health professional), then transitioning to performing this procedure in the home.

(b)(4)

Regards,
Dan

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Colleen Silcox <Colleen.Silcox@gatesfoundation.org>
Sent Date:	2020/03/12 20:33:35
Delivered Date:	2020/03/12 20:33:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Cote, Mick (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user9459b24b>
CC:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	Swabs
Date:	2020/03/14 11:38:00
Priority:	Normal
Type:	Note

Mick,

(b)(5)

BG

Many thanks

BG

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Cote, Mick (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user9459b24b>; Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Sent Date:	2020/03/14 11:38:07
Delivered Date:	2020/03/14 11:38:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>
Subject:	COVID Testing
Date:	2020/03/11 07:02:00
Start Date:	2020/03/11 08:30:00
End Date:	2020/03/11 09:00:00
Priority:	Normal
Type:	Schedule.Meeting.Request
Location:	(b)(6) Participant: (b)(6)
Attendees:	Shuren, Jeff (FDA/CDRH); Stenzel, Timothy (FDA/CDRH); Monroe, Steve (CDC/DDPHSS/OLSS/OD); Lenihan, Keagan (FDA/OC); Kellogg, Rachel (HHS/OASH); Bante, Katie (OS/OASH)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>
Sent Date:	2020/03/11 07:02:57
Delivered Date:	2020/03/11 07:02:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Colleen Silcox <Colleen.Silcox@gatesfoundation.org>; Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Subject:	FW: Technical approach to
Date:	2020/03/12 20:36:00
Priority:	Normal
Type:	Note

This is the only deck I received from Colleen

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Colleen Silcox <Colleen.Silcox@gatesfoundation.org>
Sent: Thursday, March 12, 2020 7:15 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Trevor Mundel <Trevor.Mundel@gatesfoundation.org>; Andrew Trister <Andrew.Trister@gatesfoundation.org>; Arunan Skandarajah <Arunan.Skandarajah@gatesfoundation.org>; Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Subject: RE: Technical approach to

Dear Adm Giroir,

It appears that one of our attachments did not load on the previous email. Adding the additional file here.

Regards,
Colleen

From: Dan Wattendorf
Sent: Thursday, March 12, 2020 4:04 PM
To: Brett Giroir (brett.giroir@hhs.gov) <brett.giroir@hhs.gov>
Cc: Trevor Mundel (Trevor.Mundel@gatesfoundation.org) <Trevor.Mundel@gatesfoundation.org>; Andrew Trister (Andrew.Trister@gatesfoundation.org) <Andrew.Trister@gatesfoundation.org>; Arunan Skandarajah <Arunan.Skandarajah@gatesfoundation.org>
Subject: Technical approach to

ADM Giroir (Brett),

Attached are documents describing technical information we have detailing testing via drive through kiosk at retail pharmacies, as well as an approach to stage an immediate transition from health care professional collection to consumer collection in the car at the drive through site (allowing clerk versus health professional), then transitioning to performing this procedure in the home.

(b)(4)

Regards,
Dan

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Colleen Silcox <Colleen.Silcox@gatesfoundation.org>; Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Sent Date:	2020/03/12 20:36:34
Delivered Date:	2020/03/12 20:36:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Judy Stecker (OS/ASPA) (Judy.Stecker@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>
CC:	Ryan Murphy (OS/ASPA) (Ryan.Murphy1@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>
Subject:	Re Testing in the INTERim
Date:	2020/03/07 18:51:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Judy Stecker (OS/ASPA) (Judy.Stecker@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Ryan Murphy (OS/ASPA) (Ryan.Murphy1@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>
Sent Date:	2020/03/07 18:51:39
Delivered Date:	2020/03/07 18:51:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Jill Giroir <(b)(6)@gmail.com>
Subject:	Fwd: HHS News: Health Mart Independent Pharmacies Donate Their Dispensing Services to HHS to Support the
Date:	2020/03/03 14:31:58
Priority:	Normal
Type:	Note

Sent from my iPhone

Begin forwarded message:

From: HHS Office of Public Affairs <hhsopa@hhs.gov>
Date: March 3, 2020 at 2:30:42 PM EST
To: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>
Subject: HHS News: Health Mart Independent Pharmacies Donate Their Dispensing Services to HHS to Support the
Reply-To: hhsopa@hhs.gov

□



U.S. Department of Health and
Human Services

News Release

202-690-6343
ashmedia@hhs.gov
www.hhs.gov/news
Twitter [@HHS_ASH](https://twitter.com/HHS_ASH)

FOR IMMEDIATE RELEASE
March 3, 2020

**Health Mart Independent Pharmacies Donate Their Dispensing Services to HHS to Support the
Ending the HIV Epidemic Initiative**

The U.S. Department of Health and Human Services (HHS) and Health Mart today announced that more than 3,300 Health Mart independent pharmacies agreed to donate their dispensing services to support *Ready, Set, PrEP*, the HHS program that provides free PrEP medication to uninsured individuals. As part of that donation, Health Mart pharmacies will provide patient counseling and take steps to promote medication adherence as well as provide free PrEP medications in store at no cost for those eligible.

“Ensuring all people in both urban and rural communities have access to HIV prevention and care services is critical to Ending the HIV Epidemic,” said Assistant Secretary for Health Brett P. Giroir, M.D. “Health Mart independent pharmacies will play an important role in further expanding patient access to free PrEP medications in these traditionally underserved areas.” The announcement was made today at Grubb’s Pharmacy in Washington, D.C.’s Anacostia neighborhood.

The program is a key component of the initiative, *Ending the HIV Epidemic (EHE): A Plan for America*. EHE aims to reduce the number of new HIV infections in the United States by 75% in five years and by 90% in 10 years. By increasing awareness of PrEP and its access, the *Ready, Set, PrEP* program can provide thousands of people a safe, effective way to prevent HIV and bring the U.S. one step closer to ending the HIV epidemic.

“We are proud to do our part in ending the HIV epidemic,” said Health Mart President Nimesh Jhaveri. “Health Mart independent pharmacists understand the important role they play in patient care. Participating in this initiative and donating their time and resources showcase their commitment to improving the health of their communities.”

Although more than one million people at risk for HIV in the United States could benefit from PrEP medications, only a small fraction get them. The Centers for Disease Control and Prevention and the U.S. Preventive Services Task Force recommend PrEP for individuals at risk of acquiring HIV. When taken daily, PrEP is highly effective for preventing HIV.

For More Information

Beginning no later than March 30, 2020, qualified patients can obtain the PrEP medications at the more than 24,500 participating pharmacy locations throughout 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands or through mail order—all at no cost to patients. These donating pharmacies represent about a third of all the pharmacies in the United States.

Eligibility requirements are available at GetYourPrEP.com or by calling 855-447-8410. To learn more about PrEP’s role in ending the HIV epidemic, visit *Ending the HIV Epidemic: A Plan for America*. For an explanation of how the program works and more information about HIV/AIDS prevention, testing, treatment, and research, visit HIV.gov. To learn more about *Ready, Set, PrEP*, please visit GetYourPrEP.com and hiv.gov.

Follow @HIVgov on Twitter, like HIV.gov on Facebook, and sign up for the HIV.gov listserv to stay up to date on the latest developments on *Ending the HIV Epidemic: A Plan for America*.

About Health Mart

Health Mart is the nation’s fastest-growing independent pharmacy franchise with more than 5,000 locally owned community pharmacies across all 50 states. Health Mart pharmacists provide personalized care and take the time to help patients understand their prescription-drug coverage, how to safely manage multiple medications, and how to take advantage of lower-cost medication options. Patients can find a locally-owned Health Mart pharmacy by visiting healthmart.com.

As an important member of the healthcare team, Health Mart pharmacists possess strong clinical knowledge and collaborate with patients and other healthcare providers to help patients manage and improve their health. The Health Mart franchise is owned by Health Mart Systems, Inc., which is part of McKesson Corporation. Pharmacists and pharmacy owners interested in learning more can explore join.healthmart.com.

###

Connect with HHS and sign up for [HHS email updates](#)



[Facebook](#)



[Twitter](#)



[Link to Youtube](#)

If you would rather not receive future communications from U.S. Department of Health and Human Services (HHS), let us know by clicking [here](#).
U.S. Department of Health and Human Services (HHS), 200 Independence Avenue, SW 6th Floor Room 647-D, Washington, DC 20201 United States

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Jill Giroir (b)(6) @gmail.com>
Sent Date:	2020/03/03 14:31:57
Delivered Date:	2020/03/03 14:31:58

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Broido, Tara (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c3cd5c5afe049b6a8b48c25324c7465-Broido, Tar>
CC:	Heck, Mia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70dbe2065d644b8dadbfa56c5d63553d-Heck, Mia>; Migliaccio-Grabill, Kate (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f902e34652a84a61ac85adaa853d80f6-Migliaccio,>; Valentine, Steven (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd508090f8984b1caf04069bc6000dc2-Valentine,>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	RE: WSJ: HHS Secretary Is Largely Sidelined in U.S. Effort to Battle Coronavirus
Date:	2020/03/11 17:49:00
Priority:	Normal
Type:	Note

Thank you

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>
Sent: Wednesday, March 11, 2020 5:48 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Heck, Mia (HHS/OASH) <Mia.Heck@hhs.gov>; Migliaccio-Grabill, Kate (HHS/OASH) <Kate.Migliaccio-Grabill@hhs.gov>; Valentine, Steven (HHS/OASH) <Steven.Valentine@hhs.gov>; Haddad, Carla (HHS/OASH) <Carla.Haddad@hhs.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>
Subject: WSJ: HHS Secretary Is Largely Sidelined in U.S. Effort to Battle Coronavirus

FYI, you are mentioned

HHS, which responded on behalf of Mr. Azar, said the department did nothing to delay testing. Dr. Kadlec was unavailable for comment. HHS Assistant Secretary Brett Giroir, speaking for him, denied that Dr. Kadlec and Mr. Azar had slowed down the distribution of tests.

HHS Secretary Is Largely Sidelined in U.S. Effort to Battle Coronavirus

Alex Azar's role in fighting epidemic wanes; supporters say he is being unfairly scapegoated

By Stephanie Armour and Thomas M. Burton

March 11, 2020 3:00 pm ET

Health and Human Services Secretary Alex Azar appeared taken aback late last month when lawmakers questioned whether someone else should lead the nation's response to coronavirus.

"I serve as the lead on this while it's a public-health emergency," he said at a congressional budget hearing on Feb. 26. "It's just the longstanding doctrine that this should be led by HHS with a public-health emergency."

About six hours later, President Trump made an appearance in the White House briefing room after a trip from India to say he was putting Vice President Mike Pence in charge. The vice president, he said, has "a certain talent for this."

After emerging early on as the White House's public face in the battle against coronavirus and the head of a task force formed to wage it, Mr. Azar has since been noticeably absent from a number of task-force briefings even though he officially still leads the group. The president has voiced his continued support for Mr. Azar and praised him for doing a "great job."

Still, the evident decision to downsize his role reflects Mr. Trump's vote of no confidence in the nation's top health official and suggests that Mr. Azar wields waning influence in the White House on health-policy decisions, according to interviews with about a dozen people in the Trump administration and on Capitol Hill.

As head of the task force, Mr. Azar adopted an approach to managing the coronavirus task force that alienated some other officials at HHS and other government entities, according to people familiar with the situation. They say

he played favorites when deciding who would travel or appear in public events and briefings, micromanaged decisions to such a degree that agencies couldn't act swiftly, and didn't keep everyone in the loop.

Mr. Azar, a former pharmaceutical-industry executive who likes to quote management theory, praised the president for increasing Mr. Pence's role. Several people who support Mr. Azar said his job is so vast that it makes sense to have him less focused on coronavirus as cases mushroom. They praise his work on Mr. Trump's signature issues, such as reducing opioid overdose deaths, and say he is being unfairly scapegoated over coronavirus.

Two people familiar with discussions said Mr. Azar's job could be on the line, but another person said Mr. Trump was unlikely to pursue a major shake up that could reflect executive turmoil during the outbreak.

The president has defended Mr. Azar's handling of coronavirus.

"It is FAKE NEWS that @HHSgov @SecAzar is "sidelined" from the great job he is doing on the CoronaVirus Task Force. He has the total confidence of the @VP and myself, and is doing a fantastic job, as the numbers would indicate!" Mr. Trump tweeted on March 6.

Problems began early on. About a month ago, Joe Grogan, the director of the White House's Domestic Policy Council, and Maria Bonner, a special assistant to the president for domestic policy, pushed for giving U.S. patients broad access to diagnostic coronavirus tests, a senior government official said.

Fast development of widespread diagnostic tests was the best way to get ahead of the virus, Mr. Grogan and Ms. Bonner said, according to the senior official. These would have included lab-developed tests made at about 400 major U.S. academic hospitals, as well as tests made by big commercial makers of diagnostics, including Roche Holding AG, Abbott Laboratories and Laboratory Corp. of America Holdings.

The lab-developed tests needed an emergency-use authorization from the Food and Drug Administration—an agency within HHS—to move ahead. It took until Feb. 29 for the FDA to clear them, largely because Mr. Azar and Robert Kadlec, an assistant secretary at HHS, wanted the Centers for Disease Control and Prevention—another HHS agency—to make and distribute the nation's diagnostic tests, according to one of the people familiar with the matter. A lack of tests has frustrated state leaders who are trying to contain the virus.

HHS, which responded on behalf of Mr. Azar, said the department did nothing to delay testing. Dr. Kadlec was unavailable for comment. HHS

Assistant Secretary Brett Giroir, speaking for him, denied that Dr. Kadlec and Mr. Azar had slowed down the distribution of tests.

Mr. Azar's office also hampered the flow of information, according to three people familiar with the situation. At one point, HHS called drug manufacturers to track possible drug shortages rather than having FDA do the work, according to one person familiar with the planning. The decision caused officials at FDA to worry their agency wouldn't get fast or accurate information directly from companies that had provided it to others in HHS, the person said.

The makeup of the coronavirus task force angered some in the various agencies because it excluded leaders such as FDA chief Stephen Hahn, some people familiar with the matter said. Mr. Azar dictated who would travel to certain coronavirus briefings or events and at times sidelined officials, according to three of those people.

The situation spiraled in the waning days of February. Mr. Azar said the virus was "contained" in a Feb. 25 news briefing, but at the time very few Americans had been tested. Critics including New York Gov. Andrew Cuomo accused the administration of mixed messaging.

The same day, a top CDC official said to expect community spread in the country and the stock market lurched downward. Mr. Trump, who was in India, became livid, according to two people familiar with the situation. The president felt Mr. Azar was losing control of the administration's message, which was that the situation was under control, according to the people. The complaints are the latest trouble for Mr. Azar, a close ally of Mr. Pence who already had detractors when he took the lead on the coronavirus task force. For months, HHS was roiled by an internal battle between Mr. Azar and Seema Verma, who heads up a division at HHS that oversees Medicare and Medicaid.

The feud turned so rancorous that the vice president called Mr. Azar and Ms. Verma to a meeting in December to broker an uneasy truce.

Mr. Azar has also clashed with Mr. Grogan, who disagreed with his proposal to halt drug rebates. And in January, an angry Mr. Trump yelled on the phone at Mr. Azar, saying there hadn't been enough progress on lowering drug prices, according to two people familiar with the situation.

SHARE YOUR THOUGHTS

How has the federal government handled the coronavirus outbreak so far? Join the conversation below.

Responding on behalf of Mr. Azar, HHS said Mr. Trump and Mr. Azar have a great relationship. It also said all relevant members of the administration have been involved in the virus response, and that travel requirements change quickly depending on the rapidly evolving situation.

Mr. Azar continues to sound upbeat.

“Our testing in the United States has been very consistent, if not more aggressive, than similarly impacted countries,” he said in a March 5 news briefing.

About 8,500 people have been tested in CDC and public-health labs as of Wednesday, federal data shows, as doctors, administrators and state officials continue to say demand isn’t being met. South Korea has said it can test as many as 10,000 patients a day.

<https://www.wsj.com/articles/hhs-secretary-is-largely-sidelined-in-u-s-effort-to-battle-coronavirus-11583953145?mod=searchresults&page=1&pos=1>

Sender:	Giroir, Brett (HHS/OASH) </o=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Broido, Tara (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c3cd5c5afe049b6a8b48c25324c7465-Broido, Tar>; Heck, Mia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70dbe2065d644b8dadbfa56c5d63553d-Heck, Mia>; Migliaccio-Grabill, Kate (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f902e34652a84a61ac85adaa853d80f6-Migliaccio,>; Valentine, Steven (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd508090f8984b1caf04069bc6000dc2-Valentine,>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Sent Date:	2020/03/11 17:49:27
Delivered Date:	2020/03/11 17:49:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Pence, Laura (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>; Carla Haddad (HHS/OASH) (Carla.Haddad@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>
CC:	Arbes, Sarah (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=106db0ac70a241a8b1323647c093d9bf-Arbes, Sara>
Subject:	RE: 11:15 friday
Date:	2020/03/05 17:11:00
Priority:	Normal
Type:	Note

Carla setting up with you
She is my new COS

We can make it work

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

-----Original Message-----

From: Pence, Laura (HHS/ASL) <Laura.Pence@hhs.gov>
Sent: Thursday, March 5, 2020 4:57 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Harder, Kristina (HHS/IOS) <Kristina.Harder@hhs.gov>
Cc: Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>
Subject: 11:15 friday

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Pence, Laura (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>; Carla Haddad (HHS/OASH) (Carla.Haddad@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Arbes, Sarah (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=106db0ac70a241a8b1323647c093d9bf-Arbes, Sara>
Sent Date:	2020/03/05 17:11:10
Delivered Date:	2020/03/05 17:11:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
CC:	Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Valentine, Steven (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd508090f8984b1caf04069bc6000dc2-Valentine,>
Subject:	RE: For review by 11:30 AM: draft Sec. Azar coronavirus update
Date:	2020/03/10 11:55:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>
Sent: Tuesday, March 10, 2020 11:00 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Haddad, Carla (HHS/OASH) <Carla.Haddad@hhs.gov>; Valentine, Steven (HHS/OASH) <Steven.Valentine@hhs.gov>
Subject: FW: For review by 11:30 AM: draft Sec. Azar coronavirus update

(b)(5)

(b)(5)

From: Brennan, Patrick (OS/ASPA) <Patrick.Brennan@hhs.gov>

Sent: Tuesday, March 10, 2020 10:18 AM

To: Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Janik, Heather (FDA/OC) <Heather.Janik@fda.hhs.gov>; Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>; Lepore, Loretta (CDC/OD/OCS) <phf7@cdc.gov>; Stimson, Brian (HHS/OGC) <Brian.Stimson@hhs.gov>; Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>; Morse, Sara (HHS/ASL) <Sara.Morse@hhs.gov>; Pence, Laura (HHS/ASL) <Laura.Pence@hhs.gov>; Moughalian, Jen (HHS/ASFR) <Jen.Moughalian@hhs.gov>; Shuy, Caitrin (HHS/ASFR) <Caitrin.Shuy@hhs.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Zebley, Kyle (HHS/OS/OGA) <Kyle.Zebley@hhs.gov>; Grigsby, Garrett (HHS/OS/OGA) <Garrett.Grigsby@hhs.gov>; Hittle, Taylor (HHS/ASFR) <Taylor.Hittle@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; CDC IMS JIC OADC LNO -2 <eocevent202@cdc.gov>; Heldman, Amy B. (CDC/OD/OADC) <evd4@cdc.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>

Cc: ASPA-Deputies <ASPA-Deputies@hhs.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Beck, Gary (OS/IEA) <Gary.Beck@hhs.gov>

Subject: For review by 11:30 AM: draft Sec. Azar coronavirus update

Hi all,

Attached is a draft section of a speech the Secretary is going to give this afternoon, (b)(5)

(b)(5)

If CDC and any others who wish to look can look at this by 11:30 AM, that would be great. Thank you!

- Patrick

From: Brennan, Patrick (OS/ASPA)

Sent: Friday, March 6, 2020 1:04 PM

To: Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Janik, Heather (FDA/OC) <Heather.Janik@fda.hhs.gov>; Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>; Lepore, Loretta (CDC/OD/OCS) <phf7@cdc.gov>; Stimson, Brian (HHS/OGC) <Brian.Stimson@hhs.gov>; Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>; Morse, Sara (HHS/ASL) <Sara.Morse@hhs.gov>; Pence, Laura (HHS/ASL) <Laura.Pence@hhs.gov>; Moughalian, Jen (HHS/ASFR) <Jen.Moughalian@hhs.gov>; Shuy, Caitrin (HHS/ASFR) <Caitrin.Shuy@hhs.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Zebley, Kyle (HHS/OS/OGA) <Kyle.Zebley@hhs.gov>; Grigsby, Garrett

(HHS/OS/OGA) <Garrett.Grigsby@hhs.gov>; Hittle, Taylor (HHS/ASFR) <Taylor.Hittle@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; CDC IMS JIC OADC LNO -2 <eocevent202@cdc.gov>; Heldman, Amy B. (CDC/OD/OADC) <evd4@cdc.gov>

Cc: ASPA-Deputies <ASPA-Deputies@hhs.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Beck, Gary (OS/IEA) <Gary.Beck@hhs.gov>

Subject: For review by 4:30 PM: draft Sec. Azar coronavirus update for nurse practitioners

Hi all,

(b)(5)

(b)(5)

(b)(5)

Please let me know if you have edits to this by 4:30 PM.

Best,
Patrick

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Valentine, Steven (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd508090f8984b1caf04069bc6000dc2-Valentine,>
Sent Date:	2020/03/10 11:55:06
Delivered Date:	2020/03/10 11:55:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Bradway, Courtney (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1dc2091f111a4f09bbeedf41dea697c8-Bradway, Co>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>
CC:	Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbee2d9b4db2a0f-Jernigan, D>
Subject:	RE: Nevada
Date:	2020/03/07 19:19:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Bradway, Courtney (HHS/ASL) <Courtney.Bradway@hhs.gov>
Sent: Saturday, March 7, 2020 7:15 PM
To: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Subject: Re: Nevada

(b)(5)

(b)(5)

On Mar 6, 2020, at 8:52 PM, Giroir, Brett (HHS/OASH)
<Brett.Giroir@hhs.gov>wrote:



Thank you

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>

Sent: Friday, March 6, 2020 8:47 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Jernigan, Daniel B.
(CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Cc: Bradway, Courtney (HHS/ASL) <Courtney.Bradway@hhs.gov>; Monroe, Steve
(CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>

Subject: Re: Nevada

(b)(5)

Steve Monroe, PhD
CDC

Sent using [Outlook for Android](#)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, March 6, 2020, 8:06 PM

To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID); Monroe, Steve
(CDC/DDPHSS/OLSS/OD)

Cc: Bradway, Courtney (HHS/ASL)

Subject: Nevada

(b)(5)

BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Bradway, Courtney (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1dc2091f111a4f09bbe9df41dea697c8-Bradway, Co>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbec2d9b4db2a0f-Jernigan, D>
Sent Date:	2020/03/07 19:19:09
Delivered Date:	2020/03/07 19:19:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Alexander Billioux <Alexander.Billioux@la.gov>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	RE: Louisiana Testing Site Discussion
Date:	2020/03/14 11:55:00
Priority:	Normal
Type:	Note

Sorry Sir.

The FEMA Deputy is in contact with your Emergency Manager. We are getting good information and am synching up with the FEMA Deputy shortly. Louisiana has expressed interest and he is getting clear requirements.

Best
BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Alexander Billioux <Alexander.Billioux@la.gov>
Sent: Saturday, March 14, 2020 11:02 AM
To: Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Re: Louisiana Testing Site Discussion

Sorry if there was a miscommunication about me missing this email and call. We are VERY interested in high throughout testing here in Louisiana and New Orleans specifically. We are eager to talk today.

Alex

Sent from my iPhone

On Mar 13, 2020, at 8:15 PM, Alexander Billioux
<Alexander.Billioux@la.gov>wrote:



Hello Rachel,

Thank you for reaching out and my apologies for having to miss the call with the ASH. Our Governor held a press conference shortly after the President completed his remarks. I would be able to speak tonight certainly. I am also happy to speak tomorrow if that is preferred.

Thanks,
Alex

From: Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>
Sent: Friday, March 13, 2020 7:35 PM
To: Alexander Billioux <Alexander.Billioux@la.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Louisiana Testing Site Discussion

EXTERNAL EMAIL: Please do not click on links or attachments unless you know the content is safe.

Good evening Mr. Billioux,

ADM Brett Giroir, HHS Assistant Secretary for Health, held a phone call this evening with select state and city health officials from multiple states, including Louisiana, to discuss testing sites. We would love to discuss Louisiana's interest in setting up these sites. We have interest from many counties already and want to discuss Louisiana's needs. Would you be available to talk with ADM Giroir tonight or tomorrow morning? Thanks so much.

Best,
Rachel Kellogg

Rachel Kellogg, RN
Policy Advisor
Office of the Assistant Secretary for Health
U.S. Department of Health & Human Services
Mobile: (b)(6)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Alexander Billioux <Alexander.Billioux@la.gov>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>

Sent Date:	2020/03/14 11:55:28
Delivered Date:	2020/03/14 11:55:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Ettinger, Michael (Legal) <Michael.Ettinger@henryschein.com>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>
CC:	Bergman, Stanley <StanleyM.Bergman@henryschein.com>; Mlotek, Mark <Mark.Mlotek@henryschein.com>; Bhansali, Seema <Seema.Bhansali@henryschein.com>
Subject:	RE: Matt Bassett said to give the Admiral a call.
Date:	2020/03/13 16:52:00
Priority:	Normal
Type:	Note

received

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Ettinger, Michael (Legal) <Michael.Ettinger@henryschein.com>
Sent: Friday, March 13, 2020 2:47 PM
To: Haddad, Carla (HHS/OASH) <Carla.Haddad@hhs.gov>
Cc: Bergman, Stanley <StanleyM.Bergman@henryschein.com>; Mlotek, Mark <Mark.Mlotek@henryschein.com>; Bhansali, Seema <Seema.Bhansali@henryschein.com>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Matt Bassett said to give the Admiral a call.

Hi Carla,

Matt Bassett said to reach out to the Admiral. We called the Admiral's office, but were told to email you.

(b)(4)

(b)(4)

If helpful, our CEO and other senior executives would welcome the opportunity to get on a phone call with you immediately to discuss the details of our plan how we can move this forward quickly before these tests get deployed to other parts of the world.

Besides myself (my contacts are below), you can reach out to our Chairman, Stan Bergman at 631.704.2852 or Mark Mlotek at 917.847.3445.

Best Regards,

Michael S. Ettinger
Senior Vice President,
Corporate & Legal Affairs and
Chief of Staff
Henry Schein, Inc.
135 Duryea Road
Melville, NY 11747
631.843.5993 (o)
631.843.5660 (f)
(b)(6) (c)

Please consider the environment before printing this email.

E-mail messages may contain viruses, worms, or other malicious code. By reading the message and opening any attachments, the recipient accepts full responsibility for taking protective action against such code. Henry Schein is not liable for any loss or damage arising from this message.

The information in this email is confidential and may be legally privileged. It is intended solely for the addressee(s). Access to this e-mail by anyone else is unauthorized.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Ettinger, Michael (Legal) <Michael.Ettinger@henryschein.com>; Haddad, Carla (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>; Bergman, Stanley <StanleyM.Bergman@henryschein.com>; Mlotek, Mark <Mark.Mlotek@henryschein.com>; Bhansali, Seema <Seema.Bhansali@henryschein.com>
Sent Date:	2020/03/13 16:52:44
Delivered Date:	2020/03/13 16:52:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>
Subject:	RE: Coronavirus test NOT Allowed despite Admiral Brett P. Giroir, assistant secretary of health Advice
Date:	2020/03/16 22:01:00
Priority:	Normal
Type:	Note

TY

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>
Sent: Monday, March 16, 2020 10:01 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Re: Coronavirus test NOT Allowed despite Admiral Brett P. Giroir, assistant secretary of health Advice

I took care of it.

Sent from my iPhone

On Mar 16, 2020, at 8:34 PM, Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov> wrote:

☐

Thank you for your service.

(b)(5)

BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: carle b <(b)(6)>@gmail.com>

Sent: Monday, March 16, 2020 7:17 PM

To: Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Collins, Christine (OS/ASPR/EMMO) <Christine.Collins@hhs.gov>

Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Subject: Coronavirus test NOT Allowed despite Admiral Brett P. Giroir, assistant secretary of health Advice

Dr Yeskey and CPT Collins,

I asked for a CV test before going home on March 17t I am 70 year old nurse on DMAT for 23 years and left 14 day deployment at Pt Magu and came directly to Miramar and completed 4 day deployment . I had direct contact with PPE on properly taking care of 4 positive patients in hotel at Miramar. Despite explaining why I wanted test to Kathryn the safety officer over phone and to Pam Evans who delivered a RTW letter saying I was a lo risk. I received the same letter after working 14 days at PT Magu with little interaction with a healthy guest. Today at the White House an update was given by the Administration and the following was stated by Admiral Giroir:
Admiral Brett P. Giroir, assistant secretary of health at the Department of Health and Human Services, said gear and federal health care workers were being shipping out Monday. Health officials said they were focusing those tests on two groups: **Healthcare workers and first responders**, as well as those who are 65 and older with a symptoms of respiratory problems and a fever of at least 99.6 degrees. The officials implored Americans to help prioritize those two groups.

I am de mobbing tomorrow and still want a test before I leave because of the 4 patients with positives and my age. I told Pam Evans that was wrong to deny me a test . I would like to know if you , Dr Yeskey can approve a swab before I leave San Diego tomorrow.

Respectfully,

Carle

Carle Brunochelli

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group

	(FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>
Sent Date:	2020/03/16 22:01:10
Delivered Date:	2020/03/16 22:01:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Robert R. Redfield (CDC/OD) (olx1@cdc.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9ab74a26317547b8a754285d9eaa847c-robert.redf>
Subject:	FDA FAQ
Date:	2020/03/14 13:49:00
Priority:	Normal
Type:	Note

Q: I am having trouble obtaining viral transport media/universal transport media (VTM/UTM) to collect and transport patient samples. Are there alternatives that I can use?

A: While VTM/UTM remains the preferred transport media, FDA believes that the following alternative transport media could be used to collect and transport patient samples for molecular RT-PCR SARS-CoV-2 assays in a manner that will stabilize the RNA without meaningful degradation:

- Liquid Amies-based transport media.
 - Supplies:
 - E-Swab by Copan (Catalogue # 481C and 482C) with regular or flex minitip applicator
 - Opti-Swab by Puritan (Catalogue # LA-117), swab included in kit (Catalog#3317-H).
 - Storage: Up to 72 hours at 4°C, or frozen for longer storage.

If the above are not available, FDA believes that the following could be used to collect and transport samples for molecular RT-PCR SARS-CoV-2 assays:

- Dry swab in saline
 - Supplies:
 - Puritan: 25-3317-H, 25-3316-U, 25-3316-H, 25-3317-U, 25-3318-U, 25-3318-H, 3316-U, 3317-U, 3318-U, 25-3319-H, 3316-H, 3318-H, 25-3320-U, 25-3320-U EMB 100MM, 25-3320-U EMB 80MM, 25-3320-H and 25-3320-H EMB 80MM
 - Copan: 501CS01, 503CS01, 516CS01, 518CS01 and 534CS01
 - Storage: Up to 72 hours at 4°C, or frozen for longer storage.

Please be aware that the CDC does not recommend use of calcium alginate swabs or swabs with wooden shafts, as they may contain substances that inactivate some viruses and inhibit PCR testing.

We are continuing to evaluate other options for specimen collection supplies, and we will update this list accordingly as this information becomes available.

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Robert R. Redfield (CDC/OD) (olx1@cdc.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9ab74a26317547b8a754285d9eaa847c-robert.redf>
Sent Date:	2020/03/14 13:49:52
Delivered Date:	2020/03/14 13:49:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbee2d9b4db2a0f-Jernigan, D>
CC:	Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>
Subject:	RE: New York
Date:	2020/03/07 08:38:00
Priority:	Normal
Type:	Note

That is terrific
Thank you

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Saturday, March 7, 2020 8:34 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: New York

(b)(5)

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

**Center for Devices and Radiological Health
U.S. Food and Drug Administration**

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration

White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993

Ph: 301-796-7692

Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Saturday, March 7, 2020 7:30 AM

To: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Jernigan, Daniel B (CDC) <dbj0@cdc.gov>; Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Cc: Berger, Sherri (CDC) <sob8@cdc.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Subject: RE: New York

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, March 6, 2020 11:11 PM

To: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>

Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: New York

(b)(5)

V/r
BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbee2d9b4db2a0f-Jernigan, D>; Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>
Sent Date:	2020/03/07 08:38:35
Delivered Date:	2020/03/07 08:38:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Horahan, Kevin (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user09957bb0>; Greene, Jonathan (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1b692a4d6cff4afabbeea99d35336ece-Greene, Jon>
CC:	Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>; Phillips, Sally (OS/ASPR/SPPR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5d6ce8134846423cb83b5b28464edb60-Phillips, S>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>
Subject:	RE: CMS Call on Nursing Home Task Force
Date:	2020/03/10 14:06:00
Priority:	Normal
Type:	Note

I will lean into this as soon as I return
Sally or Jonathan – can you make sure I intersect on this?

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
Sent: Tuesday, March 10, 2020 12:59 PM
To: Horahan, Kevin (OS/ASPR/EMMO) <Kevin.Horahan@hhs.gov>; Greene, Jonathan (OS/ASPR/EMMO) <Jonathan.Greene@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Phillips, Sally (OS/ASPR/SPPR) <Sally.Phillips@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>
Subject: CMS Call on Nursing Home Task Force

(b)(5)

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Horahan, Kevin (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user09957bb0>; Greene, Jonathan (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1b692a4d6cff4afabbbea99d35336ece-Greene, Jon>; Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>; Phillips, Sally (OS/ASPR/SPPR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5d6ce8134846423cb83b5b28464edb60-Phillips, S>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>
Sent Date:	2020/03/10 14:06:30
Delivered Date:	2020/03/10 14:06:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbec2d9b4db2a0f-Jernigan, D>
CC:	Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>
Subject:	RE: New York
Date:	2020/03/07 08:41:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Saturday, March 7, 2020 8:34 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: New York

(b)(5)

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

**Center for Devices and Radiological Health
U.S. Food and Drug Administration**
Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Saturday, March 7, 2020 7:30 AM

To: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Jernigan, Daniel B (CDC) <dbj0@cdc.gov>; Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Cc: Berger, Sherri (CDC) <sob8@cdc.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Subject: RE: New York

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, March 6, 2020 11:11 PM

To: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>

Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Lenihan, Keagan (FDA/OC)

<Keagan.Lenihan@fda.hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Subject: New York

(b)(5)

V/r
BG

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbee2d9b4db2a0f-Jernigan, D>; Berger, Sherri (CDC/OCOO/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=813a9180b08c4a24a48d1d674a7b6b42-Berger, She>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>
Sent Date:	2020/03/07 08:41:47
Delivered Date:	2020/03/07 08:41:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Bradshaw, Sheldon <SBradshaw@KSLAW.com>; HHS ASH (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2101ba7c65214377be8e163423ca9c70-ASH>
CC:	Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	RE: Urgent -- Coronavirus Test Kits
Date:	2020/03/13 16:56:00
Priority:	Normal
Type:	Note

On it

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Bradshaw, Sheldon <SBradshaw@KSLAW.com>
Sent: Friday, March 13, 2020 3:53 PM
To: HHS ASH (HHS/OASH) <ASH@hhs.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>
Subject: Urgent -- Coronavirus Test Kits
Importance: High

Dr. Giroir and Rachel,

Based on my prior experience as Chief Counsel of the FDA, I know how busy you are right now and would not be writing unless it was urgent. I'm writing on behalf of my client, Henry Schein, the world's largest distributor of medical devices. (b)(4)

(b)(4)

(b)(4)

My client is anxious to speak with your office and can schedule a call at your earliest convenience. Please let me know if you have any questions. Take care,

Sheldon

(b)(4)

Sheldon Bradshaw

Partner

King & Spalding LLP

1700 Pennsylvania Ave., NW | Washington, DC 20006

+1 202.626.9225 | +1 202.626.3737 | sbradshaw@kslaw.com

King & Spalding Confidentiality Notice:

This message is being sent by or on behalf of a lawyer. It is intended exclusively for the individual or entity to which it is addressed. This communication may contain information that is proprietary, privileged or confidential or otherwise legally exempt from disclosure. If you are not the named addressee, you are not authorized to read, print, retain, copy or disseminate this message or any part of it. If you have received this message in error, please notify the sender immediately by e-mail and delete all copies of the message. [Click here to view our Privacy Notice.](#)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Bradshaw, Sheldon <SBradshaw@KSLAW.com>; HHS ASH (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2101ba7c65214377be8e163423ca9c70-ASH>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Sent Date:	2020/03/13 16:56:07
Delivered Date:	2020/03/13 16:56:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Subject:	call me please
Date:	2020/03/14 14:30:00
Priority:	Normal
Type:	Note

Q: I am having trouble obtaining viral transport media/universal transport media (VTM/UTM) to collect and transport patient samples. Are there alternatives that I can use?

A: While VTM/UTM remains the preferred transport media, FDA believes that the following alternative transport media could be used to collect and transport patient samples for molecular RT-PCR SARS-CoV-2 assays in a manner that will stabilize the RNA without meaningful degradation:

- Liquid Amies-based transport media.
 - Supplies:
 - E-Swab by Copan (Catalogue # 481C and 482C) with regular or flex minitip applicator
 - Opti-Swab by Puritan (Catalogue # LA-117), swab included in kit (Catalog#3317-H).
 - Storage: Up to 72 hours at 4°C, or frozen for longer storage.

If the above are not available, FDA believes that the following could be used to collect and transport samples for molecular RT-PCR SARS-CoV-2 assays:

- Dry swab in saline
 - Supplies:
 - Puritan: 25-3317-H, 25-3316-U, 25-3316-H, 25-3317-U, 25-3318-U, 25-3318-H, 3316-U, 3317-U, 3318-U, 25-3319-H, 3316-H, 3318-H, 25-3320-U, 25-3320-U EMB 100MM, 25-3320-U EMB 80MM, 25-3320-H and 25-3320-H EMB 80MM
 - Copan: 501CS01, 503CS01, 516CS01, 518CS01 and 534CS01
 - Storage: Up to 72 hours at 4°C, or frozen for longer storage.

Please be aware that the CDC does not recommend use of calcium alginate swabs or swabs with wooden shafts, as they may contain substances that inactivate some viruses and inhibit PCR testing.

We are continuing to evaluate other options for specimen collection supplies, and we will update this list accordingly as this information becomes available.

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)

200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Sent Date:	2020/03/14 14:30:48
Delivered Date:	2020/03/14 14:30:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	Valentine, Steven (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd508090f8984b1caf04069bc6000dc2-Valentine,>; Roman, Ruth (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f2dbfff46c6d4311bbfda930989f8723-Roman, Ruth>; Trent-Adams, Sylvia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=650dc3276414421693345147bfafd132-Trent-Adams>
Subject:	RE: Need Input/Concurrence for OMB Information Request Due 10am on Mondays
Date:	2020/03/08 21:31:00
Priority:	Normal
Type:	Note

Yes

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Valentine, Steven (HHS/OASH) <Steven.Valentine@hhs.gov>
Sent: Sunday, March 8, 2020 9:06 PM
To: Roman, Ruth (HHS/OASH) <Ruth.Roman@hhs.gov>; Trent-Adams, Sylvia (HHS/OASH) <Sylvia.Trent-Adams@hhs.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Re: Need Input/Concurrence for OMB Information Request Due 10am on Mondays

(b)(5)

On: 08 March 2020 20:51, "Roman, Ruth (HHS/OASH)" <Ruth.Roman@hhs.gov>wrote:

(b)(5)

Ruth Roman, MPH
Executive Officer
Office of the Assistant Secretary for Health

200 Independence Ave, SW
Washington, DC 20201
Office: 202-205-0677/DC
Office: 240-453-6028/Rockville
Work Cell: (b)(6)
Email: Ruth.Roman@hhs.gov

From: Trent-Adams, Sylvia (HHS/OASH) <Sylvia.Trent-Adams@hhs.gov>
Sent: Sunday, March 8, 2020 8:25 PM
To: Roman, Ruth (HHS/OASH) <Ruth.Roman@hhs.gov>
Cc: Valentine, Steven (HHS/OASH) <Steven.Valentine@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Re: Need Input/Concurrence for OMB Information Request Due 10am on Mondays

(b)(5)

Sent from my iPhone

On Mar 8, 2020, at 3:57 PM, Roman, Ruth (HHS/OASH) <Ruth.Roman@hhs.gov> wrote:



(b)(5)

(b)(5)

(b)(5)

Thanks,
Ruth

Ruth Roman, MPH
Executive Officer
Office of the Assistant Secretary for Health
200 Independence Ave, SW
Washington, DC 20201
Office: 202-205-0677/DC
Office: 240-453-6028/Rockville
Work Cell: (b)(6)
Email: Ruth.Roman@hhs.gov

From: "Kim, Shalley (OS/ASA)"
<Shalley.Kim@hhs.gov>
Date: March 7, 2020 at 2:14:05 PM EST
To: OS - OPDIV Executive Officers
<OS.OPDIVExecutiveOfficers@ees.hhs.gov>, OS -
STAFFDIV Executive Officers <OS-STAFFDIVExecutiveOfficers@ees.hhs.gov>
Subject: OMB Information Request Due 10am on
Mondays



Executive Officers:

(b)(5)

(b)(5)

Thank you.

Shalley

Shalley Kim

Office of the Assistant Secretary for Administration

Desk: 202.260.6229

Mobile: 202.389.2394

U.S. Department of Health & Human Services

200 Independence Avenue, SW

Washington, DC 20201

<Agency Reporting COVID 19.docx>

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Valentine, Steven (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd508090f8984b1caf04069bc6000dc2-Valentine,>; Roman, Ruth (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f2dbfff46c6d4311bbfda930989f8723-Roman, Ruth>; Trent-Adams, Sylvia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=650dc3276414421693345147bfafd132-Trent-Adams>
Sent Date:	2020/03/08 21:31:39
Delivered Date:	2020/03/08 21:31:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Becker, Scott APHL <Scott.Becker@aphl.org>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>
CC:	Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Emergency Center APHL <eoc@aphl.org>; !CoreTeamNovelCoronavirus <!CoreTeamNovelCoronavirus@aphl.org>
Subject:	RE: High-throughput extraction capacity in PHLs?
Date:	2020/03/11 08:49:00
Priority:	Normal
Type:	Note

Hi Scott

Let's stay in touch

I really need a pulse of the labs about who is up and running, who has shortages and of what. And making sure we connect them to whom they need

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Becker, Scott | APHL <Scott.Becker@aphl.org>
Sent: Wednesday, March 11, 2020 8:48 AM
To: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Emergency Center | APHL <eoc@aphl.org>; !CoreTeamNovelCoronavirus <!CoreTeamNovelCoronavirus@aphl.org>
Subject: RE: High-throughput extraction capacity in PHLs?

Good morning Steve, I will see what information we have on this.

Scott

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Wednesday, March 11, 2020 8:45 AM
To: Becker, Scott | APHL <Scott.Becker@aphl.org>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Monroe, Stephan <stm2@cdc.gov>
Subject: High-throughput extraction capacity in PHLs?

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Scott,

Given the supply chain issues with extraction kits, do you know how many / which PHLs have one, or more, of the high-throughput extraction platforms currently cleared for influenza testing?

<https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2>

Q: What happens if I do not have the instruments referenced in the authorization of CDC's EUA-authorized test?

A: FDA believes that the CDC's EUA-authorized test could be performed on the following instruments designed to detect RNA viruses, and which were FDA cleared in K190302 for CDC's RNA-based influenza panel:

- Applied Biosystems™ 7500 Fast Dx Real-Time PCR Instrument with SDS software version 1.4
- Applied Biosystems™ QuantStudio™ Dx with version 1.0.3 software
- QIAGEN Rotor-Gene Q MDx with AssayManager version 1.0.4.1 and Epsilon version 1.0.1 software

Steve Monroe, PhD

Associate Director for Laboratory Science and Safety

Director, Office of Laboratory Science and Safety

Centers for Disease Control and Prevention (CDC)

+1-404-639-2391 (direct)

(b)(6) (mobile)

smonroe@cdc.gov

EA: Ms. Kimberly Guyton / KGuyton@cdc.gov / +1-404-718-7415

<http://www.cdc.gov/labs/>



Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Becker, Scott APHL <Scott.Becker@aphl.org>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Emergency Center APHL <eoc@aphl.org>; !CoreTeamNovelCoronavirus <!CoreTeamNovelCoronavirus@aphl.org>
Sent Date:	2020/03/11 08:49:03
Delivered Date:	2020/03/11 08:49:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Stephen Tang <STang@orasure.com>
CC:	Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Bright, Rick (OS/ASPR/BARDA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=53034752f35a4317aa74f46348442d39-Bright, Ric>
Subject:	RE: SUMMARY: Urgent Commendation for COVID-19 Point-of-Care Testing
Date:	2020/03/16 22:12:00
Priority:	Normal
Type:	Note

Copying FDA Dr Shuren and BARDA Dr Bright.
How can I help?

BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Joni Messenlehner <JMessenlehner@orasure.com>**On Behalf Of** Stephen Tang
Sent: Monday, March 16, 2020 8:51 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: SUMMARY: Urgent Commendation for COVID-19 Point-of-Care Testing

Dear Admiral Giroir,

In the interest of time, I thought it would be helpful to summarize my earlier email:

I believe rapid "at home" or self-testing providing results in 20 minutes can dramatically increase the capacity for COVID-19 testing. Rapid point-of-care tests are quick, accurate, affordable and easy to use. Patients could be tested at home, helping maintain social distancing and curbing the spread of coronavirus.

OraSure Technologies, Inc. is uniquely positioned and has a tremendous track record in the development of point-of-care tests to respond to public health crises such as COVID-19. We have vast experience in developing rapid point-of-care testing for complex diagnostic problems such as HIV and HCV on a global scale.

I can be reached at 484-353-1500, or via email at stang@orasure.com to discuss how we can engage the Department of Health and Human Services, the U.S. Coronavirus Task Force, and other relevant agencies/officials to accelerate the development of a rapid test that could have an impact on the current situation. More details can be found below and in the attached letter.



OTI Corp letterhead logo

The Honorable Brett P. Giroir, MD
Assistant Secretary for Health
U.S. Department of Health and Human Services
200 Independence Avenue, SW
Washington, DC 20201

RE: Urgent Recommendation for COVID-19 Point-of-Care Testing

March 16, 2020

Dear Admiral Giroir,

I am writing with a proposed solution to significantly increase the capacity for COVID-19 testing: a rapid “at home” or self-test for coronavirus, whereby results could be known in 20 minutes. Rapid point-of-care tests are the ideal solution. They are quick, accurate, affordable and easy to use. Patients could be tested at home, helping maintain social distancing and curbing the spread of coronavirus. Capacity is limited only by how many tests could be made. Point-of-care tests are not a replacement of laboratory testing. Instead they are a proven addition that in the case of HIV and HCV has dramatically increased testing capabilities -- and can do the same for COVID-19.

OraSure Technologies, Inc. is uniquely positioned and has a tremendous track record in the development of point-of-care tests to respond to public health crises such as COVID-19. We have vast experience in developing easy-to-use solutions for complex diagnostic problems on a global scale. We are second to none in rapid point-of-care self-testing.

- Our oral fluid self-test for HIV is the first and only WHO-prequalified oral fluid test; it is used in developing countries to end HIV transmissions. In Q4 of 2019, we shipped 2.9 million self-tests.
- We have the first and only FDA-approved over-the-counter HIV rapid test; it is currently being used in the federal government’s Ending the HIV Epidemic: A Plan for America initiative.

- Our OraQuick Ebola Rapid Antigen test received FDA clearance in October. This is just one example of our experience in rapidly developing point-of-care diagnostics in partnership with the government.

Existing testing methods are not able to keep up with the need for COVID-19 testing. News reports note that CDC has tested approximately 11,000 specimens as of March 13th; a sharp contrast to the reported 20,000 patient a day test rate in South Korea. It's been difficult to build capacity, let alone build an adequate supply of tests quickly. In addition, the performance characteristics of existing tests are not ideal. And the tests are too complex, requiring transport and intervention by a lab technician.

The March 13th announcement of strategies to expand coronavirus testing is a good step, but more needs to be done. OraSure is currently engaged in discussions with government agencies such as BARDA and the DoD about how to potentially fund, produce, qualify and deploy an antigen screening system to positively identify acutely infected individuals for coronavirus.

However, time is of the essence. It is clear that PCR tests are unable to keep up with demand for reagents, limiting the number of people that can be tested. A rapid screen for pan corona viral antigen is viewed as the best way to identify infected individuals at the highest risk of spreading COVID-19 disease. OraSure would like to work with you and other officials to accelerate the development of a rapid test that could have an impact on the current situation.

Please contact me at 484-353-1500, or via email at stang@orasure.com to advise how we can engage the Department of Health and Human Services, the U.S. Coronavirus Task Force, and other relevant agencies/officials in an effort to get started right away on this important opportunity to address COVID-19 testing needs during this public health crisis.

Sincerely,



SST Electronic Signature

Stephen S. Tang, Ph.D.
President and Chief Executive Officer
OraSure Technologies, Inc.
220 E. First Street
Bethlehem, PA 18015

CC: The Honorable Michael Pence, Vice President
The Honorable Alex Azar, Secretary of Health and Human Services
Anthony Fauci, MD; Director, National Institute of Allergy and Infectious Diseases

Robert Redfield, MD; Director, Centers for Disease Control and Prevention
 Jerome Adams, MD; U.S. Surgeon General
 Seema Verma, MPH; Administrator, Centers for Medicare and Medicaid Services
 Stephen Hahn, MD; Commissioner, Food and Drug Administration
 Ambassador Deborah Birx, MD; U.S. Department of State

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Stephen Tang <STang@orasure.com>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Bright, Rick (OS/ASPR/BARDA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=53034752f35a4317aa74f46348442d39-Bright, Ric>
Sent Date:	2020/03/16 22:12:55
Delivered Date:	2020/03/16 22:12:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>
CC:	Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>
Subject:	RE: CDC Data
Date:	2020/03/12 22:42:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>
Sent: Thursday, March 12, 2020 10:34 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <Shannon.Sartin@cms.hhs.gov>
Subject: CDC Data

Admiral Giroir –

(b)(5)

Thanks,

Brad

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>
Sent Date:	2020/03/12 22:43:27
Delivered Date:	2020/03/12 22:42:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Johns, Matthew (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00adfdcc85e145f589fea508b0f530b9-Johns, Matt>; Trent-Adams, Sylvia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=650dc3276414421693345147bfafd132-Trent-Adams>
CC:	AvilesMendoza, Guillermo (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e0364bceaec8465ea5ac8efd7c1e2f3d-Aviles-Mond>
Subject:	RE: Update on COVID-19 from Region 9 (Sunday 3/8/2020)
Date:	2020/03/09 12:09:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Johns, Matthew (HHS/OASH) <Matthew.Johns@hhs.gov>
Sent: Monday, March 9, 2020 12:06 PM
To: Trent-Adams, Sylvia (HHS/OASH) <Sylvia.Trent-Adams@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: AvilesMendoza, Guillermo (OS/OASH) <Guillermo.Aviles-Mendoza@hhs.gov>
Subject: Re: Update on COVID-19 from Region 9 (Sunday 3/8/2020)

Thank you ADM Giroir and RADM Trent-Adams,

(b)(5)

(b)(5)

Thank you for your consideration.

Kind regards,

CDR Johns

Matthew C. Johns, MPH

Commander, United States Public Health Service

Regional Health Administrator-Region 9

Office of the Assistant Secretary for Health

Office of the Secretary

United States Department of Health and Human Services

90 7th Street, Suite 5-100

San Francisco, CA 94103

Phone: (415)437-8102

Mobile: (b)(6)

Email: Matthew.Johns@HHS.gov

Website: <https://www.hhs.gov/ash/about-ash/regional-offices/region-9/index.html>

HHS Region 9: In the Service of Health (In Officio Salutis) for Arizona, California, Nevada, Hawaii, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands and the Republic of Palau.....and 150 Federally-recognized Tribes.

On: 09 March 2020 03:49,

"Trent-Adams, Sylvia (HHS/OASH)" <Sylvia.Trent-Adams@hhs.gov>wrote:

Thank you CDR Johns. (b)(5) If you need anything do not hesitate to call.

Sent from my iPhone

On Mar 9, 2020, at 5:53 AM, Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>wrote:

This is a very useful update.

Thank you

Do you need anything from us at this time?

(b)(5)

BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Johns, Matthew (HHS/OASH) <Matthew.Johns@hhs.gov>

Sent: Sunday, March 8, 2020 11:47 PM

To: AvilesMendoza, Guillermo (OS/OASH) <Guillermo.Aviles-Mendoza@hhs.gov>; Trent-Adams, Sylvia (HHS/OASH) <Sylvia.Trent-Adams@hhs.gov>

Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Subject: Update on COVID-19 from Region 9 (Sunday 3/8/2020)

RADM, CDR,

(b)(5)

(b)(5)

Kind regards,

CDR Johns

Matthew C. Johns, MPH

Commander, United States Public Health Service

Regional Health Administrator-Region 9

Office of the Assistant Secretary for Health

Office of the Secretary

United States Department of Health and Human Services

90 7th Street, Suite 5-100

San Francisco, CA 94103

Phone: (415)437-8102

Mobile: (b)(6)

Email: Matthew.Johns@HHS.gov

Website: <https://www.hhs.gov/ash/about-ash/regional-offices/region-9/index.html>

HHS Region 9: In the Service of Health (In Officio Salutis) for Arizona, California, Nevada, Hawaii, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands and the Republic of Palau.....and 150 Federally-recognized Tribes.

<Guidance_Cleared_Updated_7Mar2020_9am.pdf>

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Johns, Matthew (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00adfdc85e145f589fea508b0f530b9-Johns, Matt>; Trent-Adams, Sylvia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=650dc3276414421693345147bfafd132-Trent-Adams>; AvilesMendoza, Guillermo (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e0364bceaec8465ea5ac8efd7c1e2f3d-Aviles-Mond>
Sent Date:	2020/03/09 12:09:18
Delivered Date:	2020/03/09 12:09:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Cote, Mick (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user9459b24b>
Subject:	Swabs
Date:	2020/03/14 14:50:00
Priority:	Normal
Type:	Note

(b)(5)

Q: I am having trouble obtaining viral transport media/universal transport media (VTM/UTM) to collect and transport patient samples. Are there alternatives that I can use?

A: While VTM/UTM remains the preferred transport media, FDA believes that the following alternative transport media could be used to collect and transport patient samples for molecular RT-PCR SARS-CoV-2 assays in a manner that will stabilize the RNA without meaningful degradation:

- Liquid Amies-based transport media.
 - Supplies:
 - E-Swab by Copan (Catalogue # 481C and 482C) with regular or flex minitip applicator
 - Opti-Swab by Puritan (Catalogue # LA-117), swab included in kit (Catalog#3317-H).
 - Storage: Up to 72 hours at 4°C, or frozen for longer storage.

If the above are not available, FDA believes that the following could be used to collect and transport samples for molecular RT-PCR sARS-CoV-2 assays:

- Dry swab in saline
 - Supplies:
 - Puritan: 25-3317-H, 25-3316-U, 25-3316-H, 25-3317-U, 25-3318-U, 25-3318-H, 3316-U, 3317-U, 3318-U, 25-3319-H, 3316-H, 3318-H, 25-3320-U, 25-3320-U EMB 100MM, 25-3320-U EMB 80MM, 25-3320-H and 25-3320-H EMB 80MM
 - Copan: 501CS01, 503CS01, 516CS01, 518CS01 and 534CS01
 - Storage: Up to 72 hours at 4°C, or frozen for longer storage.

Please be aware that the CDC does not recommend use of calcium alginate swabs or swabs with wooden shafts, as they may contain substances that inactivate some viruses and inhibit PCR testing.

We are continuing to evaluate other options for specimen collection supplies, and we will update this list accordingly as this information becomes available.

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Cote, Mick (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user9459b24b>
Sent Date:	2020/03/14 14:50:06
Delivered Date:	2020/03/14 14:50:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>
CC:	Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	FW: Offer of assistance to Coronavirus Task Force - Ensure smooth testing with appointments
Date:	2020/03/16 10:55:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Rucker, Donald (OS/ONC) <Donald.Rucker@hhs.gov>
Sent: Monday, March 16, 2020 10:44 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>
Cc: Richards, Chesley MD (CDC/DDPHSS/OD) <cir6@cdc.gov>; Gundlapalli, Adi (CDC/DDPHSS/CSELS/OD) <ibk8@cdc.gov>; Brady, Will (HHS/IOS) <William.Brady@hhs.gov>
Subject: FW: Offer of assistance to Coronavirus Task Force - Ensure smooth testing with appointments

(b)(5)

From: Cimarron Buser <cbuser@timetrade.com>
Sent: Monday, March 16, 2020 10:22 AM
To: Rucker, Donald (OS/ONC) <Donald.Rucker@hhs.gov>
Cc: Don Rucker <donrucker@outlook.com>
Subject: Offer of assistance to Coronavirus Task Force - Ensure smooth testing with appointments


Hi Don – I'd appreciate your help in getting an introduction to the WH Coronavirus Task Force (or perhaps you are on it?). We'd like to offer our capabilities to ensure appointments can be used for testing to **avoid the risk of crowding, lines, and confusion**. We're already "set up" for this – just need to

make sure we connect with the team to coordinate making this smooth. Thanks, Cimarron

Summary of Proposal for Coronavirus Test Appointment System

TimeTrade will assist the US Coronavirus Task Force by providing a way for **anyone seeking COVID-19 testing to schedule an appointment** at any available testing location in the US. This will ensure an orderly way to provide testing at wide scale, reducing the risk of crowding, lines, and confusion as the program is rolled out.

The solution would enable anyone to search on Google with a term such as “coronavirus testing near me” or similar, and then see a list of the closest locations. Once a location is selected, a person picks a date and time for their appointment (same day appointments work if available). They will then receive an email notification, as well as be able to get directions to the location.



TimeTrade is uniquely able to provide this service:

- TimeTrade already connects with Google’s scheduling solution (Reserve with Google) and can provide updated location feeds every 24 hours; availability results are real-time
- TimeTrade provides location appointment scheduling for companies including Quest Diagnostics, and can quickly configure and load locations and appointments for Target, Walmart, Walgreens, CVS, and any other businesses as required
- TimeTrade is a trusted, secure, enterprise grade, cloud-based solution – we support 400+ enterprises and can handle 100’s of millions of appointments

- TimeTrade will provide system configuration, enable onboarding of locations, coordinate appointment flows, and provide instant reporting and analytics
- TimeTrade is prepared to execute on this plan TODAY and has all necessary technology, staff and integration with Google to turn on a live system within 48 hours

Cimarron Buser

SVP Business Development

phone | +1.978.654.6808

mobile | (b)(6)

book a meeting | www.timetrade.com/cbuser

timetrade

100 Ames Pond Drive, Tewksbury, MA 01876 USA

Website [LinkedIn](#) [Twitter](#) [Facebook](#)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Sent Date:	2020/03/16 10:55:41
Delivered Date:	2020/03/16 10:55:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; <(b)(6)>@gmail.com>; Rachael Baitel <rbaitel@usaid.gov>
Subject:	FW: URGENT: Swab Testing for Influenza Consuming LIMITED SUPPLY OF VIRAL Swabs and Test Kits
Date:	2020/03/16 10:56:00
Importance:	High
Priority:	Urgent
Type:	Note

FYSA

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
Sent: Monday, March 16, 2020 10:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Adams, Steven A. (ASPR/SNS) <saa1@cdc.gov>; Ottem, Ronald (Ron) (ASPR/SNS) <rco9@cdc.gov>; Harrison, Brian (HHS/IOS) <Brian.Harrison@hhs.gov>; Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>; Mecher, Carter (VA.GOV) <carter.mecher@va.gov>
Subject: URGENT: Swab Testing for Influenza Consuming LIMITED SUPPLY OF VIRAL Swabs and Test Kits
Importance: High

All-I discussions with major domestic manufacturer of viral swabs need for COVID testing learned demand for flu testing has dramatically increased diverting swabs available from COVID testing(e.g. 800K swabs made by this manufacturer being sent to support flu testing this week)
In talking with clinicians in NY and NY, limits in availability of hospital testing and dependence

on PH lab testing an delays have them testing all suspect cases for flu and if negative managing patients as presumptive COVID positive AND using large quantities of PPE.
Epi data indicates below indicates in areas where COVID transmission high ROK and WA and NY circulating lab diagnosis flu low.

We need to speak medical and public health community that as we transition to wide scale COVD testing to **STOP** testing for flu! We are burning both swabs and PPE.

—

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; <(b)(6)>@gmail.com>; Rachael Baitel <rbaitel@usaid.gov>
Sent Date:	2020/03/16 10:57:19
Delivered Date:	2020/03/16 10:56:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>
CC:	Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	RE: CDC Data
Date:	2020/03/12 22:53:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Giroir, Brett (HHS/OASH)
Sent: Thursday, March 12, 2020 10:47 PM
To: Smith, Brad (CMS/OA) <brad.smith@cms.hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <shannon.sartin@cms.hhs.gov>
Subject: RE: CDC Data

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>
Sent: Thursday, March 12, 2020 10:34 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <Shannon.Sartin@cms.hhs.gov>
Subject: CDC Data

Admiral Giroir –

(b)(5)

Thanks,

Brad

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Sent Date:	2020/03/12 22:53:10
Delivered Date:	2020/03/12 22:53:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Heck, Mia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70dbe2065d644b8dadbfa56c5d63553d-Heck, Mia>
CC:	Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>
Subject:	RE: CBS News Coronavirus questions
Date:	2020/03/10 14:16:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Heck, Mia (HHS/OASH) <Mia.Heck@hhs.gov>
Sent: Tuesday, March 10, 2020 2:15 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: FW: CBS News Coronavirus questions

ADM Giroir,

(b)(5)

From: McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>
Sent: Tuesday, March 10, 2020 1:41 PM
To: Heck, Mia (HHS/OASH) <Mia.Heck@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Haynes, Benjamin (CDC/OD/OADC) <fxq2@cdc.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>
Subject: FW: CBS News Coronavirus questions

(b)(5)

From: Dore, Maggie
Sent: Tuesday, March 10, 2020 1:25 PM
To: Caitlin.Oakley@HHS.GOV; Matt.Lloyd@hhs.gov; Evelyn.Stauffer@hhs.gov
Subject: CBS News Coronavirus questions

Hi All. Apologies for the mass email, I want to make sure the right person at HHS gets it. We need several questions answered for our Coronavirus report tonight on the CBS Evening News, deadline ASAP:

--drill down on the 1.1m tests that Secretary Azar testified were shipped as of the end of this past week:

1. does the 1.1m refer to the number of patients who can be tested? Or does it refer to the number of swabs that can be tested. There are two swabs for every patient (nose + throat) – so if 1.1m swabs, would cover 550k patients for a one-time test.
2. Is there any bottleneck in the diagnostic process right now: for example, after the kits are shipping to a lab, do all the labs have the capability and manpower (Trained techs) to process them quickly
3. How many different manufacturers are ramping up their capacity and can you give us a breakdown laboratory by laboratory of what that will be over the next two weeks
4. Is HHS or any other agency currently tracking in a central database how many tests have been performed, how many negative results there are, and how many positive results there are? (please confirm whether than includes private testing results or just state labs)
5. Given the technical problems with the tests coming out of the CDC, was any consideration given to as a stopgap measure to using a test from another source such as the WHO?

Thanks!

Maggie Dore
Producer, CBS Evening News
202 457-4385

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Heck, Mia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70dbe2065d644b8dadbf56c5d63553d-Heck, Mia>; Bante, Katie (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dc7b1305e642648084faafdc789697-Bante, Kati>
Sent Date:	2020/03/10 14:16:47
Delivered Date:	2020/03/10 14:16:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	Dozor, Joshua (fema.dhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1b4e4edf94e440d884661b28b378bb41-Joshua.Doza>
Subject:	FW: Coronavirus Testing
Date:	2020/03/14 17:13:00
Priority:	Normal
Type:	Note

LA Governor

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: JBE <jbe@la.gov>
Sent: Saturday, March 14, 2020 5:11 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Re: Coronavirus Testing

Dr. Giroir:

Thank you for your work on this pandemic emergency.

There are now 77 presumptive positive cases in Louisiana, with the vast majority being in Orleans and Jefferson Parish. An hour ago we announced the first death — a 58 year old gentleman from New Orleans with chronic health conditions.

On a per capita basis, I believe Louisiana has the third most cases in the country.

We have imposed significant mitigation measures to slow the spread of Coronavirus (COVID-19), but I am afraid the testing is nowhere near as robust as necessary to identify more positive cases that can then be isolated/quarantined so that we can in a significant way slow the spread, flatten the curve, and better ensure that our medical/hospital capacity is not overwhelmed.

Please make every effort to significantly increase our testing capacity and testing through put as soon as possible.

Feel free to respond to me or to have someone on your team contact Dr. Alex Billioux, Assistant Secretary for the Office of Public Health.

Thank you.

John Bel

Sent from my iPhone

On Mar 14, 2020, at 8:50 AM, JBE <jbe@la.gov>wrote:

☐ Thanks. We will take you up on your offer. My public health folks will contact your team shortly.

Sent from my iPhone

On Mar 13, 2020, at 7:34 PM, Giroir, Brett (HHS/OASH)
<Brett.Giroir@hhs.gov>wrote:

☐

EXTERNAL EMAIL: Please do not click on links or attachments unless you know the content is safe.

Sir,

We had your health team on the line this evening. White House is offering to assist with setting up drive through testing sites at hot spots. And NOLA and Jefferson Parrish are on our list. Totally your call but this could be helpful to you. We are waiting to hear back from your team.

V/r
BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Dozor, Joshua (fema.dhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1b4e4edf94e440d884661b28b378bb41-Joshua.Doza>
Sent Date:	2020/03/14 17:13:23
Delivered Date:	2020/03/14 17:13:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	McKeogh, Katherine (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c652f2c415b44dff8369dd7f4596f030-McKeogh, Ka>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>
CC:	Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Caccamo, Stephanie (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3b415b3f6cff4b18980c5f723fad2ce0-stephanie.c>
Subject:	RE: WSJ questions on COVID-19 test capacity
Date:	2020/03/07 21:40:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>

Sent: Saturday, March 7, 2020 8:18 PM

To: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Cc: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>

Subject: RE: WSJ questions on COVID-19 test capacity

(b)(5)

(b)(5)

(b)(5)

From: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>
Sent: Saturday, March 7, 2020 7:18 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>
Subject: Re: WSJ questions on COVID-19 test capacity

(b)(5)

Sent from my iPhone

On Mar 7, 2020, at 7:14 AM, Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov> wrote:

☐

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>
Sent: Saturday, March 7, 2020 12:44 AM
To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: RE: WSJ questions on COVID-19 test capacity

(b)(5)

From: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Sent: Friday, March 6, 2020 10:05 AM
To: OS Media (HHS/ASPA) <media@hhs.gov>; CDC OADC Media Review <OADCMediaReview@cdc.gov>; ASPRCOMMS <ASPRCOMMS@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>
Subject: RE: WSJ questions on COVID-19 test capacity

(b)(5)

From: OS Media (HHS/ASPA) <media@hhs.gov>
Sent: Friday, March 6, 2020 9:24 AM
To: CDC OADC Media Review <OADCMediaReview@cdc.gov>; ASPRCOMMS <ASPRCOMMS@hhs.gov>
Cc: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; OS Media (HHS/ASPA) <media@hhs.gov>
Subject: FW: WSJ questions on COVID-19 test capacity

From: Loftus, Peter <peter.loftus@wsj.com>
Sent: Friday, March 6, 2020 8:38 AM
To: OS Media (HHS/ASPA) <media@hhs.gov>
Subject: WSJ questions on COVID-19 test capacity

Hello, can HHS provide an update for Friday, 3/6, on the current U.S. testing capacity for the new coronavirus? Will the U.S. meet the goal of one million tests by the end of this week, as laid out this week by FDA Commissioner Hahn and Secretary Azar (who also said that would be enough for about 400,000 people)?

Can you say how many CDC test kits have been shipped to public health labs so far?

Also, VP Pence said yesterday there are not enough tests to meet anticipated demand - can you comment on that?

This is for a story likely to run later today.

--

Peter Loftus
REPORTER

<image002.jpg>

M: (b)(6) O: +1 215 881 7127
E: peter.loftus@wsj.com
Twitter: @Loftus

<image002.jpg>

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	McKeogh, Katherine (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c652f2c415b44dff8369dd7f4596f030-McKeogh, Ka>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Caccomo, Stephanie (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3b415b3f6cff4b18980c5f723fad2ce0-stephanie.c>
Sent Date:	2020/03/07 21:40:45
Delivered Date:	2020/03/07 21:40:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
CC:	Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>
Subject:	RE: Order of priority of testing IDT QC lots (509 > 295)
Date:	2020/03/11 09:06:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Wednesday, March 11, 2020 8:58 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: RE: Order of priority of testing IDT QC lots (509 >295)

(b)(5)

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

**Center for Devices and Radiological Health
U.S. Food and Drug Administration**
Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell
Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Wednesday, March 11, 2020 8:56 AM
To: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>
Subject: RE: Order of priority of testing IDT QC lots (509 >295)

(b)(5)

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Wednesday, March 11, 2020 8:54 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: FW: Order of priority of testing IDT QC lots (509 >295)

(b)(5)

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

**Center for Devices and Radiological Health
U.S. Food and Drug Administration**

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>
Sent: Wednesday, March 11, 2020 8:48 AM
To: Terrill, Roman <rterill@idtdna.com>; Lindstrom, Stephen (CDC) <sql5@cdc.gov>
Cc: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Monroe, Stephan S (CDC) <stm2@cdc.gov>
Subject: RE: Order of priority of testing IDT QC lots (509 >295)

Roman, please see attached for the QC approval for the lot that we received yesterday.

Thanks, wendi

Wendi Kuhnert-Tallman
Office - 404-639-3103
Mobile - (b)(6)

From: Terrill, Roman <rterrill@idtdna.com>
Sent: Tuesday, March 10, 2020 9:53 PM
To: Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>; Lindstrom, Stephen (CDC/DDID/NCIRD/DVD) <sql5@cdc.gov>
Cc: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>
Subject: Order of priority of testing IDT QC lots (509 >295)
Importance: High

Hello Wendi, Steve and Tim:

I wanted to add urgency and provide clarity on the order of priority for the QC of lots of IDT kits at CDC.

As we discussed today, QC test lot (507295, aka '295) arrived at CDC earlier this morning (Tuesday 3-10) from the last of our smaller scale builds. This lot will approve another ~700 kits or 350,000 tests. We used these smaller scale builds so that we always had sellable inventory available last week and early this week.

Tonight we are shipping an additional set of test kits from our scale up process. This new lot of QC samples (Lot # 507509, aka '509) will be arriving tomorrow at the CDC by 10:30am on FedEx Tracking 1707 6170 3009. This will release **4,000 kits (2 Million tests)**.

If we can urge CDC to prioritize the Wednesday receipt, lot '509, over the testing of the Tuesday receipt, lot '295, that would be very beneficial to our inventory. We are approaching stock-out levels, and the approval of the larger lot tomorrow Wednesday may be necessary to continue to provide "same day shipment" to testing labs nationwide.

Thank you in advance for your attention to this email, and for your cooperation.

Sincerely,

Roman Terrill
Senior Vice President
IDT

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>
Sent Date:	2020/03/11 09:06:45
Delivered Date:	2020/03/11 09:06:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	<p>Brennan, Patrick (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b51c3d9a49fd4882951eca2417c19dcf-Brennan, Pa>; Conrad, Patricia (NIH/NIAID) [E] </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3793ae43a1744d8f8aa56b600c0c975b-patricia.co>; Bonds, Michelle E. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=458a7c66b66a4e9ca7bc1963da0bcb81-michelle.bo>; Galatas, Kate (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9e6fa4be928e48408ba114add868123e-Galatas, Ka>; Billet, Courtney (NIH/NIAID) [E] </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cb5c51123f2f41b98b61a37383994a8d-courtney.bi>; Michael, Gretchen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0632b4526d6447b5af26552afde05c33-Michael, Gr>; Caliguri, Laura (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40352e099c9a46dca3310df0ac5afd0e-laura.calig>; Lepore, Loretta (CDC/OD/OCS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5089268744434ae3836b66685f37d8d4-loretta.lep>; Arbes, Sarah (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=106db0ac70a241a8b1323647c093d9bf-Arbes, Sara>; Morse, Sara (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=eb3a04f7dbde41049bfd10f490d3e178-Morse, Sara>; Pence, Laura (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>; Moughalian, Jen (HHS/ASFR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a1ec840c6a2d4adbb91e420a23c7eaf-Moughalian,>; Shuy, Caitrin (HHS/ASFR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1f12cde7b4764f1aad8b20c0dceae0a7-Shuy, Caitr>; Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcb4c6ea342c08d58f63e37d997e7-Trueman, La>; Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Johnston, Darcie (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6a8047840ca4406b5ac6bc5cf259937-Johnston, D>; Kane, Elleen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user25dbd6c7>; Zebley, Kyle (HHS/OS/OGA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b81a0e4749994f969ff1063b9a3a0b1f-Zebley, Kyl>; Grigsby, Garrett (HHS/OS/OGA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7cd78b4810d44b17b8711aaede9a9023-Grigsby, Gl>; Hittle, Taylor (HHS/ASFR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4a6a08d06d8648fda1e44f515f35eebb-Hittle, Pat>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Galatas, Kate (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9e6fa4be928e48408ba114add868123e-Galatas, Ka>; CDC IMS JIC OADC LNO -2 <eoevent202@cdc.gov>; Heldman, Amy B. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=83a9fa86982a40238ae2f162b869ef39-Burnett, Am>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Caccamo, Stephanie (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3b415b3f6cff4b18980c5f723fad2ce0-stephanie.c>; Charrow, Robert (HHS/OGC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00531138af454ce3ac0b5885bead345f-Charrow, Ro>; Keveney, Sean (HHS/OGC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2e13823250af4ccf93b3de562380e78e-Keveney, Se></p>
CC:	<p>ASPA-Deputies </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=884d75c735db47cca76a4c0fc74a06b8-ASPA-Deputi>; McGowan, Robert (Kyle) (CDC/OD/OCS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a2046e75239f48a28d2854bedbe5f899-robert.mcgo>; Beck, Gary (OS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a049f8137013412bbf472fc1833391be-Beck, Miche></p>

Subject:	RE: For review by 8 AM tomorrow: draft Sec. Azar statement on POTUS address
Date:	2020/03/11 22:32:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Brennan, Patrick (OS/ASPA) <Patrick.Brennan@hhs.gov>

Sent: Wednesday, March 11, 2020 10:09 PM

To: Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>; Lepore, Loretta (CDC/OD/OCS) <phf7@cdc.gov>; Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>; Morse, Sara (HHS/ASL) <Sara.Morse@hhs.gov>; Pence, Laura (HHS/ASL) <Laura.Pence@hhs.gov>; Moughalian, Jen (HHS/ASFR) <Jen.Moughalian@hhs.gov>; Shuy, Caitrin (HHS/ASFR) <Caitrin.Shuy@hhs.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Zebley, Kyle (HHS/OS/OGA) <Kyle.Zebley@hhs.gov>; Grigsby, Garrett (HHS/OS/OGA) <Garrett.Grigsby@hhs.gov>; Hittle, Taylor (HHS/ASFR) <Taylor.Hittle@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; CDC IMS JIC OADC LNO -2 <eoevent202@cdc.gov>; Heldman, Amy B. (CDC/OD/OADC) <evd4@cdc.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Charrow, Robert (HHS/OGC) <Robert.Charrow@hhs.gov>; Keveney, Sean (HHS/OGC) <Sean.Keveney@hhs.gov>
Cc: ASPA-Deputies <ASPA-Deputies@hhs.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Beck, Gary (OS/IEA) <Gary.Beck@hhs.gov>

Subject: For review by 8 AM tomorrow: draft Sec. Azar statement on POTUS address

Hi all,

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Brennan, Patrick (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b51c3d9a49fd4882951eca2417c19dcf-Brennan, Pa>; Conrad, Patricia (NIH/NIAID) [E] </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3793ae43a1744d8f8aa56b600c0c975b-patricia.co>; Bonds, Michelle E. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=458a7c66b66a4e9ca7bc1963da0bcb81-michelle.bo>; Galatas, Kate (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9e6fa4be928e48408ba114add868123e-Galatas, Ka>; Billet, Courtney (NIH/NIAID) [E] </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cb5c51123f2f41b98b61a37383994a8d-courtney.bi>; Michael, Gretchen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0632b4526d6447b5af26552afde05c33-Michael, Gr>; Caliguiri, Laura (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=40352e099c9a46dca3310df0ac5afd0e-laura.calig>; Lepore, Loretta (CDC/OD/OCS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5089268744434ae3836b66685f37d8d4-loretta.lep>; Arbes, Sarah (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=106db0ac70a241a8b1323647c093d9bf-Arbes, Sara>; Morse, Sara (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=eb3a04f7dbde41049bfd10f490d3e178-Morse, Sara>; Pence, Laura (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group

	(FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>; Moughalian, Jen (HHS/ASFR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a1ec840c6a2d4adbbc91e420a23c7eaf-Moughalian,>; Shuy, Caitrin (HHS/ASFR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1f12cde7b4764f1aad8b20c0dceae0a7-Shuy, Caitr>; Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcb4c6ea342c08d58f63e37d997e7-Trueman, La>; Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Johnston, Darcie (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6a8047840ca4406b5ac6bc5cf259937-Johnston, D>; Kane, Elleen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user25dbd6c7>; Zebley, Kyle (HHS/OS/OGA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b81a0e4749994f969ff1063b9a3a0b1f-Zebley, Kyl>; Grigsby, Garrett (HHS/OS/OGA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7cd78b4810d44b17b8711aaede9a9023-Grigsby, Gl>; Hittle, Taylor (HHS/ASFR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4a6a08d06d8648fda1e44f515f35eebb-Hittle, Pat>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Galatas, Kate (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9e6fa4be928e48408ba114add868123e-Galatas, Ka>; CDC IMS JIC OADC LNO -2 <eocevent202@cdc.gov>; Heldman, Amy B. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=83a9fa86982a40238ae2f162b869ef39-Burnett, Am>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Caccommo, Stephanie (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3b415b3f6cff4b18980c5f723fad2ce0-stephanie.c>; Charrow, Robert (HHS/OGC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=00531138af454ce3ac0b5885bead345f-Charrow, Ro>; Keveney, Sean (HHS/OGC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2e13823250af4ccf93b3de562380e78e-Keveney, Se>; ASPA-Deputies </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=884d75c735db47cca76a4c0fc74a06b8-ASPA-Deputi>; McGowan, Robert (Kyle) (CDC/OD/OCS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a2046e75239f48a28d2854bedbe5f899-robert.mcgo>; Beck, Gary (OS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a049f8137013412bbf472fc1833391be-Beck, Miche>
Sent Date:	2020/03/11 22:32:25
Delivered Date:	2020/03/11 22:32:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Brian Harrison (HHS/IOS) (Brian.Harrison@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d145efc9c35c4865aca6e9d47786b204-Harrison, B>
CC:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>
Subject:	FW: Diagnostics
Date:	2020/03/03 17:23:00
Priority:	Normal
Type:	Note

Brian,

(b)(5)

V/r

BG

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Sent: Tuesday, March 3, 2020 5:19 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Subject: Diagnostics

(b)(5)

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Brian Harrison (HHS/IOS) (Brian.Harrison@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d145efc9c35c4865aca6e9d47786b204-Harrison, B>; Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>
Sent Date:	2020/03/03 17:23:26
Delivered Date:	2020/03/03 17:23:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>; Bright, Rick (OS/ASPR/BARDA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=53034752f35a4317aa74f46348442d39-Bright, Ric>
Subject:	RE: SUMMARY: Urgent Commendation for COVID-19 Point-of-Care Testing
Date:	2020/03/16 22:52:00
Priority:	Normal
Type:	Note

(b)(5)

Brett

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Sent: Monday, March 16, 2020 10:40 PM
To: Bright, Rick (OS/ASPR/BARDA) <Rick.Bright@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Re: SUMMARY: Urgent Commendation for COVID-19 Point-of-Care Testing

(b)(5)

From: Bright, Rick (OS/ASPR/BARDA) <Rick.Bright@hhs.gov>
Date: March 16, 2020 at 10:17:43 PM EDT
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>
Cc: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Subject: Re: SUMMARY: Urgent Commendation for COVID-19 Point-of-Care Testing

(b)(5)

On Mar 16, 2020, at 10:12 PM, Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>wrote:

Copying FDA Dr Shuren and BARDA Dr Bright.
How can I help?

BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Joni Messenlehner <JMessenlehner@orasure.com>**On Behalf Of** Stephen Tang
Sent: Monday, March 16, 2020 8:51 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: SUMMARY: Urgent Commendation for COVID-19 Point-of-Care Testing

Dear Admiral Giroir,

In the interest of time, I thought it would be helpful to summarize my earlier email:

I believe rapid "at home" or self-testing providing results in 20 minutes can dramatically increase the capacity for COVID-19 testing. Rapid point-of-care tests are quick, accurate, affordable and easy to use. Patients could be tested at home, helping maintain social distancing and curbing the spread of coronavirus.

OraSure Technologies, Inc. is uniquely positioned and has a tremendous track record in the development of point-of-care tests to respond to public health crises such as COVID-19. We have vast experience in developing rapid point-of-care testing for complex diagnostic problems such as HIV and HCV on a global scale.

I can be reached at 484-353-1500, or via email at stang@orasure.com to discuss how we can engage the Department of Health and Human Services, the U.S. Coronavirus Task Force, and other relevant agencies/officials to accelerate the development of a rapid test that could have an impact on the current situation. More details can be found below and in the attached letter.

<image001.jpg>

The Honorable Brett P. Giroir, MD
Assistant Secretary for Health
U.S. Department of Health and Human Services
200 Independence Avenue, SW
Washington, DC 20201

RE: Urgent Recommendation for COVID-19 Point-of-Care Testing

March 16, 2020

Dear Admiral Giroir,

I am writing with a proposed solution to significantly increase the capacity for COVID-19 testing: a rapid “at home” or self-test for coronavirus, whereby results could be known in 20 minutes. Rapid point-of-care tests are the ideal solution. They are quick, accurate, affordable and easy to use. Patients could be tested at home, helping maintain social distancing and curbing the spread of coronavirus. Capacity is limited only by how many tests could be made. Point-of-care tests are not a replacement of laboratory testing. Instead they are a proven addition that in the case of HIV and HCV has dramatically increased testing capabilities -- and can do the same for COVID-19.

OraSure Technologies, Inc. is uniquely positioned and has a tremendous track record in the development of point-of-care tests to respond to public health crises such as COVID-19. We have vast experience in developing easy-to-use solutions for complex diagnostic problems on a global scale. We are second to none in rapid point-of-care self-testing.

- Our oral fluid self-test for HIV is the first and only WHO-prequalified oral fluid test; it is used in developing countries to end HIV transmissions. In Q4 of 2019, we shipped 2.9 million self-tests.
- We have the first and only FDA-approved over-the-counter HIV rapid test; it is currently being used in the federal government’s Ending the HIV Epidemic: A Plan for America initiative.
- Our OraQuick Ebola Rapid Antigen test received FDA clearance in October. This is just one example of our experience in rapidly developing point-of-care diagnostics in partnership with the government.

Existing testing methods are not able to keep up with the need for COVID-19 testing. News reports note that CDC has tested approximately 11,000 specimens as of March 13th; a

sharp contrast to the reported 20,000 patient a day test rate in South Korea. It's been difficult to build capacity, let alone build an adequate supply of tests quickly. In addition, the performance characteristics of existing tests are not ideal. And the tests are too complex, requiring transport and intervention by a lab technician.

The March 13th announcement of strategies to expand coronavirus testing is a good step, but more needs to be done. OraSure is currently engaged in discussions with government agencies such as BARDA and the DoD about how to potentially fund, produce, qualify and deploy an antigen screening system to positively identify acutely infected individuals for coronavirus.

However, time is of the essence. It is clear that PCR tests are unable to keep up with demand for reagents, limiting the number of people that can be tested. A rapid screen for pan corona viral antigen is viewed as the best way to identify infected individuals at the highest risk of spreading COVID-19 disease. OraSure would like to work with you and other officials to accelerate the development of a rapid test that could have an impact on the current situation.

Please contact me at 484-353-1500, or via email at stang@orasure.com to advise how we can engage the Department of Health and Human Services, the U.S. Coronavirus Task Force, and other relevant agencies/officials in an effort to get started right away on this important opportunity to address COVID-19 testing needs during this public health crisis.

Sincerely,

<image003.jpg>

Stephen S. Tang, Ph.D.
President and Chief Executive Officer
OraSure Technologies, Inc.
220 E. First Street
Bethlehem, PA 18015

CC: The Honorable Michael Pence, Vice President

The Honorable Alex Azar, Secretary of Health and Human Services
Anthony Fauci, MD; Director, National Institute of Allergy and Infectious Diseases
Robert Redfield, MD; Director, Centers for Disease Control and Prevention
Jerome Adams, MD; U.S. Surgeon General
Seema Verma, MPH; Administrator, Centers for Medicare and Medicaid Services
Stephen Hahn, MD; Commissioner, Food and Drug Administration
Ambassador Deborah Birx, MD; U.S. Department of State

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>; Bright, Rick (OS/ASPR/BARDA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=53034752f35a4317aa74f46348442d39-Bright, Ric>
Sent Date:	2020/03/16 22:52:07
Delivered Date:	2020/03/16 22:52:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	OS Secretarys Operations Center </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=32b1f28d808b43b6903c00083291303e-Secretarys>
Subject:	Re: Princess Grand Cruise Ship, Possible COVID-19
Date:	2020/03/05 06:18:23
Priority:	Normal
Type:	Note

(b)(5)

(b)(6)

Sent from my iPhone

On Mar 5, 2020, at 4:27 AM, OS Secretarys Operations Center
<hhs.soc@hhs.gov>wrote:

□

UNCLASSIFIED // FOR OFFICIAL USE ONLY

Good morning Dr. Kadlec,

(b)(5)

(b)(5)

Very Respectfully,

Secretary's Operations Center

U.S. Department of Health and Human Services (HHS)
Assistant Secretary for Preparedness and Response (ASPR)
200 Independence Ave. S.W.
Washington D.C. 20201
Office (202) 619-7800
Fax: 800-514-4256
Email: hhs.soc@hhs.gov

<image001.jpg>

Data enclosed in this email are subject to the Privacy Act of 1974, as amended. Contents shall not be disclosed, discussed, or shared with individuals unless they have a direct need-to-know in the performance of their official duties. Unauthorized disclosure of this information may result in civil or criminal penalties.

CONFIDENTIALITY NOTICE: This e-mail communication and any attachments may contain confidential and privileged information for the use of the designated recipients. If you are not the intended recipient, (or authorized to receive for the recipient) you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please destroy all copies of this communication and any attachments and contact the sender by reply e-mail or telephone (202-619-7800).

UNCLASSIFIED // FOR OFFICIAL USE ONLY

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	OS Secretarys Operations Center </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=32b1f28d808b43b6903c00083291303e-Secretarys>
Sent Date:	2020/03/05 06:18:23

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>
CC:	Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Wainwright, Jacob (HHS/OASH/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e9885a97dc204683b2156dc539b5f86c-Wainwright,>
Subject:	RE: CDC Data
Date:	2020/03/12 23:08:00
Importance:	High
Priority:	Urgent
Type:	Note

Cheers
BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>
Sent: Thursday, March 12, 2020 10:34 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <Shannon.Sartin@cms.hhs.gov>
Subject: CDC Data

Admiral Giroir –

(b)(5)

Thanks,

Brad

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
----------------	---

Recipient:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Wainwright, Jacob (HHS/OASH/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e9885a97dc204683b2156dc539b5f86c-Wainwright,>
Sent Date:	2020/03/12 23:08:58
Delivered Date:	2020/03/12 23:08:00

From:	Giroir, Brett (HHS/OASH) </o=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bced884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
CC:	Hahn, Stephen <SH1@fda.hhs.gov>; Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Schwartz, Suzanne (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bce62c458594ca8b15ecc04fe792094-suzanne.sch>
Subject:	Re: Swab data
Date:	2020/03/13 17:52:45
Priority:	Normal
Type:	Note

(b)(5)

Sent from my iPhone

On Mar 13, 2020, at 9:36 AM, Shuren, Jeff <Jeff.Shuren@fda.hhs.gov> wrote:

☐ (b)(5)

Jeff

From: Shuren, Jeff
Sent: Friday, March 13, 2020 9:03 AM
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>; Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Smith, Brad (CMS) <Brad.Smith@cms.hhs.gov>; Kellogg, Rachel (OS) <Rachel.Kellogg@hhs.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>
Subject: RE: Swab data

The team is reviewing. Will circle back soon.

Jeff

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Date: March 13, 2020 at 8:55:13 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>, Smith, Brad (CMS) <Brad.Smith@cms.hhs.gov>, Kellogg, Rachel (OS) <Rachel.Kellogg@hhs.gov>
Subject: RE: Swab data

Standing by

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Hahn, Stephen <SH1@fda.hhs.gov>
Sent: Friday, March 13, 2020 8:53 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>; Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>
Subject: Re: Swab data

Thx Brett. (b)(5)

(b)(5) Thx
S

Sent from my iPhone

On Mar 12, 2020, at 11:16 PM, Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov> wrote:



Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Dan Wattendorf <Dan.Wattendorf@gatesfoundation.org>
Sent: Thursday, March 12, 2020 8:42 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Swab data

Attachment 1

Get [Outlook for iOS](#)

(b)(4)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Hahn, Stephen <SH1@fda.hhs.gov>; Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Schwartz, Suzanne (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3bce62c458594ca8b15ecc04fe792094-suzanne.sch>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
Sent Date:	2020/03/13 17:52:45

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	JBE <jbe@la.gov>
Subject:	RE: Coronavirus Testing
Date:	2020/03/14 17:20:00
Priority:	Normal
Type:	Note

We are on it Sir.
I am ready for some gumbo after this

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: JBE <jbe@la.gov>
Sent: Saturday, March 14, 2020 5:11 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Re: Coronavirus Testing

Dr. Giroir:
Thank you for your work on this pandemic emergency.
There are now 77 presumptive positive cases in Louisiana, with the vast majority being in Orleans and Jefferson Parish. An hour ago we announced the first death — a 58 year old gentleman from New Orleans with chronic health conditions.
On a per capita basis, I believe Louisiana has the third most cases in the country.
We have imposed significant mitigation measures to slow the spread of Coronavirus (COVID-19), but I am afraid the testing is nowhere near as robust as necessary to identify more positive cases that can then be isolated/quarantined so that we can in a significant way slow the spread, flatten the curve, and better ensure that our medical/hospital capacity is not overwhelmed.
Please make every effort to significantly increase our testing capacity and testing through put as soon as possible.
Feel free to respond to me or to have someone on your team contact Dr. Alex Billioux, Assistant Secretary for the Office of Public Health.
Thank you.
John Bel

Sent from my iPhone

On Mar 14, 2020, at 8:50 AM, JBE <jbe@la.gov>wrote:

☐ Thanks. We will take you up on your offer. My public health folks will contact your team shortly.

Sent from my iPhone

On Mar 13, 2020, at 7:34 PM, Giroir, Brett (HHS/OASH)
<Brett.Giroir@hhs.gov>wrote:

☐

EXTERNAL EMAIL: Please do not click on links or attachments unless you know the content is safe.

Sir,

We had your health team on the line this evening. White House is offering to assist with setting up drive through testing sites at hot spots. And NOLA and Jefferson Parrish are on our list. Totally your call but this could be helpful to you. We are waiting to hear back from your team.

V/r

BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	JBE <jbe@la.gov>
Sent Date:	2020/03/14 17:20:09
Delivered Date:	2020/03/14 17:20:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	Marta Bralic Kerns <(b)(6)@gmail.com>
Subject:	RE: Key messages related to RNA extraction & nation-wide testing capacity
Date:	2020/03/16 11:03:00
Priority:	Normal
Type:	Note

Thank you

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Marta Bralic Kerns <(b)(6)@gmail.com>
Sent: Monday, March 16, 2020 11:00 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Key messages related to RNA extraction & nation-wide testing capacity

Admiral,

(b)(5)

Thanks,
Marta

(b)(5)

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Marta Bralic Kerns <(b)(6)@gmail.com>
Sent Date:	2020/03/16 11:03:23
Delivered Date:	2020/03/16 11:03:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Pollard, Ashton (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9d4c26448ed441b0aa555971f3c73d6d-Pollard, As>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>
Subject:	RE: Pandemic testing
Date:	2020/03/12 12:21:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Thursday, March 12, 2020 12:20 PM
To: Pollard, Ashton (OS/IOS) <Ashton.Pollard@hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>; Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: RE: Pandemic testing

(b)(5)

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

**Center for Devices and Radiological Health
U.S. Food and Drug Administration**

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Pollard, Ashton (OS/IOS) <Ashton.Pollard@hhs.gov>
Sent: Thursday, March 12, 2020 11:34 AM
To: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>; Mango, Paul (OS) <Paul.Mango@hhs.gov>; Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Cc: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>
Subject: RE: Pandemic testing

Hi All,

(b)(5)

Thanks,
Ashton

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Sent: Thursday, March 12, 2020 8:24 AM
To: Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>; Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Pollard, Ashton (OS/IOS) <Ashton.Pollard@hhs.gov>
Subject: Re: Pandemic testing

Paul,

(b)(5)

Jeff

From: Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>
Date: March 12, 2020 at 8:13:27 AM EDT
To: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>, Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Cc: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>, Pollard, Ashton (OS) <Ashton.Pollard@hhs.gov>
Subject: Fwd: Pandemic testing

(b)(5)

Sent from my iPhone

Begin forwarded message:

From: "Azar, Alex (OS/IOS)" <Alex.Azar@HHS.GOV>
Date: March 12, 2020 at 7:55:05 AM EDT
To: "Mango, Paul (HHS/IOS)" <Paul.Mango@hhs.gov>
Cc: "Pollard, Ashton (OS/IOS)" <Ashton.Pollard@hhs.gov>
Subject: FW: Pandemic testing

□

From: Kirstjen Nielsen <knielsen@lhstrat.com>
Sent: Wednesday, March 11, 2020 11:17 PM
To: Azar, Alex (OS/IOS) <Alex.Azar@HHS.GOV>
Subject: Pandemic testing

Hi Alex

Upfront should say- do not have any financial or contractual arrangement with the company. I know about them b/c I had hoped we could deploy rapid DNA technology on our southern border for a variety of reasons. They have a solid tech that is making a huge difference where deployed. Their approach - esp that it can be used within quarantined areas and doesn't require the sample to be shipped for processing- seems right on to address the current outbreak (of course I am not a medical test expert by any means :-))

Would greatly appreciate any thoughts you might have as to how to set up call with the right folks at HHS, CDC et. (I do not need to be in the loop) and Jim or Kumar. I am, as I know you are, worried that we need something much better than we have to help the readiness of everyone but also the feds and health care providers

Here is the description of the solution from the company.

"We have an established and broadly validated tool that was developed collaboratively with the US DOD for other applications that can relatively quickly be applied to the COVID-19 threat. We can demonstrate solid diagnostic performance beyond the capabilities of current qPCR testing for the COVID-19 threat in 5 to 12 weeks. We request an opportunity to brief you on the technology and its potential global impact in controlling the spread of contagious disease. The system is focused on high reliability DNA processing using the techniques applied

everyday by scientists around the world in large brick and mortar labs - but it does so rapidly in a rugged, mobile and automated way that enables essentially untrained personnel to conduct fast and reliable screening at virtually any location. Uniquely this system can be used in contaminated and quarantined areas eliminating the need to remove samples for shipment to outside labs.

* A recent use of the technology was the US raid which killed terrorist Abu Bakr Al Baghdadi - ANDE Rapid DNA was used on scene for DNA identity confirmation.

The ANDE 6C is the only federally approved Rapid DNA technology. It was developed with US DoD and other government support and engagement. ANDE can be configured to provide substantially improved diagnostics for the current COVID-19 infections. ANDE technology has been proven on the battlefield and has been approved for domestic use in forensics by the US FBI as well as a number of other governments around the world. Systems are currently in use in more than 20 countries and more than 40 public safety agencies in the US. It takes the function of a traditional DNA lab and reduces it to a process that resides in a single disposable cartridge. The ANDE system is operable by non-technical staff. It is US DOD certified as MIL-STD-810G (rugged) and can be deployed in austere environments where it reliably produces high quality results.

The underlying performance of the system is substantially stronger than the existing qPCR diagnostics used broadly for Corona virus testing and which require brick and mortar lab engagement.

The testing process is simple: 1) collect a sample from the person being tested 2) place the swab in the Rapid DNA disposable chip 3) put the chip in the instrument and wait approx 90 minutes and the answer is presented automatically in a secure data environment.

Configuration of the ANDE system for this purpose would also yield an integrated approach to dealing with novel infectious diseases by enabling very rapid testing response in the future - we estimate the time to a solid diagnostic test from identification to be 10 days. This means literally 10 days from the discovery and sequencing of a new threat the new test needed would be ready for manufacturing and distribution.

I am also attaching two summaries, one that is non-technical and very high-level and a second that is more directed to science types. I am also attaching a copy of the CV of our Founder and Chief Science Officer, Richard Kessler.

If there are any questions, they can be directed to Kumar Kibble (copied above) at [571-444-9283](tel:571-444-9283) or Jim Davis at [720-879-1408](tel:720-879-1408).

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Pollard, Ashton (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9d4c26448ed441b0aa555971f3c73d6d-Pollard, As>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bced884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>
Sent Date:	2020/03/12 12:21:43
Delivered Date:	2020/03/12 12:21:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>
CC:	Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Susan Orsega (OS/OASH) (Susan.Orsega@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8171c34a0cd4581a49f33cb8f60f684-Orsega, Sus>
Subject:	FDA - materials
Date:	2020/03/13 18:19:00
Priority:	Normal
Type:	Note

- • Liquid Amies-based transport media.
 - • Supplies:
 - • E-Swab by Copan (Catalogue # 481C and 482C) with regular or flex minitip applicator
 - • Opti-Swab by Puritan (Catalogue # LA-117), swab included in kit (Catalog#3317-H).
 - • Storage: Up to 72 hours at 4°C, or frozen for longer storage.

If the above are not available, FDA believes that the following could be used to collect and transport samples for molecular RT-PCR sARS-CoV-2 assays:

- • Dry swab in saline
 - • Supplies:
 - • Puritan: 25-3317-H, 25-3316-U, 25-3316-H, 25-3317-U, 25-3318-U, 25-3318-H, 3316-U, 3317-U, 3318-U, 25-3319-H, 3316-H, 3318-H, 25-3320-U, 25-3320-U EMB 100MM, 25-3320-U EMB 80MM, 25-3320-H and 25-3320-H EMB 80MM
 - • Copan: 501CS01, 503CS01, 516CS01, 518CS01 and 534CS01
 - • Storage: Up to 72 hours at 4°C, or frozen for longer storage.

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

Sender: Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

	(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Susan Orsega (OS/OASH) (Susan.Orsega@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8171c34a0cd4581a49f33cb8f60f684-Orsega, Sus>
Sent Date:	2020/03/13 18:19:24
Delivered Date:	2020/03/13 18:19:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Hahn, Stephen <SH1@fda.hhs.gov>; Keagan Lenihan (FDA/OC) (Keagan.Lenihan@fda.hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Laura Pence (HHS/IOS) (Laura.Pence@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>
CC:	Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Ryan Murphy (OS/ASPA) (Ryan.Murphy1@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Judy Stecker (OS/ASPA) (Judy.Stecker@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Brett Giroir (HHS/OASH) (Brett.Giroir@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a56fce4755704c4ca031d621b46fd6f7-Girori, Bre>
Subject:	Current Numbers in the System.
Date:	2020/03/11 09:19:00
Priority:	Normal
Type:	Note

(b)(5)

(b)(5)

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Hahn, Stephen <SH1@fda.hhs.gov>; Keagan Lenihan (FDA/OC) (Keagan.Lenihan@fda.hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Laura Pence (HHS/IOS) (Laura.Pence@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>; Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Ryan Murphy (OS/ASPA) (Ryan.Murphy1@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Judy Stecker (OS/ASPA) (Judy.Stecker@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>;

	Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Brett Giroir (HHS/OASH) (Brett.Giroir@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a56fce4755704c4ca031d621b46fd6f7-Girori, Bre>
Sent Date:	2020/03/11 09:19:20
Delivered Date:	2020/03/11 09:19:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Marta Bralic Kerns <(b)(6)@gmail.com>
Subject:	Re: Key messages related to RNA extraction & nation-wide testing capacity
Date:	2020/03/16 11:07:28
Priority:	Normal
Type:	Note

Can you call me super quick?

(b)(6)

Sent from my iPhone

On Mar 16, 2020, at 11:01 AM, Marta Bralic Kerns

(b)(6)@gmail.com>wrote:

☐

Admiral,

(b)(5)

Thanks,

Marta

(b)(5)

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Marta Bralic Kerns <(b)(6)@gmail.com>
Sent Date:	2020/03/16 11:07:27
Delivered Date:	2020/03/16 11:07:28

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>
CC:	Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>
Subject:	RE: CDC Data
Date:	2020/03/12 23:32:00
Priority:	Normal
Type:	Note

<https://www.cdc.gov/coronavirus/2019-ncov/testing-in-us.html>

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>
Sent: Thursday, March 12, 2020 11:16 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <Shannon.Sartin@cms.hhs.gov>
Subject: RE: CDC Data

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Thursday, March 12, 2020 10:47 PM
To: Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <Shannon.Sartin@cms.hhs.gov>
Subject: RE: CDC Data

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>
Sent: Thursday, March 12, 2020 10:34 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <Shannon.Sartin@cms.hhs.gov>
Subject: CDC Data

Admiral Giroir –

(b)(5)

Thanks,

Brad

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>
Sent Date:	2020/03/12 23:32:18
Delivered Date:	2020/03/12 23:32:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Chang, William (HHS/OGC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cf70c842da144ab9bee61f353d932a0-Chang, Will>; Kane, Eileen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user25dbd6c7>; Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcba4c6ea342c08d58f63e37d997e7-Trueman, La>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Johnston, Darcie (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6a8047840ca4406b5ac6bc5cf259937-Johnston, D>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>; Greene, Jonathan (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1b692a4d6cff4afabbeea99d35336ece-Greene, Jon>; Michael, Gretchen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0632b4526d6447b5af26552afde05c33-Michael, Gr>
CC:	Bonds, Michelle E. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=458a7c66b66a4e9ca7bc1963da0bcb81-michelle.bo>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Arbes, Sarah (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=106db0ac70a241a8b1323647c093d9bf-Arbes, Sara>
Subject:	RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST
Date:	2020/03/09 21:40:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

From: Chang, William (HHS/OGC) <William.Chang@hhs.gov>
Sent: Monday, March 9, 2020 6:58 PM

To: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Greene, Jonathan (OS/ASPR/EMMO) <Jonathan.Greene@hhs.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>
Cc: Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST

(b)(5)

Office of the General Counsel
U.S. Department of Health and Human Services
202-690-7741 (o)

(b)(6)

(c)

From: Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>
Sent: Monday, March 9, 2020 5:52 PM
To: Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Greene, Jonathan (OS/ASPR/EMMO) <Jonathan.Greene@hhs.gov>; Chang, William (HHS/OGC) <William.Chang@hhs.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>
Cc: Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST

(b)(5)

(b)(5)

From: Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>
Sent: Monday, March 9, 2020 5:39 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Greene, Jonathan (OS/ASPR/EMMO) <Jonathan.Greene@hhs.gov>; Chang, William (HHS/OGC) <William.Chang@hhs.gov>; Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>
Cc: Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Monday, March 9, 2020 5:21 PM
To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Greene, Jonathan (OS/ASPR/EMMO) <Jonathan.Greene@hhs.gov>; Chang, William (HHS/OGC) <William.Chang@hhs.gov>; Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>
Cc: Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST

Try this one

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>

Sent: Monday, March 9, 2020 5:06 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Greene, Jonathan (OS/ASPR/EMMO) <Jonathan.Greene@hhs.gov>; Chang, William (HHS/OGC) <William.Chang@hhs.gov>; Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>

Cc: Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>

Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Monday, March 9, 2020 5:05 PM

To: Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Greene, Jonathan (OS/ASPR/EMMO) <Jonathan.Greene@hhs.gov>; Chang, William (HHS/OGC) <William.Chang@hhs.gov>

Cc: Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Arbes, Sarah (HHS/ASL) <Sarah.Arbes@hhs.gov>

Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW

Washington, DC 20201
Office Phone: 202-690-7694

From: Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>
Sent: Monday, March 9, 2020 5:03 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>;
Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Shuy, Bryan (OS/ASPR/IO)
<Bryan.Shuy@hhs.gov>; Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Greene, Jonathan
(OS/ASPR/EMMO) <Jonathan.Greene@hhs.gov>; Chang, William (HHS/OGC)
<William.Chang@hhs.gov>
Cc: Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Trueman, Laura (HHS/IEA)
<Laura.Trueman@hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Arbes, Sarah (HHS/ASL)
<Sarah.Arbes@hhs.gov>
Subject: RE: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST

(b)(5)

Darcie L. Johnston
Director, Intergovernmental Affairs
U.S. Department of Health and Human Services
Office of the Secretary
202-690-1058 (office)

(b)(6)

(cell)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Monday, March 9, 2020 4:26 PM
To: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Murphy, Ryan (OS/ASPA)
<Ryan.Murphy1@hhs.gov>

Cc: Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>
Subject: FW: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST
Importance: High

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Monday, March 9, 2020 3:48 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Subject: FW: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST

(b)(5)

From: Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>
Sent: Monday, March 9, 2020 3:29 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Cc: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Patrick, Kera (CDC/OD/OADC) <ihn7@cdc.gov>; CDC IMS JIC OADC LNO -2 <eocevent202@cdc.gov>
Subject: FW: nCoV - ASPR - Washington Post on quarantining Lackland evacuees/ URGENT REQUEST

(b)(5)

(b)(5)

From: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>
Sent: Monday, March 9, 2020 1:21 PM
To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Cc: Michael, Gretchen (OS/ASPR/OEA) <Gretchen.Michael@hhs.gov>; Kane, Elleen (OS/ASPR/OEA) <Elleen.Kane@hhs.gov>; Waters, Cicely (OS/ASPR/OEA) <Cicely.Waters@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Rigas, Laura (HHS/IEA) <Laura.Rigas@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>

Subject: Re: PLEASE READ FW: Washington Post reporter -- story on COVID-19 response on quarantining Lackland patients that ASPR has now taken over. deadline urgent

(b)(5)

Sent from my iPhone

On Mar 9, 2020, at 12:54 PM, Murphy, Ryan (OS/ASPA)
<Ryan.Murphy1@hhs.gov>wrote:

 (b)(5)

- Ryan

From: Thorman, Caroline (ACF) <Caroline.Thorman@acf.hhs.gov>

Sent: Monday, March 9, 2020 12:40 PM

To: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>

Subject: FW: Washington Post reporter -- story on COVID-19 response on quarantining Lackland patients that ASPR has now taken over. deadline urgent

Can you confirm ASPR is now in charge? Will ASPR continue to allow releasing quarantined people from Lackland to leave after 14 days and two sequential negative tests, for those that agree to be tested, even though San Antonio filed an unsuccessful emergency lawsuit asking that the number of tests be three and the quarantine period be extended to 28 days? And what will the protocol be for those who test positive at the base and must be treated at a hospital or go to a negative pressure room for 14 days if they're asymptomatic? Will they also be allowed to go after two sequential negative tests? Importantly, our story will also note that the UNMC protocol for positive COVID-19 patients is different; it's THREE sequential tests, not two.

Many thanks,

Caroline Thorman
Director of Communications
Administration for Children & Families (ACF)
Health and Human Services (HHS)
Desk: (202) 401-4777
Cell: (b)(6)

From: Satija, Neena <Neena.Satija@washpost.com>

Sent: Sunday, March 8, 2020 6:03 PM

To: Thorman, Caroline (ACF) <Caroline.Thorman@acf.hhs.gov>

Subject: Fw: Washington Post reporter -- story on COVID-19 response on quarantining Lackland patients that ASPR has now taken over. deadline urgent

Neena Satija

Investigative Reporter

Washington Post

202-334-7054

@neenareports

From: Satija, Neena <Neena.Satija@washpost.com>

Sent: Sunday, March 8, 2020 3:51 PM

To: gretchen.michael@hhs.gov <gretchen.michael@hhs.gov>; elaine.kane@hhs.gov

<elaine.kane@hhs.gov>

Subject: Washington Post reporter -- story on COVID-19 response on quarantining Lackland patients that ASPR has now taken over. deadline urgent

Dear Gretchen and Elaine,

My name is Neena Satija and I'm a reporter for the Washington Post. I have been trying to get in touch with HHS on a story about coronavirus response when it comes to the Wuhan and Diamond Princess (and soon, Grand Princess) cohorts sent to Lackland Air Force Base, and I have had no luck with the CDC. So I'm going to you -- also because we have been told today that ASPR is now in charge of those quarantine ops instead of the CDC. Getting in touch with HHS in general for the past few weeks has been tough; in fact it took me several days simply to confirm, for instance, that OCEPHR was involved in the repatriation effort ... and we really do want to be fair and accurate, so I'm really hoping you can help!!

My colleague Arelis Hernandez and I have a story that may run tomorrow or the following day about the frustration among state and local officials in Texas, especially officials in San Antonio, regarding lack of communication from the administration on COVID-19 response, in particular, what to do with cohorts from Wuhan and the Diamond Princess (and, soon, the Grand Princess) cruise ship. We will report that state and local officials were assured that anyone sent to Lackland from Wuhan back on Feb. 1 would remain quarantined on base -- but instead, after the plane landed, San Antonio officials were immediately called upon not only to take the one woman who tested positive and had symptoms to a community hospital to be treated, but even to secure an ambulance to take her off Lackland.

Essentially state and local officials were given no advanced warning that the DOD would now allow anyone who tested positive for COVID-19 to stay on base, whether asymptomatic or not. It appears as though state and local authorities had the tools in place to plan for these issues quickly. But what happened raises serious questions about the administration's handling of this public health emergency, especially after the release of that patient from Wuhan before a positive test result came back.

I have contacted CDC multiple times for comment on our story with no answer. Then I found out today that ASPR is now in charge of quarantining protocols going forward as opposed to CDC. It's all the more important we hear from you now that dozens more cruise ship passengers, this time from the Grand Princess cruise ship, are now headed to Lackland. The administration has assured folks that it will quarantine them at the base. But what about those who test positive?

Can you confirm ASPR is now in charge? Will ASPR continue to allow releasing quarantined people from Lackland to leave after 14 days and two sequential

negative tests, for those that agree to be tested, even though San Antonio filed an unsuccessful emergency lawsuit asking that the number of tests be three and the quarantine period be extended to 28 days? And what will the protocol be for those who test positive at the base and must be treated at a hospital or go to a negative pressure room for 14 days if they're asymptomatic? Will they also be allowed to go after two sequential negative tests? Importantly, our story will also note that the UNMC protocol for positive COVID-19 patients is different; it's THREE sequential tests, not two.

I'm hoping you can help me confirm some of the basic details and perhaps provide any other comment. You can also reach me on my cell at 301-768-9239.

Thanks!

Neena Satija

Investigative Reporter

Washington Post

202-334-7054

@neenareports

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Chang, William (HHS/OGC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cf70c842da144ab9bee61f353d932a0-Chang, Will>; Kane, Elleen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user25dbd6c7>; Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcb4c6ea342c08d58f63e37d997e7-Trueman, La>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Johnston, Darcie (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6a8047840ca4406b5ac6bc5cf259937-Johnston, D>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>; Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>; Greene, Jonathan (OS/ASPR/EMMO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1b692a4d6cff4afabb6ea99d35336ece-Greene, Jon>; Michael, Gretchen (OS/ASPR/OEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0632b4526d6447b5af26552afde05c33-Michael, Gr>; Bonds, Michelle E. (CDC/OD/OADC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=458a7c66b66a4e9ca7bc1963da0bcb81-michelle.bo>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>; Arbes, Sarah (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=106db0ac70a241a8b1323647c093d9bf-Arbes, Sara>
Sent Date:	2020/03/09 21:40:06

Delivered Date:	2020/03/09 21:40:00
------------------------	---------------------

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=07bb5761d38348fcaa1881a0255ba2c9-dana.meaney>
CC:	Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbee2d9b4db2a0f-Jernigan, D>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=eac7af7ae9754d4290d7aa8cdb537078-Rosenstein>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>
Subject:	RE: One Swab Guidance
Date:	2020/03/11 09:20:00
Priority:	Normal
Type:	Note

Ok great

Can you send that 2/1 link?

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>
Sent: Wednesday, March 11, 2020 9:18 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Subject: RE: One Swab Guidance

We put out revised guidance 2 days ago for combined OP/NP testing—going from 2 swabs/2 tests to 2 swabs/1 test.

(b)(5)

Gregory Armstrong, MD | currently assigned to CDC Coronavirus Response as Deputy Incident Manager | garmstrong@cdc.gov

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Wednesday, March 11, 2020 9:11 AM
To: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>
Subject: RE: One Swab Guidance

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>
Sent: Wednesday, March 11, 2020 8:59 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>
Subject: Re: One Swab Guidance

ADM Giroir,

(b)(5)

Best,
Dana

Dana Meaney-Delman, MD MPH
Principal Deputy IM
COVID-19 Response
Centers for Disease Control and Prevention

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Wednesday, March 11, 2020 8:50 AM
To: Schuchat, Anne MD (CDC/OD); Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID)
Subject: One Swab Guidance

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=07bb5761d38348fcaa1881a0255ba2c9-dana.meaney>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbee2d9b4db2a0f-Jernigan, D>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=eac7af7ae9754d4290d7aa8cdb537078-Rosenstein>; Schuchat, Anne MD (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b6e506fd4b204294906aa26f44d2f2c8-Schuchat, A>
Sent Date:	2020/03/11 09:20:14
Delivered Date:	2020/03/11 09:20:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Berger, James J. (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcaf2b2f7b1a479d82a2d970d3bef40e-Berger, Jam>; Beckham, Tammy (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=79787474893348a48f149dd5a1064e6c-Beckham, Ta>; Broido, Tara (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c3cd5c5afe049b6a8b48c25324c7465-Broido, Tar>
CC:	Hayes, Kaye (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=325e577483dc469dba2a7e975abb21f4-Hayes, Kaye>; Post, Todd (HHS/OASH) (CTR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4126c9e6c00142b5b8ed85e958dc62a2-Post, Todd>
Subject:	RE: Blood Shortage
Date:	2020/03/17 05:56:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Berger, James J. (HHS/OASH) <James.Berger@hhs.gov>
Sent: Tuesday, March 17, 2020 3:20 AM
To: Beckham, Tammy (HHS/OASH) <Tammy.Beckham@hhs.gov>; Broido, Tara (HHS/OASH) <Tara.Broido@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Hayes, Kaye (HHS/OASH) <Kaye.Hayes@hhs.gov>; Post, Todd (HHS/OASH) (CTR) <Todd.Post@hhs.gov>
Subject: Blood Shortage

ADM Giroir,

(b)(5)

Jim

From: Mike Fitzpatrick <MFitzpatrick@cellphire.com>
Sent: Monday, March 16, 2020 11:03 PM
To: Berger, James J. (HHS/OASH) <James.Berger@hhs.gov>; Homer, Mary (OS/ASPR/BARDA) <Mary.Homer@hhs.gov>
Cc: james peake [peakejb1@yahoo.com] <(b)(6)@yahoo.com>; Peake James

(Jim.Peake@cgifederal.com) <jim.peake@cgifederal.com>; Holcomb, John B <(b)(6)@uabmc.edu>
Subject: Fwd: Shortage

Mary and Jim,

Recent info from Dr. Holcomb regarding the blood supply and ARC supply.

Mike

Get [Outlook for iOS](#)

From: Holcomb, John B <(b)(6)@uabmc.edu>
Sent: Monday, March 16, 2020 10:31:49 PM
To: Mike Fitzpatrick <MFitzpatrick@cellphire.com>
Subject: Shortage

Check it out

----- Original Message -----

From: Mike Fitzpatrick <MFitzpatrick@cellphire.com>
Date: Mon, March 16, 2020 4:55 PM -0500
To: "Terry B.. Gernsheimer" <(b)(6)@uw.edu>, Joan Pehta <(b)(6)@aol.com>, "Lauren S. Baker, PhD" <lbaker@boston-biomedical.com>, "Holcomb, John B" <(b)(6)@uabmc.edu>, Anne Hale <AHale@cellphire.com>, Ruth Biehl <RBiehl@cellphire.com>, Ben Antebi <bantebi@cellphire.com>, Thom Landro <TLandro@cellphire.com>
CC: Anna Yu <AYu@cellphire.com>
Subject: EXT MSG Re: Urgent Question from J Pehta/ Thrombosomes-Need about 10 min your time this AM to discuss emergency releasse

Anna,

Can you set up a call for 10AM our time 7AM Terry's time for all involved to talk with Terry,

Mike

From: Terry B. Gernsheimer <(b)(6)@uw.edu>
Sent: Monday, March 16, 2020 4:04 PM
To: Joan Pehta <(b)(6)@aol.com>
Cc: Mike Fitzpatrick <MFitzpatrick@cellphire.com>
Subject: RE: Urgent Question from J Pehta/ Thrombosomes-Need about 10 min your time this AM to discuss emergency releasse

Sorry. Just saw this. I am on the leukemia unit as the attending for the rest of the month and we usually don't finish rounds until around 1pm PDT.

I would be happy to set up a call for 7am my time or later in the afternoon.

Thanks,

Terry

Terry B. Gernsheimer, MD
Professor of Medicine, Division of Hematology
University of Washington
Medical Director of Transfusion
Seattle Cancer Care Alliance

For information and scheduling requests please contact my Administrative Assistant,
Anyango Gaya at (b)(6)@uw.edu or call 206-598-5690

This message and any attachments to it is protected by coordinated quality improvement/risk management/peer review confidentiality under RCW 70.41.200/4.24.250/43.70.510. Privileged confidential patient identifiable information also may be contained in this message. This information is meant only for the use of the intended recipients. If you are not the intended recipient or if the message has been addressed to you in error, do not read, disclose, reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the sender by reply email and then destroy all copies of the message and any attachments.

From: JCPehta [mailto:(b)(6)@aol.com]
Sent: Monday, March 16, 2020 8:38 AM
To: Terry B. Gernsheimer
Cc: mfitzpatrick@cellphire.com
Subject: Urgent Question from J Pehta/ Thrombosomes-Need about 10 min your time this AM to discuss emergency release

Hi

We are discussing emergency release of Thrombosomes to critical patients who do not have complete access to platelet products. We very much interested in your input on patient selection criteria. We see this unfolding as individual patient releases to begin with possible treatment protocol later.

We would very much appreciate your input to selection criteria for this patient population. Thanks for considering. I am free up until 1 PM ET today, then have an FDA call, and out of pocket until 2.30 ET. Hopefully we can discuss before 1 PM ET

Joan
cell (b)(6)

Joan C. Pehta, MD
The Alpha Bio Group, LLC
17 Autumn Lane
New Canaan, CT 06840

phone: 203 972 0481
fax: 203 972 6705

email: (b)(6)@aol.com

The content of this email is confidential, may contain trade secrets, and is intended for the recipient specified in message only. It is strictly forbidden to share any part of this message with any third party, without a written consent of the sender. If you received this message by mistake, please reply to this message and follow with its deletion, so that we can ensure such a mistake does not occur in the future.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Berger, James J. (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dcaf2b2f7b1a479d82a2d970d3bef40e-Berger, Jam>; Beckham, Tammy (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=79787474893348a48f149dd5a1064e6c-Beckham, Ta>; Broido, Tara (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c3cd5c5afe049b6a8b48c25324c7465-Broido, Tar>; Hayes, Kaye (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=325e577483dc469dba2a7e975abb21f4-Hayes, Kaye>; Post, Todd (HHS/OASH) (CTR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4126c9e6c00142b5b8ed85e958dc62a2-Post, Todd>
Sent Date:	2020/03/17 05:56:35
Delivered Date:	2020/03/17 05:56:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	RE: IRR data - March 12, 2020
Date:	2020/03/12 12:27:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>
Sent: Thursday, March 12, 2020 12:26 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: RE: IRR data - March 12, 2020

(b)(5)

From: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Sent: Thursday, March 12, 2020 11:38 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Campbell, Amanda (CDC/OD/OCS) <ons3@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: FW: IRR data - March 12, 2020

ADM Giroir,

(b)(5)

Steve Monroe, PhD
Director, Office of Laboratory Science and Safety
CDC

(b)(5)



(b)(5)



(b)(5)

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Sent Date:	2020/03/12 12:27:05
Delivered Date:	2020/03/12 12:27:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Hahn, Stephen <(b)(6)@fda.hhs.gov>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Pence, Laura (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>
CC:	Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>
Subject:	RE: Current Numbers in the System.
Date:	2020/03/11 09:22:00
Priority:	Normal
Type:	Note

UPDATE:

Current guidance from CDC is that the NP and OP swab CAN be combined into one test. So independent of single swab for NP, we can combine 2 swabs into one test NOW


Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Wednesday, March 11, 2020 9:19 AM
To: Hahn, Stephen <(b)(6)@fda.hhs.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Pence, Laura (HHS/ASL) <Laura.Pence@hhs.gov>
Cc: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Current Numbers in the System.

(b)(5)

(b)(5)



Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Hahn, Stephen <(b)(6)@fda.hhs.gov>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Pence, Laura (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>
Sent Date:	2020/03/11 09:22:18
Delivered Date:	2020/03/11 09:22:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Haigwood, Patricia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6f7552ba649f42369f5d2cce45889841-Haigwood, P>
Subject:	RE: Guidance
Date:	2020/03/12 23:48:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

From: Haigwood, Patricia (HHS/OASH) <Patricia.Haigwood@hhs.gov>
Sent: Thursday, March 12, 2020 5:55 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Fwd: Guidance

(b)(5)

Begin forwarded message:

From: "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>
Date: March 12, 2020 at 1:22:53 PM EDT
To: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>, "Campbell, Amanda (CDC/OD/OCS)" <ons3@cdc.gov>
Cc: "Haigwood, Patricia (HHS/OASH)" <Patricia.Haigwood@hhs.gov>
Subject: RE: Guidance

☐

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Thursday, March 12, 2020 12:58 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>

Cc: Haigwood, Patricia (HHS/OASH) <Patricia.Haigwood@hhs.gov>
Subject: RE: Guidance

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, March 12, 2020 12:55 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Haigwood, Patricia (HHS/OASH) <Patricia.Haigwood@hhs.gov>
Subject: Re: Guidance

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Thursday, March 12, 2020 12:31:10 PM
To: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Cc: Haigwood, Patricia (HHS/OASH) <Patricia.Haigwood@hhs.gov>
Subject: Guidance

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service

Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Haigwood, Patricia (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6f7552ba649f42369f5d2cce45889841-Haigwood, P>
Sent Date:	2020/03/12 23:48:14
Delivered Date:	2020/03/12 23:48:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
CC:	Hahn, Stephen <SH1@fda.hhs.gov>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Pence, Laura (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>
Subject:	RE: Current Numbers in the System.
Date:	2020/03/11 09:29:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>

Sent: Wednesday, March 11, 2020 9:27 AM

To: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>

Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Hahn, Stephen <SH1@fda.hhs.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Pence, Laura (HHS/ASL) <Laura.Pence@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>

Subject: Re: Current Numbers in the System.

(b)(5)

Sent from my iPhone

On Mar 11, 2020, at 9:26 AM, Stenzel, Timothy
<Timothy.Stenzel@fda.hhs.gov> wrote:



These numbers are accurate:

(b)(6)

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

**Center for Devices and Radiological Health
U.S. Food and Drug Administration**
Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Wednesday, March 11, 2020 9:22 AM

To: Hahn, Stephen <SH1@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Pence, Laura (OS) <Laura.Pence@hhs.gov>

Cc: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS) <Judy.Stecker@hhs.gov>; Mango, Paul (OS) <Paul.Mango@hhs.gov>

Subject: RE: Current Numbers in the System.

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Wednesday, March 11, 2020 9:19 AM

To: Hahn, Stephen <SH1@fda.hhs.gov>; Lenihan, Keagan (FDA/OC)

<Keagan.Lenihan@fda.hhs.gov>; Pence, Laura (HHS/ASL) <Laura.Pence@hhs.gov>

Cc: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>;

Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>; Giroir, Brett (HHS/OASH)

<Brett.Giroir@hhs.gov>

Subject: Current Numbers in the System.

(b)(5)

(b)(5)

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Hahn, Stephen <SH1@fda.hhs.gov>; Lenihan, Keagan (FDA/OC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Pence, Laura (HHS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1027e80d2334093870fdb436c5576cd-Pence, Laur>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group

	(FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>
Sent Date:	2020/03/11 09:29:38
Delivered Date:	2020/03/11 09:29:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>
CC:	Armstrong, Gregory (CDC/DDID/NCEZID/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e5650d24c4b64bf5aee4e3fe0799026-Armstrong,>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbec2d9b4db2a0f-Jernigan, D>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=eac7af7ae9754d4290d7aa8cdb537078-Rosenstein>
Subject:	RE: One Swab Guidance
Date:	2020/03/11 09:30:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>
Sent: Wednesday, March 11, 2020 9:21 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>
Subject: RE: One Swab Guidance

ADM Giroir,

(b)(5)

Are you available at 1pm to join the CDC meeting?

Are you joining the 11 am PMO? I will join by phone.

Best

Dana

Dana Meaney-Delman MD MPH
Principal Deputy Incident Manager
COVID-19 Response
Cell (b)(6)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Wednesday, March 11, 2020 9:11 AM
To: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>
Subject: RE: One Swab Guidance

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>
Sent: Wednesday, March 11, 2020 8:59 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>
Subject: Re: One Swab Guidance

ADM Giroir,

(b)(5)

Best,
Dana

Dana Meaney-Delman, MD MPH
Principal Deputy IM
COVID-19 Response
Centers for Disease Control and Prevention

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Wednesday, March 11, 2020 8:50 AM
To: Schuchat, Anne MD (CDC/OD); Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID)
Subject: One Swab Guidance

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e5650d24c4b64bf5aaee4e3fe0799026-Armstrong,>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbee2d9b4db2a0f-Jernigan, D>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=eac7af7ae9754d4290d7aa8cdb537078-Rosenstein>
Sent Date:	2020/03/11 09:30:32
Delivered Date:	2020/03/11 09:30:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>
CC:	Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Orsega, Susan (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8171c34a0cd4581a49f33cb8f60f684-Orsega, Sus>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>
Subject:	RE: FDA - materials
Date:	2020/03/13 21:00:00
Priority:	Normal
Type:	Note

Thanks Bob.

These are alternatives posted by the FDA today. IF we don't have viral transport media, we can use saline, etc.

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>

Sent: Friday, March 13, 2020 6:53 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Cc: Yeskey, Kevin (OS/ASPR/IO) <Kevin.Yeskey@hhs.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Orsega, Susan (OS/OASH) <Susan.Orsega@hhs.gov>; Shuy, Bryan (OS/ASPR/IO) <Bryan.Shuy@hhs.gov>

Subject: Re: FDA - materials

(b)(5)

Sent from my iPhone

On Mar 13, 2020, at 6:19 PM, Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>wrote:

- • Liquid Amies-based transport media.
 - • Supplies:
 - • E-Swab by Copan (Catalogue # 481C and 482C) with regular or flex minitip applicator
 - • Opti-Swab by Puritan (Catalogue # LA-117), swab included in kit (Catalog#3317-H).

○ • Storage: Up to 72 hours at 4°C, or frozen for longer storage.
If the above are not available, FDA believes that the following could be used to collect and transport samples for molecular RT-PCR sARS-CoV-2 assays:

- • Dry swab in saline
 - • Supplies:
 - • Puritan: 25-3317-H, 25-3316-U, 25-3316-H, 25-3317-U, 25-3318-U, 25-3318-H, 3316-U, 3317-U, 3318-U, 25-3319-H, 3316-H, 3318-H, 25-3320-U, 25-3320-U EMB 100MM, 25-3320-U EMB 80MM, 25-3320-H and 25-3320-H EMB 80MM
 - • Copan: 501CS01, 503CS01, 516CS01, 518CS01 and 534CS01
 - • Storage: Up to 72 hours at 4°C, or frozen for longer storage.

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
----------------	---

Recipient:	Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Yeskey, Kevin (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6fe6cf13518445fd9c3a1c254e166b3f-Yeskey, Kev>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>; Orsega, Susan (OS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8171c34a0cd4581a49f33cb8f60f684-Orsega, Sus>; Shuy, Bryan (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fdeb5ca04b6b4ed19fec2209b5f571e7-Shuy, Bryan>
Sent Date:	2020/03/13 21:00:47
Delivered Date:	2020/03/13 21:00:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject:	RE: Lab Numbers
Date:	2020/03/09 12:51:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Monday, March 9, 2020 12:47 PM
To: Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Caliguri, Laura (FDA/OC) <Laura.Caliguri@fda.hhs.gov>; McWilliams, Carly (FDA/OC) <Carly.McWilliams@fda.hhs.gov>
Subject: RE: Lab Numbers

(b)(5)

From: Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>
Sent: Monday, March 9, 2020 12:45 PM
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>
Cc: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Caliguri, Laura <Laura.Caliguri@fda.hhs.gov>; McWilliams, Carly <Carly.McWilliams@fda.hhs.gov>
Subject: RE: Lab Numbers

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Monday, March 09, 2020 12:40 PM
To: Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>

Cc: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; McWilliams, Carly <Carly.McWilliams@fda.hhs.gov>

Subject: RE: Lab Numbers

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>

Sent: Monday, March 9, 2020 12:35 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Cc: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>; McWilliams, Carly (FDA/OC) <Carly.McWilliams@fda.hhs.gov>

Subject: RE: Lab Numbers

(b)(5)

Thank you,

Stephanie Caccamo
Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: 240.762.8873
stephanie.caccomo@fda.hhs.gov



From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Monday, March 09, 2020 12:23 PM

To: Caccomo, Stephanie <Stephanie.Caccomo@fda.hhs.gov>

Cc: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Subject: Lab Numbers

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Lenihan, Keagan < Keagan.Lenihan@fda.hhs.gov >
Sent Date:	2020/03/09 12:51:58
Delivered Date:	2020/03/09 12:51:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>
Subject:	RE: Patient Clay Bentley Rome Georgia on CNN.
Date:	2020/03/11 09:50:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

-----Original Message-----

From: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>

Sent: Wednesday, March 11, 2020 9:45 AM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; Campbell, Amanda (CDC/OD/OCS) <ons3@cdc.gov>; Berger, Sherri (CDC/OCOD/OD) <sob8@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>
 Subject: Re: Patient Clay Bentley Rome Georgia on CNN.

(b)(5)

Sent from my iPhone

> On Mar 11, 2020, at 9:32 AM, Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov> wrote:

>
 (b)(5)

> Pre decisional/deliberative

>

> Sent from my iPhone

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>

Sent Date:	2020/03/11 09:50:03
Delivered Date:	2020/03/11 09:50:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject:	RE: Germany
Date:	2020/03/03 22:30:00
Priority:	Normal
Type:	Note

Got it

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Tuesday, March 3, 2020 9:16 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Germany

(b)(5)

(b)(5)

Sent from my iPhone

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent Date:	2020/03/03 22:30:29
Delivered Date:	2020/03/03 22:30:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Hahn, Stephen (b)(6)@fda.hhs.gov>
CC:	Keagan Lenihan (FDA/OC) (Keagan.Lenihan@fda.hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>
Subject:	ThermoFisher
Date:	2020/03/13 05:54:00
Priority:	Normal
Type:	Note

Good Morning Steve,

(b)(5)

BG

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Hahn, Stephen (b)(6)@fda.hhs.gov>; Keagan Lenihan (FDA/OC) (Keagan.Lenihan@fda.hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>
Sent Date:	2020/03/13 05:54:54
Delivered Date:	2020/03/13 05:54:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcb4c6ea342c08d58f63e37d997e7-Trueman, La>
CC:	Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
Subject:	RE: NY Testing
Date:	2020/03/08 09:54:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>
Sent: Sunday, March 8, 2020 8:38 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Fwd: NY Testing

Could you look at NYC Mayor's Rebecca question and provide answer/clarification?

Thanks!
Laura

From: "Kagan, Rebecca" <rkagan@cityhall.nyc.gov>
Subject: Re: NY Testing
Date: 08 March 2020 08:21
To: "Trueman, Laura (HHS/IEA)" <Laura.Trueman@hhs.gov>

Good morning-

Wanted to rephrase and clarify my question last night: our understanding is that the FDA has approved the EUA for companies -- including GenMark and Cepheid -- to utilize alternative automated testing methods developed specifically for COVID-19. Our hospitals utilize these

systems and we are eager to begin automated testing to increase our speed and efficiency in diagnosing COVID-19 cases.

Have these companies been notified that they have received your approval? If not, is there a timeframe for doing so?

Also happy to pull our lab team on a call if that is easier.

Thanks,
Rebecca

Rebecca Kagan Sternhell
Director
New York City Office of Federal Affairs
601 New Jersey Ave, NW Suite 410
Washington DC
Desk: 202.624.5906
Cell: (b)(6)

Please note that email communications may be subject to New York City and State FOIL requirements

From: rkagan@cityhall.nyc.gov <rkagan@cityhall.nyc.gov>
Sent: Saturday, March 7, 2020 6:40:46 PM
To: Trueman, Laura (HHS/IEA) <laura.trueman@hhs.gov>
Subject: Re: NY Testing

Thanks, I think it may but want to confirm:
Does "Any NY lab doing CDC kit can immediately use same instruments" mean "yes, private labs, northwell, etc" are approved for automatic COVID systems ?

Rebecca Kagan Sternhell
Director
New York City Office of Federal Affairs
601 New Jersey Ave, NW Suite 410
Washington DC
Desk: 202.624.5906
Cell: (b)(6)

Please note that email communications may be subject to New York City and State FOIL requirements

From: Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>
Sent: Saturday, March 7, 2020 6:18:58 PM
To: rkagan@cityhall.nyc.gov <rkagan@cityhall.nyc.gov>
Subject: NY Testing

Let me know if this does not answer your question!

Begin Forwarded Message:

From: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>
Subject: FW: Readout from Cuomo's press conference today
Date: 07 March 2020 16:21
To: "Trueman, Laura (HHS/IEA)" <Laura.Trueman@hhs.gov>

See below

They can use automation now

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Saturday, March 7, 2020 4:19 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: RE: Readout from Cuomo's press conference today

Just confirmed, our FDA team gave NY Wadsworth approval to add 2 extractor types. Any NY lab doing CDC kit can immediately use same instruments. Gettin mor details now. Anyway will work in real-time with NY.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcba4c6ea342c08d58f63e37d997e7-Trueman, La>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
Sent Date:	2020/03/08 09:54:36
Delivered Date:	2020/03/08 09:54:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Alexander Billioux <Alexander.Billioux@la.gov>; Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Sylvia Trent-Adams (HHS/OASH) (Sylvia.Trent-Adams@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=650dc3276414421693345147bfafd132-Trent-Adams>
CC:	Omar Khalid <Omar.Khalid@LA.GOV>; Carla Haddad (HHS/OASH) (Carla.Haddad@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>
Subject:	RE: Request for clarification on staffing drive-through testing centers
Date:	2020/03/16 14:06:00
Priority:	Normal
Type:	Note

These are all answerable.

I am at WH and will let my leadership ops team work with you. But briefly

1. We are not setting up any specific requirement for staffing, to my knowledge. This is state led and federal supported. The PHS can also support a few personnel to assist or supervise
2. Test throughput depends on the size of your POD system. We will review your requirements with our FEMA team. Carla, can you do this?
3. We do not know the turnaround time as yet. We are expecting 48 hours but cannot guarantee. Please note: We can support the drive thru with our own swabs and PPE.

We want to support your priorities and system. We can adapt to what you need.

I can spend more time on this with you later.

BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Alexander Billioux <Alexander.Billioux@la.gov>

Sent: Monday, March 16, 2020 1:51 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Cc: Omar Khalid <Omar.Khalid@LA.GOV>

Subject: Request for clarification on staffing drive-through testing centers

Dear Adm. Giroir,

Thank you for your update this morning with the President. I do have a few questions as we are looking at the logistics for the drive through testing centers, and I would appreciate you directing me to the person who might be able to work with us to answer these questions:

- Staffing of PODs: We will likely not be able to operate these drive through centers if the staffing requirement remains a MD overseeing nurses. We think a model with a resident or APRN overseeing EMT/paramedics would be more workable.
- Volume/through-put of tests: We would need to understand the daily limit on processing of our tests. This will dictate the daily volume of tests we aim to achieve.
- Result Turn around Times: We wanted to confirm the turn around time for these results? We are currently processing samples from the priority populations you are targeting (health care workers, nursing home residents, prisoners, and hospitalized patients) in our hospital labs. If the turn around time for these will be longer (48 hours) we would prefer to use the swabs in our hospitals (as they have a critical shortage of swabs and viral transport medium that would be best allocated to those priority populations (most of which will not be able to drive to a drive through testing center)

Thank you for your help and connecting me to anyone on your team who I can further discuss these questions with.

Thanks,
Alex

Alexander Billioux, MD DPhil FACP

Pronouns: He/Him/His

Assistant Secretary

Office of Public Health

Louisiana Department of Health

628 North 4th Street

Baton Rouge, LA 70802

Email: alexander.billioux@la.gov

Office: 225-342-6188

Cell: (b)(6)



cid:image005.png@01D52B45.11586080



cid:image002.jpg@01D51AB4.7B8ECFD0

Sender: Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

	(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Alexander Billioux <Alexander.Billioux@la.gov>; Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Sylvia Trent-Adams (HHS/OASH) (Sylvia.Trent-Adams@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=650dc3276414421693345147bfafd132- Trent-Adams>; Omar Khalid <Omar.Khalid@LA.GOV>; Carla Haddad (HHS/OASH) (Carla.Haddad@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>
Sent Date:	2020/03/16 14:06:49
Delivered Date:	2020/03/16 14:06:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcba4c6ea342c08d58f63e37d997e7-Trueman, La>
Subject:	Call me
Date:	2020/03/02 07:15:08
Priority:	Normal
Type:	Note

(b)(6)

Sent from my iPhone

On Feb 28, 2020, at 10:17 PM, Trueman, Laura (HHS/IEA)
<Laura.Trueman@hhs.gov> wrote:

□

Dear Colleagues:

COVID-19 continues to be the first order of the day. Some of you have asked what it is like to work at the Department in the middle of a pandemic. Besides exhausting, it is supremely satisfying because I get to see anew the range of expertise and leadership that we have in our federal, state, and local leaders and public health officials. It is also ever evolving, as each morning there are critical developments to absorb and communicate to a broad range of stakeholders, which keeps us on our toes!

Speaking of stakeholders, many of you deal with various interest groups. I am attaching a document which outlines COVID-19 resources for various constituencies, from businesses to schools to healthcare professionals. These are all on the CDC Coronavirus website, but perhaps this list will come in handy.

Weekly COVID-19 update

This week has been full of updates. In keeping with our efforts to be aggressively transparent, the Administration has held numerous press briefings to continually update on the situation.

On Tuesday, Secretary Azar and our other public health leaders briefed the press on the Administration's response to COVID-19. You can find Secretary Azar's remarks and watch a video of the press conference [here](#).

Wednesday, President Donald J. Trump and members of the Coronavirus Task Force briefed reporters on the extensive efforts underway to continue effectively combatting coronavirus. You can see the full video of the news conference [here](#).

We welcomed a few new task force members as well: Surgeon General Adams, Treasury Secretary Mnuchin, NEC Director Kudlow, and Ambassador Birx.

Updated testing guidance for persons under investigation (PUI):

Revisions were made to the Criteria to Guide Evaluation of PUI for COVID-19 on Thursday. The guidance for determining if an individual is a PUI has been broadened to allow more discretion from the frontline physician. The new guidance can be found [here](#).

As always, for more information please visit the Coronavirus Disease 2019 Outbreak Page at: www.cdc.gov/COVID19.

CPAC

It's back! CPAC, an educational conference hosted annually by the American Conservative Union, brings in thousands who support limited government. Their agenda is 27 pages long, but tomorrow Secretary Alex Azar will be on the main stage with VA Secretary Wilkie talking about how our Administration is working to get the government out of the business of micromanaging healthcare by reducing regulations, giving more choice, and tackling specific problems confronting the country like the Opioid Crisis. Thursday, Deputy Secretary Eric Hargan spoke on the family and how this Administration believes and enacts policies that affirm the family as the primary building block in a stable society, including respecting life and religious liberty.

New Chair of the National Advisory Committee on Rural Health and Human Services

Secretary Azar appointed former Kansas Governor Jeff Colyer to serve as the Chair of the National Advisory Committee on Rural Health and Human Services (NACRHHS). The Committee is an integral part of the Administration's efforts to be more focused on developing policy and program changes needed to improve rural health care in America. As a former Kansas doctor and Governor, Colyer is well aware of how important health care is in rural communities. We welcome Governor Colyer to HHS!

Release of HIV/AIDS funding from HRSA

Wednesday, the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), awarded approximately \$117 million to expand access to HIV care, treatment, medication, and prevention services. This investment is a critical component of the Administration's Ending the HIV Epidemic: A Plan for America (EHE) initiative, which aims to reduce the number of new HIV infections in the United States by 90 percent by 2030.

Does Everyone Who Calls an Ambulance Need Hospital-Based Care?

That's the question that a new Medicare CMMI model will explore. Right now, Medicare only pays for transport to specific types of facilities, most often a hospital emergency department (ED). As you might imagine, this creates an incentive to transport all beneficiaries to the hospital even when an alternative treatment option may be more appropriate.

Our Administration is testing a new approach to counter this incentive.

CMS has announced the Emergency Triage, Treat, and Transport (ET3) Model, a payment model that creates a new set of incentives for emergency transport and care, ensuring patients get convenient, appropriate treatment by Medicare-enrolled providers and supporters. On Thursday, we took another step forward as [CMS announced the selection of 205 applicants to participate in the new payment model](#) for emergency treatment and transport. The ET3 Model is just one of the ways CMS aims to advance innovative payment structures to move our health care system to one that incentives value.

Deputy Secretary in Indian Country, Convenes 4th Maternal Health Listening Session

This week, Deputy Secretary Hargan visited several Tribal communities in South Dakota. The trip provided him an opportunity to see firsthand how HHS programs and services are implemented and delivered in both rural tribal communities and urban areas. The Pine Ridge and Rosebud Indian health Service hospitals, as well as the Oyate Health Center and Indian Health Service Clinic. He capped off his trip by providing opening remarks at the HHS Maternal and Child Health Roundtable discussion between tribal, state, and federal partners. HHS continues to work on developing our Department-wide initiative on this topic and we look forward to involving additional stakeholders throughout the process.

So, have a great weekend and enjoy the extra day tomorrow which only comes around every four years. This is a good year for an extra day, I'd say! Happy #LeapYear!

Laura C. Trueman
Director, Office of Intergovernmental and External Affairs
U.S. Department of Health and Human Services
200 Independence Avenue SW
Washington D.C. 20201
Laura.Trueman@hhs.gov
202-690-6060 (main office)

<COVID-19 Resources for Officials, Communities, Businesses.docx>

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcba4c6ea342c08d58f63e37d997e7-Trueman, La>
Sent Date:	2020/03/02 07:15:07
Delivered Date:	2020/03/02 07:15:08

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Susan Orsega (OS/OASH) (Susan.Orsega@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8171c34a0cd4581a49f33cb8f60f684-Orsega, Sus>
Subject:	FW: Summary: Responders transported to hospital for illness
Date:	2020/03/13 05:56:00
Importance:	High
Priority:	Urgent
Type:	Note

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

From: OS Secretarys Operations Center <hhs.soc@hhs.gov>
Sent: Friday, March 13, 2020 3:46 AM
To: OS Secretarys Operations Center <hhs.soc@hhs.gov>
Subject: Summary: Responders transported to hospital for illness

UNCLASSIFIED // FOR OFFICIAL USE ONLY

Good morning Dr. Kadlec,

BLUF: IMT7 (Kirkland) reports three HHS responders have been transported to the hospital for fever and/or upper respiratory symptoms.

- One has tested negative for COVID-9. She was not tested for influenza.
- A second officer was swabbed today. Those results are pending.
- A third person (NDMS Intermittent) is going to the hospital now with fever and intermittent cough and throat irritation.
- IMT-7 will follow up on the test results of these individuals as they are available.

*This notification is limited distribution and is intended for HHS Senior Leadership only. **Do not forward.** This notification was sent to the COVID-19 Senior Leadership distribution list.*

Very Respectfully,

Secretary's Operations Center

U.S. Department of Health and Human Services (HHS)
Assistant Secretary for Preparedness and Response (ASPR)
200 Independence Ave. S.W.
Washington D.C. 20201
Office (202) 619-7800
Fax: 800-514-4256
Email: hhs.soc@hhs.gov



cid:image001.png@01D5F8D4.C13440C0

Data enclosed in this email are subject to the Privacy Act of 1974, as amended. Contents shall not be disclosed, discussed, or shared with individuals unless they have a direct need-to-know in the performance of their official duties. Unauthorized disclosure of this information may result in civil or criminal penalties.

CONFIDENTIALITY NOTICE: This e-mail communication and any attachments may contain confidential and privileged information for the use of the designated recipients. If you are not the intended recipient, (or authorized to receive for the recipient) you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please destroy all copies of this communication and any attachments and contact the sender by reply e-mail or telephone (202-619-7800).

UNCLASSIFIED // FOR OFFICIAL USE ONLY

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Susan Orsega (OS/OASH) (Susan.Orsega@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8171c34a0cd4581a49f33cb8f60f684-Orsega, Sus>
Sent Date:	2020/03/13 05:56:39
Delivered Date:	2020/03/13 05:56:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	PERKINS, Mark <perkinsm@who.int>; GRAAFF, Peter Jan <graaffp@who.int>; Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>
CC:	VON EIJE, Karin <voneijek@who.int>; SIMONSON, Stewart <simonsons@who.int>
Subject:	RE: COVID test
Date:	2020/03/09 13:37:00
Priority:	Normal
Type:	Note

Thank you

Honestly, there is a lot of criticism aimed at HHS, that we should have “ordered” millions of tests from the WHO in mid-February.

I am confirming that was NOT possible at all, and certainly your first responsibility is to countries that don’t have the industrial base or the CDC. Your numbers confirm that. There is NO criticism here of WHO – absolutely the contrary.

Really many thanks

Brett

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694


From: PERKINS, Mark <perkinsm@who.int>
Sent: Monday, March 9, 2020 12:56 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; GRAAFF, Peter Jan <graaffp@who.int>; Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>
Cc: VON EIJE, Karin <voneijek@who.int>; SIMONSON, Stewart <simonsons@who.int>
Subject: RE: COVID test

Adm Giroir,

Can you tell me what this information is for?

The test we are shipping to date was selected by WHO in mid-late January based on a constellation of features (ISO13485 manufacture, chemistries based on the first validated published protocol – Jan 13, and manufacturer reputation and distribution capacity). We didn't develop the assay, but did make some changes with the manufacturer from the published academic version (removing one of the targets, flipping one of the probes). The manufactured version has undergone validation in external academic or public sector labs. It is manufactured in Germany. We ordered the first 2500 kits on 24 January I believe. Next shipment was mid-Feb, then early March. See map of delivery showing spread of testing capacity in Africa below.

Mark



cid:image001.jpg@01D5F637.F93B60B0

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Monday, March 9, 2020 4:51 PM
To: PERKINS, Mark <perkinsm@who.int>; GRAAFF, Peter Jan <graaffp@who.int>; Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>
Cc: VON EIJE, Karin <voneijek@who.int>; SIMONSON, Stewart <simonsons@who.int>
Subject: RE: COVID test

Last question:

Can you tell me when you started shipping tests and how much? For example "we started shipping 100k tests per week the week of Feb14....."

IF you had number of tests shipped per week that would be ideal – but not required if you don't have that. I promise this will be my last question.

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Giroir, Brett (HHS/OASH)

Sent: Monday, March 9, 2020 10:49 AM

To: PERKINS, Mark <perkinsm@who.int>; GRAAFF, Peter Jan <graaffp@who.int>; Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>

Cc: VON EIJE, Karin <voneijek@who.int>; SIMONSON, Stewart <simonsons@who.int>

Subject: RE: COVID test

When did you start shipping these tests?

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: PERKINS, Mark <perkinsm@who.int>

Sent: Monday, March 9, 2020 10:28 AM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; GRAAFF, Peter Jan <graaffp@who.int>; Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>

Cc: VON EIJE, Karin <voneijek@who.int>; SIMONSON, Stewart <simonsons@who.int>

Subject: RE: COVID test

We have been shipping 2500 to 5000 test kits roughly every 10 days. Each kit is 100 tests.

Mark

Dr Mark D. Perkins

Leader, Laboratory Networks

Infectious Hazards Management, WHO Health Emergencies Programme

Email: perkinsm@who.int

Desk phone: +4122-7911649 Cell: (b)(6)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Monday, March 9, 2020 3:21 PM
To: PERKINS, Mark <perkinsm@who.int>; GRAAFF, Peter Jan <graaffp@who.int>; Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>
Cc: VON EIJE, Karin <voneijek@who.int>; SIMONSON, Stewart <simonsons@who.int>
Subject: RE: COVID test

Thank you
And this is 250,000 to 500,000 tests every other week?
As opposed to test kits that may contain 100 or 1000 individual tests?

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: PERKINS, Mark <perkinsm@who.int>
Sent: Monday, March 9, 2020 10:12 AM
To: GRAAFF, Peter Jan <graaffp@who.int>; Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: VON EIJE, Karin <voneijek@who.int>; SIMONSON, Stewart <simonsons@who.int>
Subject: RE: COVID test

This time copied to Adm Giroir.

Mark

From: PERKINS, Mark
Sent: Monday, March 9, 2020 3:06 PM
To: GRAAFF, Peter Jan <graaffp@who.int>; Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>
Cc: VON EIJE, Karin <voneijek@who.int>; SIMONSON, Stewart <simonsons@who.int>
Subject: RE: COVID test

Peter,

Answers to your questions below in red.

From: GRAAFF, Peter Jan
Sent: Monday, March 9, 2020 2:25 PM
To: Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>
Cc: VON EIJE, Karin <voneijek@who.int>; PERKINS, Mark <perkinsm@who.int>; SIMONSON, Stewart

<simonsons@who.int>

Subject: Fwd: COVID test

Maria,

My previous email refers.

I understand that this is time sensitive so if Karin, Mark or yourself has a bit of bandwidth over the next hour or so.....

Thanks!

Peter

Begin forwarded message:

From: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>

Subject: RE: COVID test

Date: March 9, 2020 at 14:18:07 GMT+1

To: "SIMONSON, Stewart" <simonsons@who.int>

Cc: "GRAAFF, Peter Jan" <graaffp@who.int>, "PERKINS, Mark" <perkinsm@who.int>

Thank you.

Clarification for HHS please:

1. What laboratory materials are you shipping to countries? True test kits and reagents?
We are shipping RT PCR kits with two viral gene targets, often (usually) shipped along with RNA extraction kits and one-step qPCR polymerases.
2. And if so, are you shipping these in the thousands or ten thousands? We are shipping numbers of tests between 250,000 and 500,000 every other week (but numbers are rising)
3. Who is the manufacturer(s)? The kits are manufactured under ISO13485 by TIB Molbiol in Berlin.

We are NOT going to request materials. HHS is just trying to clarify what WHO is providing to whom and in what quantities.

FYSA: US produced 1.5 million tests last week under CDC EUA; we expect ~4 million additional this week under CDC EUA and other EUAs.

Brett

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201

Office Phone: 202-690-7694

-----Original Message-----

From: SIMONSON, Stewart <simonsons@who.int>

Sent: Monday, March 9, 2020 9:13 AM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Cc: GRAAFF, Peter Jan <graaffp@who.int>; PERKINS, Mark <perkinsm@who.int>

Subject: RE: COVID test

Dear Adm. Giroir:

Copied on this email is Dr. Mark Perkins, the head of WHO's lab network. He can answer questions about the test kit. I have also copied Peter Graaf, who is my counterpart in Geneva. Since Mark is probably oversubscribed with emails and telephone calls, Peter will help drive your query to the top of the pile.

Stew

STEWART SIMONSON
Assistant Director-General
World Health Organization
One Dag Hammarskjold Plaza
26th Floor
New York, NY 10017
(646) 626-6064 - Office
(b)(6) - Mobile

-----Original Message-----

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Monday, March 9, 2020 8:56 AM

To: SIMONSON, Stewart <simonsons@who.int>

Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Subject: RE: COVID test

ALERT: This email originates from outside of WHO. Please be cautious when opening links or attachments.

Stew

Thank you. Can you put me in touch with someone who can clarify what exactly is being

shipped and in what general quantities?
Is WHO shipping thousands of tests, and if so, who is the manufacturer?

There is confusion here about what exactly is available.
I know you are busy but I need ground truth on this

Best
Brett

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	PERKINS, Mark <perkinsm@who.int>; GRAAFF, Peter Jan <graaffp@who.int>; Dr VAN KERKHOVE, Maria <vankerkhovem@who.int>; VON EIJE, Karin <voneijek@who.int>; SIMONSON, Stewart <simonsons@who.int>
Sent Date:	2020/03/09 13:37:40
Delivered Date:	2020/03/09 13:37:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; McKeogh, Katherine (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c652f2c415b44dff8369dd7f4596f030-McKeogh, Ka>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Pratt, Michael (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c8eed0423de458d801882c30fd16c99-Pratt, Mich>
Subject:	RE: Tests that have shipped today?
Date:	2020/03/09 09:02:00
Priority:	Normal
Type:	Note

All,

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Sent: Monday, March 9, 2020 8:50 AM

To: McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Pratt, Michael (OS/ASPA) <Michael.Pratt@hhs.gov>

Subject: RE: Tests that have shipped today?

(b)(5)

From: McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>
Sent: Monday, March 9, 2020 8:39 AM
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>;
Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Stecker, Judy (OS) <Judy.Stecker@hhs.gov>; Pratt,
Michael (OS) <Michael.Pratt@hhs.gov>
Subject: Tests that have shipped today?

(b)(5)

Katie McKeogh
Press Secretary
Office of the Assistant Secretary for Public Affairs (ASPA)
U.S. Department of Health and Human Services
Katherine.McKeogh@hhs.gov

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; McKeogh, Katherine (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c652f2c415b44dff8369dd7f4596f030-McKeogh, Ka>; Murphy, Ryan (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=314e69c69a844b47bdd9f74bc60a8d44-Murphy, Rya>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Pratt, Michael (OS/ASPA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7c8eed0423de458d801882c30fd16c99-Pratt, Mich>
Sent Date:	2020/03/09 09:02:56
Delivered Date:	2020/03/09 09:02:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
CC:	Pollard, Ashton (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9d4c26448ed441b0aa555971f3c73d6d-Pollard, As>
Subject:	RE: Pandemic testing
Date:	2020/03/12 13:04:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

From: Mango, Paul (HHS/IOS) <Paul.Mango@hhs.gov>
Sent: Thursday, March 12, 2020 8:12 AM
To: Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>; Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>
Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Pollard, Ashton (OS/IOS) <Ashton.Pollard@hhs.gov>
Subject: Fwd: Pandemic testing

(b)(5)

Sent from my iPhone

Begin forwarded message:

From: "Azar, Alex (OS/IOS)" <Alex.Azar@HHS.GOV>
Date: March 12, 2020 at 7:55:05 AM EDT
To: "Mango, Paul (HHS/IOS)" <Paul.Mango@hhs.gov>
Cc: "Pollard, Ashton (OS/IOS)" <Ashton.Pollard@hhs.gov>
Subject: FW: Pandemic testing

□

From: Kirstjen Nielsen <knielsen@lhstrat.com>

Sent: Wednesday, March 11, 2020 11:17 PM

To: Azar, Alex (OS/IOS) <Alex.Azar@HHS.GOV>

Subject: Pandemic testing

Hi Alex

Upfront should say- do not have any financial or contractual arrangement with the company. I know about them b/c I had hoped we could deploy rapid DNA technology on our southern border for a variety of reasons. They have a solid tech that is making a huge difference where deployed. Their approach - esp that it can be used within quarantined areas and doesn't require the sample to be shipped for processing- seems right on to address the current outbreak (of course I am not a medical test expert by any means :-))

Would greatly appreciate any thoughts you might have as to how to set up call with the right folks at HHS, CDC et. (I do not need to be in the loop) and Jim or Kumar. I am, as I know you are, worried that we need something much better than we have to help the readiness of everyone but also the feds and health care providers

Here is the description of the solution from the company.

"We have an established and broadly validated tool that was developed collaboratively with the US DOD for other applications that can relatively quickly be applied to the COVID-19 threat. We can demonstrate solid diagnostic performance beyond the capabilities of current qPCR testing for the COVID-19 threat in 5 to 12 weeks. We request an opportunity to brief you on the technology and its potential global impact in controlling the spread of contagious disease. The system is focused on high reliability DNA processing using the techniques applied everyday by scientists around the world in large brick and mortar labs - but it does so rapidly in a rugged, mobile and automated way that enables essentially untrained personnel to conduct fast and reliable screening at virtually any location. Uniquely this system can be used in contaminated and quarantined areas eliminating the need to remove samples for shipment to outside labs.

* A recent use of the technology was the US raid which killed terrorist Abu Bakr Al Baghdadi - ANDE Rapid DNA was used on scene for DNA identity confirmation.

The ANDE 6C is the only federally approved Rapid DNA technology. It was developed with US DoD and other government support and engagement. ANDE can be configured to provide substantially improved diagnostics for the current COVID-19 infections. ANDE technology has been proven on the battlefield and has been approved for domestic use in forensics by the US FBI as well

as a number of other governments around the world. Systems are currently in use in more than 20 countries and more than 40 public safety agencies in the US. It takes the function of a traditional DNA lab and reduces it to a process that resides in a single disposable cartridge. The ANDE system is operable by non-technical staff. It is US DOD certified as MIL-STD-810G (rugged) and can be deployed in austere environments where it reliably produces high quality results.

The underlying performance of the system is substantially stronger than the existing qPCR diagnostics used broadly for Corona virus testing and which require brick and mortar lab engagement.

The testing process is simple: 1) collect a sample from the person being tested 2) place the swab in the Rapid DNA disposable chip 3) put the chip in the instrument and wait approx 90 minutes and the answer is presented automatically in a secure data environment.

Configuration of the ANDE system for this purpose would also yield an integrated approach to dealing with novel infectious diseases by enabling very rapid testing response in the future - we estimate the time to a solid diagnostic test from identification to be 10 days. This means literally 10 days from the discovery and sequencing of a new threat the new test needed would be ready for manufacturing and distribution.

I am also attaching two summaries, one that is non-technical and very high-level and a second that is more directed to science types. I am also attaching a copy of the CV of our Founder and Chief Science Officer, Richard Kessler.

If there are any questions, they can be directed to Kumar Kibble (copied above) at 571-444-9283 or Jim Davis at 720-879-1408.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
----------------	---

Recipient:	Mango, Paul (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1d8863b643654b1aad9a38c952af613e-Mango, Paul>; Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Pollard, Ashton (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9d4c26448ed441b0aa555971f3c73d6d-Pollard, As>
Sent Date:	2020/03/12 13:04:23
Delivered Date:	2020/03/12 13:04:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>
CC:	Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	FW: Country or Zip Code Level Data
Date:	2020/03/13 05:58:00
Priority:	Normal
Type:	Note

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Williams, Ian (CDC/DDID/NCEZID/DFWED) <iaw3@cdc.gov>
Sent: Thursday, March 12, 2020 11:18 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Berger, Sherri (CDC/OCOD/OD) <sob8@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>
Subject: RE: Country or Zip Code Level Data

(b)(5)

Ian

Ian Williams, PhD, MS
Novel Coronavirus (COVID-19) Response
Deputy Incident Manager
Centers for Disease Control and Prevention (CDC)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Thursday, March 12, 2020 11:08 PM

To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>

Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Williams, Ian (CDC/DDID/NCEZID/DFWED) <iaw3@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>

Subject: RE: Country or Zip Code Level Data

Thank you

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Sent: Thursday, March 12, 2020 11:06 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>

Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Williams, Ian (CDC/DDID/NCEZID/DFWED) <iaw3@cdc.gov>; Armstrong, Gregory (CDC/DDID/NCEZID/OD) <gca3@cdc.gov>

Subject: RE: Country or Zip Code Level Data

(b)(5)

Thanks
Dan.

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Thursday, March 12, 2020 10:48 PM

To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>

Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>

Subject: Country or Zip Code Level Data

Importance: High

(b)(5)

Thanks

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Sent Date:	2020/03/13 05:58:37
Delivered Date:	2020/03/13 05:58:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Redd, Stephen (CDC/DDPHSIS/OD) <scr1@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbee2d9b4db2a0f-Jernigan, D>
CC:	Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Jester, Barbara (CDC/DDID/NCIRD/ID) (CTR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b8a0efa124944dba9bffa8046f89ee0-barbara.jes>
Subject:	RE: CDC Request
Date:	2020/03/09 13:48:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Redd, Stephen (CDC/DDPHSIS/OD) <scr1@cdc.gov>
Sent: Monday, March 9, 2020 1:42 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Cc: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Jester, Barbara (CDC/DDID/NCIRD/ID) (CTR) <ipn5@cdc.gov>
Subject: Re: CDC Request

Fantastic—I am glad to have you as a single point of contact for this information.

(b)(5)

Stephen C. Redd, MD

RADM, USPHS

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Monday, March 9, 2020 12:32:58 PM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Redd, Stephen (CDC/DDPHSIS/OD) <scr1@cdc.gov>
Cc: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Jester, Barbara (CDC/DDID/NCIRD/ID) (CTR) <ipn5@cdc.gov>
Subject: CDC Request

(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Redd, Stephen (CDC/DDPHSIS/OD) <scr1@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbec2d9b4db2a0f-Jernigan, D>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>; Jester, Barbara (CDC/DDID/NCIRD/ID) (CTR) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b8a0efa124944dba9bffac8046f89ee0-barbara.jes>
Sent Date:	2020/03/09 13:48:20
Delivered Date:	2020/03/09 13:48:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Friedman, Richard (HHS/OGC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7b7cc98f>; Harder, Kristina (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2ae41a17eef54468834316f71bd8ea02-Pelekoudas,>; Tatem, Anne (HHS/OS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0e009a83879740ea939b404511c8955a-Tatem, Anne>
CC:	Throckmorton, Douglas C (FDA/CDER) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44cfe13037554ffe81729ff8f98a325c-douglas.thr>
Subject:	RE: Giroir? Reply by 9:30 am Mon. - Proposed response to OMB re: DOJ/DEA test. on SUPPORT Act Implementation
Date:	2020/03/02 11:07:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

From: Friedman, Richard (HHS/OGC) <Richard.Friedman@HHS.GOV>
Sent: Monday, March 2, 2020 10:55 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Harder, Kristina (HHS/IOS) <Kristina.Harder@hhs.gov>; Tatem, Anne (HHS/OS/ASL) <Anne.Tatem@hhs.gov>
Subject: Giroir? Reply by 9:30 am Mon. - Proposed response to OMB re: DOJ/DEA test. on SUPPORT Act Implementation

(b)(5)

Richard Friedman
 (cell) (b)(6)

From: George, Bryan [mailto:Bryan.George@fda.hhs.gov]
Sent: Monday, March 02, 2020 8:06 AM
To: Friedman, Richard (HHS/OGC); Pence, Laura (HHS/ASL); Tatem, Anne (HHS/OS/ASL); Giroir, Brett (HHS/OASH); Harder, Kristina (HHS/IOS); Schwarcz, Cristi L. (CDC/OD/CDCWO); Everett, Chris (NIH/OD) [E]

Subject: RE: Reply by 9:30 am Mon. - Proposed response to OMB re: DOJ/DEA test. on SUPPORT Act Implementation

(b)(5)

Thanks,
Bryan

From: Friedman, Richard (HHS/OGC) <Richard.Friedman@HHS.GOV>

Sent: Monday, March 02, 2020 12:14 AM

To: Pence, Laura (OS) <Laura.Pence@hhs.gov>; Tatem, Anne (OS) <Anne.Tatem@hhs.gov>; Giroir, Brett (OS) <Brett.Giroir@hhs.gov>; Harder, Kristina (OS) <Kristina.Harder@hhs.gov>; Schwarcz, Cristi L (CDC) <zcz1@cdc.gov>; Everett, Chris L (NIH) <chris.everett@nih.gov>; George, Bryan <Bryan.George@fda.hhs.gov>

Subject: FW: Reply by 9:30 am Mon. - Proposed response to OMB re: DOJ/DEA test. on SUPPORT Act Implementation

Adding ASL.

Richard Friedman

(cell) (b)(6)

From: Friedman, Richard (HHS/OGC)

Sent: Monday, March 02, 2020 12:12 AM

To: Giroir, Brett (HHS/OASH); Harder, Kristina (HHS/IOS); Schwarcz, Cristi L. (CDC/OD/CDCWO); Everett, Chris (NIH/OD) [E]; George, Bryan (FDA/OC)

Subject: Reply by 9:30 am Mon. - Proposed response to OMB re: DOJ/DEA test. on SUPPORT Act Implementation

(b)(5)

Richard Friedman

(cell) (b)(6)

(b)(5)

Richard Friedman


202-690-7766

Sender: Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

	(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Friedman, Richard (HHS/OGC) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=user7b7cc98f>; Harder, Kristina (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2ae41a17eef54468834316f71bd8ea02-Pelekoudas,>; Tatem, Anne (HHS/OS/ASL) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0e009a83879740ea939b404511c8955a-Tatem, Anne>; Throckmorton, Douglas C (FDA/CDER) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44cfe13037554ffe81729ff8f98a325c-douglas.thr>
Sent Date:	2020/03/02 11:07:02
Delivered Date:	2020/03/02 11:07:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Susan Orsega (OS/OASH) (Susan.Orsega@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8171c34a0cd4581a49f33cb8f60f684-Orsega, Sus>
CC:	Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	RE: CDC Data
Date:	2020/03/13 06:03:00
Priority:	Normal
Type:	Note

(b)(5)



(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>
Sent: Thursday, March 12, 2020 11:16 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <Shannon.Sartin@cms.hhs.gov>
Subject: RE: CDC Data

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Thursday, March 12, 2020 10:47 PM
To: Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <Shannon.Sartin@cms.hhs.gov>
Subject: RE: CDC Data

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Smith, Brad (CMS/OA) <Brad.Smith@cms.hhs.gov>
Sent: Thursday, March 12, 2020 10:34 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Sartin, Shannon (CMS/OA) <Shannon.Sartin@cms.hhs.gov>
Subject: CDC Data

Admiral Giroir –

(b)(5)

Thanks,

Brad

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Susan Orsega (OS/OASH) (Susan.Orsega@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8171c34a0cd4581a49f33cb8f60f684-Orsega, Sus>; Sartin, Shannon (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8ccd673e579843678a264204fea4107b-SCR4>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Sent Date:	2020/03/13 06:03:50
Delivered Date:	2020/03/13 06:03:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
Subject:	FW: Ready to Provide Support for COVID-19
Date:	2020/03/17 08:16:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Michaela LaBarre <michaela.labarre@milliporesigma.com>**On Behalf Of** Udit Batra
Sent: Tuesday, March 17, 2020 8:11 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Ready to Provide Support for COVID-19

Dear Assistant Secretary Giroir,

We had the pleasure of meeting last May at the World Health Assembly in Geneva, where we shared the stage with life science, government and NGO experts on building pharmaceutical and vaccine capabilities in Africa and similar geographies. I also participated in the breakfast roundtable with Secretary Azar earlier in the day to discuss the importance of decentralized vaccine manufacturing to tackling global infectious disease challenges.

MilliporeSigma is a leading provider of tools and reagents for research in life sciences, development of diagnostics and production of vaccines and other biologics. We are roughly 22,000 colleagues globally committed solving tough problems in life science in support of public health with close to 50 manufacturing sites and 100 distribution sites globally.

We are keen to support your efforts to ensure every American has access to diagnostic testing for COVID-19. At present, we provide diagnostic kits for research use only (RUO) purposes, however, our team is in discussions with CDC to provide any assistance required to meet the most urgent needs of the US population. In addition, we manufacture and supply tools, products and raw materials for our customers currently working on SARS-CoV-2 related work, including the reagents and technical expertise, e.g., RT-PCR, RT-qPCR and supporting reagents that are suitable for SARS-CoV-2 vaccine research. We also provide raw materials and/or components such as membranes, enzymes, immunoassay solutions, and custom

antibodies for use by customers in the potential development and use of diagnostic test kits (rapid/standard), as well as custom oligos for primers/probes.

For vaccine manufacturing, we have more than 40 years' experience accelerating vaccines and treatments from development to deployment. The products, services and expertise we provide, such as readily deployable biomanufacturing platforms and biosafety testing services, help advance our customer's COVID-19 vaccine and treatment development and manufacturing efforts.

Our team is at your disposal to expedite any requests by your office to procure any product related to fighting COVID-19. I am available at your convenience at +1 978-715-4785 should you have any immediate questions.

Sincerely,

Udit Batra

Udit Batra, Ph.D.
Chief Executive Officer
MilliporeSigma

MilliporeSigma

A business of Merck KGaA, Darmstadt, Germany

EMD Millipore Corporation | 400 Summit Drive | Burlington, MA 01803 | USA
Phone: +1 978-715-4785 | Email: udit.batra@emdmillipore.com
<https://protect2.fireeye.com/url?k=abc2a055-f796897e-abc2916a-0cc47a6d17cc-b2a7eb88887bae9e&u=http://www.milliporesigma.com/>

Experience our products at emdmillipore.com or sigmaaldrich.com



cid:image001.jpg@01D12B4B.9FACAB50

This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith.

Click <https://protect2.fireeye.com/url?k=88020bdd-d45622f6-88023ae2-0cc47a6d17cc-fb4ba9c009858d9d&u=http://www.merckgroup.com/disclaimer> to access the German, French, Spanish and Portuguese versions of this disclaimer.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Shuren, Jeff (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group

	(FYDIBOHF23SPDLT)/cn=Recipients/cn=bcede884c4434f4da6f4fe4b4c3885cd-jeffrey.shu>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
Sent Date:	2020/03/17 08:16:11
Delivered Date:	2020/03/17 08:16:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject:	RE: WHO
Date:	2020/03/09 13:49:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Monday, March 9, 2020 1:41 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: WHO

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent Date:	2020/03/09 13:49:11
Delivered Date:	2020/03/09 13:49:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	Keagan Lenihan (FDA/OC) (Keagan.Lenihan@fda.hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Hahn, Stephen <SH1@fda.hhs.gov>
Subject:	FW: WHO Information on Testing
Date:	2020/03/09 13:50:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Giroir, Brett (HHS/OASH)
Sent: Monday, March 9, 2020 1:35 PM
To: AMA2 (OS/IOS) <AMA2@HHS.GOV>
Cc: Harrison, Brian (HHS/IOS) <Brian.Harrison@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Steve Hahn <SH1@fda.hhs.gov>
Subject: RE: WHO Information on Testing

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: AMA2 (OS/IOS) <AMA2@HHS.GOV>
Sent: Monday, March 9, 2020 11:40 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Cc: Harrison, Brian (HHS/IOS) <Brian.Harrison@hhs.gov>; Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Steve Hahn <SH1@fda.hhs.gov>

Subject: Re: WHO Information on Testing

(b)(5)

On Mar 9, 2020, at 10:30 AM, Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov> wrote:

Sir,

(b)(5)

V/r

BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

<Lab Tests Slide WHO.pptx>

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Keagan Lenihan (FDA/OC) (Keagan.Lenihan@fda.hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cd1b7aba9034ddb936017780583af7d-keagan.leni>; Hahn, Stephen <SH1@fda.hhs.gov>
Sent Date:	2020/03/09 13:50:38
Delivered Date:	2020/03/09 13:50:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbec2d9b4db2a0f-Jernigan, D>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>
CC:	Eo.Cevent.cdc.gov (CDC.GOV) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=20c5de36d1e04d479d08269a96c1f1a7-Eo.Cevent.c>
Subject:	RE: Public Health Laboratories Running Tests
Date:	2020/03/07 11:16:00
Priority:	Normal
Type:	Note

Thank you

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Saturday, March 7, 2020 11:04 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Cc: Eo.Cevent.cdc.gov (CDC.GOV) <eocevent289@cdc.gov>
Subject: RE: Public Health Laboratories Running Tests

(b)(5)

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Saturday, March 7, 2020 10:59 AM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Subject: Public Health Laboratories Running Tests

(b)(5)

(b)(5)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ea51e17a084644918dbec2d9b4db2a0f-Jernigan, D>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Eo.Cevent.cdc.gov (CDC.GOV) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=20c5de36d1e04d479d08269a96c1f1a7-Eo.Cevent.c>
Sent Date:	2020/03/07 11:17:52
Delivered Date:	2020/03/07 11:16:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Rachael Baitel <rbaitel@usaid.gov>
Subject:	RE: Numbers
Date:	2020/03/17 08:29:00
Priority:	Normal
Type:	Note

Super
Visit early

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Rachael Baitel <rbaitel@usaid.gov>

Sent: Tuesday, March 17, 2020 8:27 AM

To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Cc: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>

Subject: Re: Numbers

(b)(5)

On Tue, Mar 17, 2020 at 8:25 AM Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov> wrote:

(b)(5)

Dan.

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Tuesday, March 17, 2020 8:15 AM

To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Rachael Baitel <rbaitel@usaid.gov>
Subject: Numbers
Importance: High

(b)(5)

BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

--

Cell: (b)(6)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Rachael Baitel <rbaitel@usaid.gov>
Sent Date:	2020/03/17 08:29:21
Delivered Date:	2020/03/17 08:29:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Sylvia Trent-Adams (HHS/OASH) (Sylvia.Trent-Adams@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=650dc3276414421693345147bfafd132-Trent-Adams>
Subject:	FW: Follow up on Bay Area testing pilot and larger scale testing for Pandemic COVID-19
Date:	2020/03/14 20:24:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Massoudi, Mehran (HHS/OASH) <Mehran.Massoudi@hhs.gov>
Sent: Saturday, March 14, 2020 8:06 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: Re: Follow up on Bay Area testing pilot and larger scale testing for Pandemic COVID-19

(b)(5)

Thank you,

v/r

Mehran

On Mar 13, 2020, at 20:05, Giroir, Brett (HHS/OASH)
<Brett.Giroir@hhs.gov> wrote:



(b)(5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Giroir, Brett (HHS/OASH)
Sent: Friday, March 13, 2020 9:04 PM
To: Johns, Matthew (HHS/OASH) <Matthew.Johns@hhs.gov>; Trent-Adams, Sylvia (HHS/OASH) <Sylvia.Trent-Adams@hhs.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Smith, Brad (CMS/OA) <brad.smith@cms.hhs.gov>
Cc: AvilesMendoza, Guillermo (OS/OASH) <Guillermo.Aviles-Mendoza@hhs.gov>; Heidig, Edward (HHS/IEA) <Edward.Heidig@hhs.gov>
Subject: RE: Follow up on Bay Area testing pilot and larger scale testing for Pandemic COVID-19

+ Rachel and Brad

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Johns, Matthew (HHS/OASH) <Matthew.Johns@hhs.gov>
Sent: Friday, March 13, 2020 8:30 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Trent-Adams, Sylvia (HHS/OASH) <Sylvia.Trent-Adams@hhs.gov>
Cc: AvilesMendoza, Guillermo (OS/OASH) <Guillermo.Aviles-Mendoza@hhs.gov>; Heidig, Edward (HHS/IEA) <Edward.Heidig@hhs.gov>

Subject: Follow up on Bay Area testing pilot and larger scale testing for Pandemic COVID-19

ADM, RADM,

I hope this message finds you both well.

(b)(5)

Kind regards,

CDR Johns

Matthew C. Johns, MPH

Commander, United States Public Health Service

Regional Health Administrator-Region 9

Office of the Assistant Secretary for Health

Office of the Secretary

United States Department of Health and Human Services

90 7th Street, Suite 5-100

San Francisco, CA 94103

Phone: (415)437-8102

Mobile: (b)(6)

Email: Matthew.Johns@HHS.gov

Website: <https://www.hhs.gov/ash/about-ash/regional-offices/region-9/index.html>

HHS Region 9: In the Service of Health (In Officio Salutis) for Arizona, California, Nevada, Hawaii, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands and the Republic of Palau.....and 150 Federally-recognized Tribes.

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Sylvia Trent-Adams (HHS/OASH) (Sylvia.Trent-Adams@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=650dc3276414421693345147bfafd132-Trent-Adams>
Sent Date:	2020/03/14 20:24:15
Delivered Date:	2020/03/14 20:24:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI,BRE>
To:	Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
Subject:	Lab Testing
Date:	2020/03/08 10:41:00
Priority:	Normal
Type:	Note

(b)(5)

My mobile is (b)(6) if you need to chat, or text me to look at anything on email I don't respond to in 30 minutes.

Best wishes
Brett

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Monroe, Steve (CDC/DDPHSS/OLSS/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89dd524133eb4ac99724fc5456424b0b-Monroe, Ste>; Stenzel, Timothy (FDA/CDRH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cba7ee2d647d476fa35a0fb86a74514c-timothy.ste>
Sent Date:	2020/03/08 10:41:39
Delivered Date:	2020/03/08 10:41:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcba4c6ea342c08d58f63e37d997e7-Trueman, La>
CC:	Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Johnston, Darcie (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6a8047840ca4406b5ac6bc5cf259937-Johnston, D>; Carla Haddad (HHS/OASH) (Carla.Haddad@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>
Subject:	RE: Speak to NACCHO Before 10:30AM Tomorrow
Date:	2020/03/02 12:51:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Trueman, Laura (HHS/IEA) <Laura.Trueman@hhs.gov>
Sent: Monday, March 2, 2020 12:05 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Stecker, Judy (OS/IOS) <Judy.Stecker@hhs.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>
Subject: Speak to NACCHO Before 10:30AM Tomorrow
Importance: High

Dr Giroir

(b)(5)

(b)(5)

Laura

Laura C. Trueman
Director, Office of Intergovernmental and External Affairs
U.S. Department of Health and Human Services
200 Independence Avenue SW
Washington D.C. 20201
Laura.Trueman@hhs.gov
202-690-6060 (main office)

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Trueman, Laura (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=99dcba4c6ea342c08d58f63e37d997e7-Trueman, La>; Stecker, Judy (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0280b227911b40b6b30a81b8574ede6b-Stecker, Ju>; Johnston, Darcie (HHS/IEA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f6a8047840ca4406b5ac6bc5cf259937-Johnston, D>; Carla Haddad (HHS/OASH) (Carla.Haddad@hhs.gov) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0345ed373884c068792954d8f18aa54-Haddad, Car>
Sent Date:	2020/03/02 12:51:42
Delivered Date:	2020/03/02 12:51:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Boehler, Adam <Adam.Boehler@dfc.gov>; Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>
CC:	Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Subject:	FDA FAQ
Date:	2020/03/13 22:42:00
Priority:	Normal
Type:	Note

- Liquid Amies-based transport media.

- Supplies:

- E-Swab by Copan (Catalogue # 481C and 482C) with regular or flex minitip applicator
 - Opti-Swab by Puritan (Catalogue # LA-117), swab included in kit (Catalog#3317-H).

- Storage: Up to 72 hours at 4°C, or frozen for longer storage.

If the above are not available, FDA believes that the following could be used to collect and transport samples for molecular RT-PCR sARS-CoV-2 assays:

- Dry swab in saline

- Supplies:

- Puritan: 25-3317-H, 25-3316-U, 25-3316-H, 25-3317-U, 25-3318-U, 25-3318-H, 3316-U, 3317-U, 3318-U, 25-3319-H, 3316-H, 3318-H, 25-3320-U, 25-3320-U EMB 100MM, 25-3320-U EMB 80MM, 25-3320-H and 25-3320-H EMB 80MM
 - Copan: 501CS01, 503CS01, 516CS01, 518CS01 and 534CS01

- Storage: Up to 72 hours at 4°C, or frozen for longer storage.

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
----------------	---

Recipient:	Boehler, Adam <Adam.Boehler@dfc.gov>; Smith, Brad (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d8094af80b6445c2a592223e5c69bd45-SRVN>; Kellogg, Rachel (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=897ed8e8d85f4105b2bf0705fc476e32-Kellogg, Ra>
Sent Date:	2020/03/13 23:11:48
Delivered Date:	2020/03/13 22:42:00

From:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
To:	Rachael Baitel <rbaitel@usaid.gov>
Subject:	FW: Numbers
Date:	2020/03/17 08:29:00
Priority:	Normal
Type:	Note

(b)(5)

Brett P. Giroir, MD
 ADM, US Public Health Service
 Assistant Secretary for Health (ASH)
 200 Independence Avenue, SW
 Washington, DC 20201
 Office Phone: 202-690-7694

From: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Sent: Tuesday, March 17, 2020 8:25 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Rachael Baitel <rbaitel@usaid.gov>
Subject: RE: Numbers

(b)(5)

Dan.

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Tuesday, March 17, 2020 8:15 AM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>; Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>
Cc: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Kellogg, Rachel (HHS/OASH) <Rachel.Kellogg@hhs.gov>; Rachael Baitel <rbaitel@usaid.gov>
Subject: Numbers
Importance: High

(b)(5)

BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

Sender:	Giroir, Brett (HHS/OASH) </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A56FCE4755704C4CA031D621B46FD6F7-GIRORI, BRE>
Recipient:	Rachael Baitel <rbaitel@usaid.gov>
Sent Date:	2020/03/17 08:29:55
Delivered Date:	2020/03/17 08:29:00